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Intermittent claudication (IC) is the commonest manifestation of atherosclerosis
affecting the lower limbs. Due to the systemic nature of atherosclerosis, it is not
unexpected that patients with IC have a high risk of thrombotic cardiac and
cerebrovascular events. However, there is some research to suggest that this may
represent more than simply associated atheroma in the coronary and cerebral arteries
- this excess risk could be provided by disturbance of the coagulation system.
Numerous studies have demonstrated an association between thrombophilic states
and peripheral arterial disease (PAD), and these seem to play a significant role in the
severity, and progression ofPAD, as well as the likelihood of success of any
interventions. As IC is known to be accompanied by a well characterised systemic
response - probably secondary to the repeated ischaemia-reperfusion seen during
exercise in claudicants, this could putatively affect the coagulation system, leading to
the increased risk of cardiovascular thrombotic events which these patients suffer
from. We aimed therefore, to study the effect of exercise on the coagulation system
in patients with IC.
Methods
Forty subjects were studied, 20 claudicants, and 20 age and sex-matched controls.
All claudicants were smokers, 10 of the controls were smokers. Subjects had
measurement of a wide variety of coagulation parameters before and after standard




All subjects had similar levels of thrombin production at baseline, but following
exercise, this was significantly higher in the subjects with IC. This was not
accompanied by an corresponding increase in fibrinolysis when compared to the
controls, resulting in probable prothrombotic state. There was increased fibrin
turnover in the claudicants at baseline, but appreciable effect of exercise. The
claudicants who could walk further seemed to have a better fibrinolytic response than
the claudicants with poorer walking distances.
Platelet activation (measured by flow cytometry) following exercise was less in the
claudicants than in the controls - probably reflecting the increased use of aspirin in
these subjects.
All groups have an increase in neutrophil activation (measured by flow cytometry)
following exercise, but this was more in the controls groups. This may reflect
sequestration of neutrophils in the peripheral (or pulmonary) circulation in the
claudicants.
Conclusion
Exercise in claudicants can lead to a prothrombotic state, characterised by increased
thrombin generation. This needs to be further evaluated to determine whether this
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• PAD is a marker for severe, multi-system
atherosclerosis affecting the cerebral, visceral
and coronary arteries.(Figure 1.3)3
• In the presence of exercise-limiting IC, even
severe ischaemic heart disease (IHD) may be
asymptomatic and thus go unrecognised and
untreated.
Epidemiology
Peripheral arterial disease (PAD) is common, with over 20% of the population
having asymptomatic disease, and up to 5% having lower limb symptoms; most
commonly, intermittent claudication (IC).1 Although IC is relatively benign in terms
of limb-loss (1-2% per year), it is associated with a vascular mortality (5-10% per
year) 2-4 times greater than that of an age and sex matched non-claudicant
population (Figures 1.1 and 1.2); a risk that is, in fact,
greater than that experienced by patients with angina.2
There are several reasons for this.
• There is a suggestion that repeated ischaemia-
reperfusion of leg muscles may lead to a
systemic inflammatory response that








Figure 1.2 The outcome for patients with intermittent claudication over 5 years.
Taken from Reference 3.
CV=cardiovascular (coronary or cerebrovascular)
Figure 1.3 The systemic nature of atherosclerosis.
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Diagnosis and investigation
A diagnosis of IC can usually be made on the basis of the patient's history. The
Edinburgh Claudication Questionnaire is highly specific (91%) and sensitive (99%)
for the condition.(Figure 1.4)5 The differential diagnosis includes both venous and
neurogenic claudication (Table 1.1). Examination usually reveals weak or absent
pulses and further investigations (duplex ultrasound, angiography) are usually
reserved for the small minority of patients in whom intervention is being
considered.(Figure 1.5)






Quality of pain Cramping 'Bursting' Electric shock-like
Onset Gradual, consistent Gradual, can be Can be immediate,
immediate T ■ , ,Inconsistent
Relieved by Standing still Elevation of leg Sitting down,
bending forward





Legs affected Usually one Usually one Often both
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Figure 1.4 The Edinburgh Claudication Questionnaire
1 Do you get a pain or discomfort in
your leg(s) when you walk?
Yes □ No □
If you answered "Yes" to question (1), please answer the following questions. Otherwise you need
not continue
2 Does this pain ever begin when you
are standing still or sitting?
Yes □ NoD





4 Do you get it if you walk at an
ordinary pace on the level?
Yes □ NoD
5 What happens to it if you stand
still?
a)usually continues for more
than 10 minutes




6 Where do you get this pain or
discomfort?
Mark the place(s) with an 'X' on
the diagrams below
Front Back
Definition of positive classification requires all of the following responses: "Yes" to (1), "No" to (2),
"Yes" to (3), grade 1 "No" to (4), grade 2 "Yes" to (4). If these criteria are fulfilled, a definite
claudicant is one who indicates the pain is in the calf, regardless of whether pain is also marked at
other sites; a diagnosis of atypical claudication is made if the pain is marked in the thigh or buttock, in
the absence of any calf pain. Subjects should not be considered to have claudication if pain is
indicated in the hamstrings, feet, shins, joints or appears to radiate in the absence of any pain in the
calf
Figure 1.5 Angiogram showing bilateral femoral artery occlusions in a patient
suffering from claudication.
Treatment
Since the main danger to patients with claudication is from general cardiovascular
disease, initial management should comprise the modification of vascular risk factors
and the implementation of Best Medical Therapy (BMT) in the expectation that this
will extend life, lower still further the risk of critical limb ischaemia and improve the
patients' functional status. Only once BMT has been instituted and given sufficient
time to take effect should any consideration be given to intervention as most patients'
symptoms improve with BMT to a point where intervention is no longer required.6
Even in patients who eventually require invasive treatment, BMT is beneficial since
the safety, immediate success and durability of intervention is greatly improved in
patients who are compliant with BMT. '8
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Traditionally, those treating PAD have tended to focus on the arterial lesion and its
surgical or endovascular (angioplasty, stenting) treatment. Unfortunately, with the
notable exception of carotid intervention for high-grade symptomatic disease,9"11
there is little or no level 1 evidence to support intervention for PAD that is not
immediately life or limb-threatening. What little data are available suggest that
invasive intervention for claudication can lead to an early (1 year) improvement in
symptoms, but there is no evidence this is sustained.7'8'12'13 Such interventions are
expensive, potentially hazardous, usually of limited durability and do not impact
upon the patients' high underling vascular risk.7'8 By contrast, there is increasing
and compelling evidence that BMT comprising anti-smoking strategies, antiplatelet
agents (APA), lipid lowering and exercise programmes dramatically reduce the
vascular risk and significant increase functional status.14'15 BMT is also relatively
inexpensive and virtually free from risk. With the release of data from the Heart
Protection Study, which included over 6000 patients with PAD and confirmed the
benefits of lipid lowering, it is timely to review what BMT should comprise and how
it can be instituted universally in patients with PAD.16
Anti-smoking strategies
There is overwhelming evidence that smoking is the single
most important risk factor for the development and
progression of PAD and that it significantly increases the
risk, and reduces the success, of peripheral arterial
intervention.14' 17"22 Despite the clear benefits of smoking
cessation in PAD patients, only a minority (11-48%) of patients manage to quit23; 23
Simple oral advice is ineffective,24 but more intensive counselling has been shown to
be effective in unselected smokers, although not in PAD patients.25 27 i\ijrntjn„
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replacement therapy (NRT), whether delivered by patch, gum, intranasal spray,
inhaler or sublingual tablet, is safe, and leads to significant improvements in smoking
cessation (odds ratio 1.72, 95% confidence interval 1.60 to 1.84); at least in the short
term.28' 29 Bupropion is at least as effective as NRT, but appears to confer no
additional benefit in combination with NRT.30 The Cochrane group on tobacco
addiction has found alternative therapies such as acupuncture, hypnotherapy, and
'aversive smoking', to be ineffective.31"33
Hypercholesterolemia
Hypercholesterolaemia is clearly an independent
risk factor for the development and progression of
PAD.2' 17' 18' 34 Cholesterol lowering has been
shown to slow the progression of peripheral
atherosclerosis in a number of large, including
randomised, anatomical and pathological studies,35; 36 although none have shown
benefit with respect to PAD symptoms. The recently concluded Heart Protection
Study has, for the first time, demonstrated a benefit of statins in PAD patients by
reducing coronary events by 20%. Furthermore, this was achieved irrespective of
starting total cholesterol.(Figure 1.6)16 Whether there is benefit from raising high
density lipoproteins (HDL), and reducing triglycerides levels is less clear.37
In summary, all patients with PAD should have their cholesterol reduced with
aggressive statin therapy, regardless of starting total cholesterol. In the longer term it
seems possible that statin therapy will be indicated for any patient with objective
evidence of asymptomatic PAD; for example, as demonstrated by a reduced
ankle:brachial pressure index. As patents expire, and generic drugs become
available, the financial consequences of these massive changes in prescribing
25
practice will ease and, of course, the prevention of large numbers of vascular events
will also help to offset the costs.
Figure 1.6 Benefit of40mg simvastatin from The Heart Protection Study.
Number of vascular events by prior disease. Data taken from www.hpsinfo.org
Baseline Simvastatin Placebo
Feature
(n=10 269) (n=10 267)
PreviousMI 1007 1225





All patients 2042 2606
Statin better Statin worse
04 0.6 0.8 1.0 1.2 1.4
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Antiplatelet Therapy
Early studies suggested APA could produce
->o
angiographic improvement, increase walking
distance,39' 40 and reduce the requirement for
vascular intervention.41 There is overwhelming
evidence from the Antiplatelet Trialists'
Collaboration that the prescription of an APA, usually aspirin, reduces vascular death
in patients with symptomatic atherosclerotic disease by about 25%.42 Most of the
studies were in patients with IHD and, when taken in isolation, data from the few
studies looking specifically at patients with PAD were not conclusive. However,
more recently, a review of 24 trials has shown that, when compared with placebo,
APA treatment reduced the risk of death by about a quarter in patients with PAD.43
In summary, all patients with PAD should be on an APA because it reduces vascular
events and death, improves the patency rates of surgery and endovascular
interventions and may improve walking distance. For reasons of cost, non-enteric
aspirin (75mg) is a reasonable first-line choice as there is no clear evidence that a
higher dose is more effective (but will cause more adverse events) or that enteric
coating is associated with less gastric upset (and is more expensive). Patients who
cannot take aspirin should be considered for clopidogrel.
Exercise
There is little doubt that exercise leads to a significant
improvement in exercise tolerance (most studies show
at least a doubling in walking distance) in patients
with PAD.44"46 It is also likely, though not specifically
proved, that exercise will reduce vascular risk. However, clinicians and academics
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alike have largely neglected this simple, inexpensive and effective therapy; and as
such, many important questions remain unanswered.
• How does exercise work? Whilst early animal studies suggested that exercise
may improve blood flow by the development of collaterals, studies in humans
using venous occlusion plethysmography, Xenon-133 clearance and duplex
ultrasonography have not confirmed this.47 Despite this, exercise training can
lead to increased clearance ofXenon-133 injected into calf muscles, possibly
indicating that blood is being diverted towards more active muscles. Exercise
training in claudicants leads to increases in oxidative enzymes, and enhanced
utilization of fatty acids in the calf muscles, maximising the use of oxygen
delivered to the tissues. Improvements in walking distance may also be due
to improvements in walking biomechanics48 and blood rheology.49
• What is the best form of exercise? It has generally been thought to be
walking but recent data have suggested that arm exercise, may be at least as
beneficial, which further questions the mechanism by which exercise
achieves its benefit.50
• Does exercise have beneficial effects on risk factor profile? A small non-
randomised controlled trail showed that exercise training for claudicants, can
lead to modest reductions in blood pressure, cholesterol and glucose levels.51
Whether this translates to a significant improvement in cardiovascular risk,
has not been specifically determined in claudicants, but data from IHD
patients suggests that it may.52
• Should exercise be supervised and, if so, how and for how long? Supervised
exercise programmes would seem intuitively to be better, but there is little
evidence to support this. Gardner and Poehlman reviewed 21 studies of
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exercise therapy in PAD, and found that supervised exercise programmes
were no better than unsupervised.44 A small randomised study of 54 patients,
comparing a 12 week supervised exercise programme and unsupervised
exercise, did suggest that the supervised programme was superior
(improvement in maximum walking distance 207% vs 70% at 6 months).46
What is unclear, is the durability of any benefit. It might be speculated that
any advantage of supervised exercise will diminish with time, although there
is no evidence to support this.
Until these issues are addressed one must approach this aspect of care in a pragmatic
way based upon local resources. PAD patients should certainly be repeatedly and
specifically informed that exercise is beneficial and that it is not (as far as we know)
harmful to try to 'walk through' their claudication pain. Written advice may be a
useful adjunct although this suggestion is not evidence-based. Although supervised
programmes may be superior, at least in the UK, such programmes are not widely
available. The ongoing, UK-based, Heath Technology Assessment funded Exercise
versus angioplasty in claudication trial (EXACT) will provide more information
about the relative benefits of exercise and angioplasty when it reports.
Diabetes
Diabetics have a 3 to 5 fold increased risk of PAD, and are at increased risk of
progression from IC to critical limb ischaemia (CLI).53; 54 The UK Prospective
Diabetes Study has shown that intensive control
decreased the risk of microvascular but not
macrovascular vascular complications of the
disease.55 However, it is extremely important that
the diagnosis of diabetes be specifically confirmed
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or excluded in patients with PAD because it will affect other areas of their treatment,
such as blood pressure and lipid control.56'57
Bloodpressure control.
The benefit of treating hypertension in terms of reducing stroke and coronary events
is well-accepted with current data suggesting a target of less than 140/85 for non-
diabetic and 140/80 for patients with type 2
CO
diabetes. However, in the short-term a reduction of
blood pressure may worsen IC. This is true of
whatever drug therapy has been instituted and there
is no evidence that B-blockers are any more
culpable.59 The HOPE study has shown that
Ramipril, an angiotensin converting enzyme
inhibitor (ACEI), reduces cardiovascular morbidity
and mortality in patients with PAD by around
25%.60; 61 Subjects did not need to be hypertensive to be included in the HOPE study
and the observed risk reduction could not be accounted for by the relatively modest
reduction in blood pressure. The implication of the HOPE study is that most patients
with PAD would benefit from an ACEI provided that therapy is not associated with a
reduction in renal function.
Other risk factors.
Hyperhomocysteinaemia is becoming increasingly recognised as an important risk
factor for development of atherosclerosis, and cross-sectional studies have linked it
specifically to PAD.62 However, the effect of reducing homocysteine (hey) levels
has yet to defined, but should be answered by several ongoing trials. Observational
studies have suggested that low levels of anti-oxidant vitamins are associated with
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PAD, although no studies, including the Heart Protection Study, have yet shown any
benefit from vitamin supplementation.63"65
The relationship between alcohol and PAD appears to be J
shaped, with minimal risk occurring at around 2 units of
alcohol per day.66 Excess alcohol consumption is clearly
associated with an increased vascular risk. Oestrogen has
been proposed as being cardio protective, on the basis of
reduced cardiovascular morbidity and mortality in women taking hormone
replacement therapy, but a recent randomised controlled trials showed no difference
in cardiovascular events between groups randomised to oestrogen/progestogen, and
67
placebo. In summary, these factors may represent important risk factors in PAD,
but at present there is insufficient evidence to justify targeting them for treatment.
Drug therapy
Cilostazol has been shown to significantly increase (35-109%) walking distance in
people with claudication in several large double-blind, placebo-controlled,
randomised trials.68"70 The precise role of Cilostazol remains to be defined but a trial
of the drug is probably indicated in patients who remain unacceptably symptomatic
despite 3-6 months of compliance with BMT.
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Prevalence of BMT use in PAD.
Despite the overwhelming evidence for BMT in patients with PAD, clinical
experience and the literature indicated that it has been poorly applied in the past
(Table 1.2). The proportion of patients taking any kind of anti-thrombotic therapy
(APA or warfarin) ranges from 39 to 66%, and prevalence of cholesterol lowering
therapy ranges from 5 to 46%. Work by our group has confirmed that patients with
PAD, and are poorly treated in terms of BMT.(Table 1.3) Patients who also have
symptomatic IHD seem more likely to be treated but, in general there seems little or
no relationship between the prevalence of treatment, the severity of the underlying
disease and thus the potential benefits of BMT.71"75 In other words, treatment is
haphazard rather that the result of evidence.
The current situation is unacceptable, and clearly strategies need to be put in place to
ensure that PAD patients do not miss out on evidence-based life saving treatment.
The initial step needs to be the education of health professionals working with PAD
patients about the increased cardiovascular risk of these patients, and the benefits of
BMT.
One strategy to increase the institution ofBMT is the use of record cards.(Figure 1.7)
These chart the level of individual risk factors over time, and allow easy recognition
for healthcare professionals of untreated, or inadequately treated risk factors. These
charts could be held in the case notes, or by the patient. Another possibility for
increasing BMT use is to have dedicated staff in out-patient clinics. This is an ideal
role for clinical nurse specialists, who are increasing in number. Whatever technique
is employed, it is important to co-ordinate the patient's care with primary care.
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Table 1.2 The use of cholesterol-lowering and antithrombotic therapy in patients
with PAD
N receiving








Clark 299 Admitted for 106 (36%) 26 (9%) 140 (47%)
(1999)71 angiography
Anand 195 Admitted for 106 (54%) 31 (16%) 94 (49%)
(1999)73 peripheral arterial
surgery
Bismuth 147 Critical limb 66 (45%) 8 (5%) 58 (39%)
(2000)72 ischaemia




Table 1.3 Proportion of patients with peripheral arterial disease receiving
appropriate BMT. Data taken from Reference 77


















There is overwhelming evidence for the efficacy of BMT in PAD, in terms of
cardiovascular risk reduction, and improvement in PAD symptoms.
Recommendations for the use of BMT, based on the best evidence available to date
are presented in Table 1.4. Despite the evidence of benefit, BMT is grossly
underused in PAD patients. If BMT use increases, this will lead to a decrease in
cardiovascular morbidity and mortality, a reduction in the requirement for peripheral
vascular intervention, and an improvement in outcome for those interventions that
are required. It is imperative that those involved in the care of patients with PAD are
aware of the benefit of BMT, and develop strategies to help improve its
implementation.
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Smoking cessation Repeated advice
Nicotine replacement therapy
Behavioural therapy (Smoking cessation classes)
Cholesterol checked yearly.
Statin therapy to lower cholesterol by >25%.
Additional treatment will be required if HDL low, or triglycerides
high (Referral to lipid clinic)
Aspirin
Clopidogrel if aspirin intolerant





Reduce blood pressure to <140/80 mmHg




Overview of thrombosis and fibrinolysis
Introduction
The haemostatic process has evolved to provide a mechanism of arresting haemorrhage,
whilst preventing unnecessary activation, or extension of the coagulation process. The
delicate balance of the system is illustrated by the fact that 10ml of plasma contains
sufficient thrombin to clot all the fibrinogen of the body in 30 seconds. This balance is
achieved by the interaction of the five components of the haemostatic system: blood
vessels, platelets, coagulation factors, coagulation factor inhibitors and fibrinolysis.
Whilst it is convenient to consider these separately, it should be borne in mind that there
are numerous complex interactions between each of these components, at many levels.
Blood Vessels
A number of blood vessel constituents are involved in haemostasis, (Table 2.1) but it is
the endothelial cells (EC's) which play the major regulatory role.
Endothelial cells.
EC's have a multitude of functions in addition to the regulation of coagulation, but this
discussion will be confined to haemostasis (Figure 2.1). EC influence haemostasis via
platelets, coagulation factors and inhibitors of the coagulation cascade.
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Table 2.1 Constituents of blood vessels involved in haemostasis
Blood vessel constituent Function
Smooth muscle Vessel constriction after trauma
Collagen Platelet adhesion (via von Willebrand
factor)
Elastin Contributes to vessel resealing after minor
trauma
Endothelial cell Procoagulant, anticoagulant and
antifibrinolytic functions (see text and
Figure 2.1)
EC -platelet interactions.
Both prostacyclin (PGI2), and nitric oxide (NO), produced by EC's, inhibit platelet
aggregation by increasing platelet intra-cellular cyclic adenosine monophosphate
(cAMP). Increased cAMP levels within platelets lead to increased uptake of calcium
into the dense tubular system, effectively lowering intracytoplasmic calcium levels,
preventing platelet aggregation and activation.
Von Willebrand factor (vWF) is produced by both endothelial cells and megakaryocytes
(and therefore present in platelets), and is an important mediator of platelet-EC
adhesion. Although secreted constitutively, its release is increased in response to a
number of stimuli, including thrombin, interleukin-1 (IL-1), and adrenaline.
38
Figure 2.1 Haemostatic functions of the endothelial cell




AT=antithrombin, TFPI=tissue factor pathway inhibitor, PSHProtein S, tPA=tissue
plasminogen activator,
EC -procoagulant.
Tissue factor (TF) is not released from resting EC's but it can be induced in response to
endotoxin, IL-1 and TNF leading to localised production of thrombin.
EC - anticoagulant.
EC's are associated with a number of anticoagulant substances. Tissue factor pathway
inhibitor (TFPI) is synthesised, and released by EC's. This anticoagulant effect is
enhanced by the presence of antithrombin (AT) on and protein S (PS) on the EC
surface. The membrane ofEC's binds heparin and a number of endogenous heparin-
like molecules - all capable of increasing the anticoagulant effect ofAT.
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A further, important component of the anticoagulant effect ofEC's is thrombomodulin
(TM). This is exclusively synthesised, and expressed by EC's. It binds thrombin,
changing the function of thrombin from procoagulant, to anticoagulant. This helps to
ensure that any coagulation event remains localised to the site of disrupted endothelium.
EC -fibrinolysis
EC's synthesise both tissue plasminogen activator (tPA) and its specific inhibitor
plasminogen activator inhibitor 1 (PAI-1). In the resting EC, release of these factors is
minimal, but is increased in response to specific stimuli. These will be discussed in
detail in the section on fibrinolysis.




Platelets are normally prevented from adhering to intact EC's by high local
concentrations ofNO and PGI2. Removal ofEC's exposes subendothelial components
such as collagen, which binds to the platelet glycoprotein (GP) Ia-Iia complex, leading
to the activation of platelets and release of dense and alpha granules. Subendothelial
collagen also binds vWF, which may help the adhesion of platelets. Activated platelets
are then able to bind vWF with the GPIIb-IIIa complex. The GPIIb-IIIa complex is also
capable ofbinding fibrinogen, which is important for platelet-platelet binding
(aggregation). The activation ofplatelets is a complex, multistep process, which
includes the release of thromboxane A2 from platelet surface (the step inhibited by
aspirin), the binding of adenosine diphosphate(ADP) by a specific receptor (inhibited
by clopidogrel and ticlodipine), and the activation of the GPIIb-IIIa complex to allow
the binding of fibrinogen (directly inhibited by GPIIb-IIIa inhibitors).
Although aggregation of platelets is sufficient to arrest haemorrhage from very small
vessels (capillaries), bleeding from larger vessels requires reinforcement of the platelet
plug with cross-linked fibrinogen. Activation of the coagulation cascade may occur
independently of platelet aggregation, via TF, but platelets contribute to coagulation by
increasing the expression of TF on EC's, and by the specific binding of coagulation
factors on the platelet surface (factors II, V, VII, VIII, IX, X and XI). This assembly of
the coagulation factors on the platelet surface, raises their local concentration, protects
them from specific inhibitors such as antithrombin (AT) and protein C (PC), allowing




The coagulation cascade is a series of reactions, which lead to the rapid production of
cross-linked fibrin. The substrates for the reactions, are soluble, inactive precursors
(zymogen), which when cleaved (or activated) is transformed into an enzyme capable of
acting upon the next protein in the cascade. This series of reactions results in a rapid
increase in the number of active factors, which is compounded by a number of positive
feedback loops, ie factor Xa and thrombin increase the activity of factors V and VIII.
Original models of the coagulation cascade identified two separate initiators:
• The 'intrinsic' pathway, activated by contact with a negatively-charged surface
(ie, glass or dextran sulphate). This leads to the activation ofFXII, which then
activates FXI, which in turn actives FX. This pathways was termed the intrinsic
pathway, as all of the components of it are present in plasma.
• The 'extrinisic' pathway, was identified by recognising that coagulation may be
triggered by the addition to plasma of certain tissue extracts (eventually
identified as TF). TF, binds to, and activates FVII. This TF-FVIIa complex
activates FIX, which then joins the pathway of the intrinsic system by activating
FX.
However, individuals with a deficiency of factors specific to the intrinsic pathway do
not suffer from a clinical bleeding tendency, leading to the belief, that in-vivo, it is the
so-called 'extrinsic pathway' which predominates.
In reality, the process is not such a neat, stepwise cascade, but involves the production
of complexes of factors on the surface of platelets, with numerous feedback loops (both
positive and negative). For instance, the TF-FVIIa complex initially activates small
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amounts of FX directly, bypassing FIX. This allows the production of a small amount
of thrombin, which can activate factors V and VIII. The presence ofFVIIIa, allows far
greater amounts ofFXa to be produced by FIXa when it is activated by TF-FVIIa.
FXa is assembled in a complex on the platelet surface with calcium ions, and FVa,
which converts FII (prothrombin) to Flla (thrombin). Thrombin then converts soluble
fibrinogen, to insoluble fibrin monomers, which then self-assemble into a finrin clot.
Factor XHIa (activated by thrombin) completes the process by chemically cross-linking
the fibrin strands.
Coagulation inhibitors
If left unchecked, once activated, the coagulation process would quickly lead to clot
forming throughout the circulation - a defect which evolution was presumably quick to
rectify. A number of mechanisms exist to prevent this unwanted propagation.
TFPI.
Following initial activation of the cascade by TF, TFPI dampens down further
activation. Production of the FVIIIa-FIXa complex continues, possibly via thrombin
activation of the 'intrinsic' pathway.
Protein Cpathway.
This is an important means of preventing extension of clot formation to areas it is not
required. Following the formation of thrombin, in the presence of intact EC's, it is
bound to EC surface TM. This alters the configuration of thrombin, such that it is
unable to catalyse the conversion of soluble fibrinogen, but instead, binds and activates
PC. Activated PC (APC) is an inhibitor ofFVa and FVIIIa, its action being potentiated
10-fold by Protein S (PS) (also found on the EC surface). APC inactivates FV, by
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cleaving between amino acids 506 and 507. When the amino acid at 506 (arginine) is
replaced by lysine (factor V Leiden mutation), it is rendered resistant to cleavage by
APC - explaining the increased thrombotic risk in this condition.
AT.
AT (formerly ATIII) is produced by the liver, but is bound to EC surface. It acts by
forming a stable complex with several coagulation factors, including thrombin and FXa.
Its activity is enhanced 2000-fold by the presence of heparin.
Fibrinolysis
Plasmin
The final component of the haemostatic system to be discussed is the fibrinolytic
system. Plasmin is activated from plasminogen by one of its activators - tPA or
urokinase plasminogen activator (uPA). Activated plasmin degrades fibrin clot to fibrin
degradadation products (FbDP). However, plasminogen can only be activated, when it
has been incorporated into a fibrin clot, and 'protected' from the various fibrinolysis
inhibitors.
tPA
tPA is synthesised by EC's, but is rapidly inactivated by circulating inhibitors. As
mentioned previously, a number of stimuli, including thrombin, and exercise increase
the amount of tPA released by EC's. Because of the excess of tPA inhibitors which
rapidly bind tPA, circulating tPA is largely inactive. This is altered when it is bound to
fibrinogen, which increases its affinity for plasmin and its resistance to inactivation.
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uPA
This is so named because it was first extracted from urine. Although capable of
activating plasminogen, its primary role is thought to be in cell-signalling rather than
fibrinolysis.
Plasminogen activator inhibitor-1
This fast, specific inhibitor of tPA is also synthesised and secreted by EC's. It mostly
circulates in an inactive form bound to tPA
Plasminogen activator inhibitor-2
This is produced by the placenta from the eighth week of pregnancy onwards, and may
contribute to the inhibition of fibrinolysis seen during this period. It is not thought to
play a role in haemostasis outside this time.
Thrombin activable fibrinolysis inhibitor
Thrombin activable fibrinolysis inhibitor (TAFI) also known as procarboxypeptidase B,
is activated by thrombomodulin-bound thrombin, inhibits the activation of plasmin,
possibly by downregulating the co-factor effect of fibrin. The physiological role of the
connection between thrombin generation and fibrinolysis that TAFI provides is not
clear.
Summary
Figure 2.2, provides an overview of the preceding discussion. Despite its complexity,
this model has been reproduced in-vitro successfully, which would seem to confirm its
veracity.
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Figure 2.2 Coagulation cascade
'Extrinsic pathway'
FVII























HMW = High molecular weight
APC = Activated protein C
XL = Cross linked
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Chapter 3
The systemic response in intermittent claudication
Introduction
The last 15 years have seen a realisation that IC is accompanied by a complex systemic
response. This is secondary to the repeated ischaemia-reperfusion of the muscles in the
leg when patients with IC walk. The full clinical relevance of this repeated ischaemia-
reperfusion injury (IRI) is not fully understood, but there are theoretical reasons why it
may be harmful - both locally in the muscles which are repeatedly ischaemic and
reperfused, and systemically. The situation is complicated by the systemic
atherosclerosis which is almost universally present in patients with IC, and the effect
this has on EC function. The effects of IRI in claudication can be divided into two
types - cellular effects and non-cellular effects, although this distinction is somewhat
artificial, as there are complex interactions between the two.(Table 3.1)
Cellular effects
Neutrophil activation.
Neumann showed that exercise in claudicants leads to a rise in neutrophil count in the
*]s~
femoral vein of the leg affected by IC. Initially, this change is not seen in the femoral
artery of the same limb (systemic blood), but after 10 minutes, similar neutrophil counts
are seen systemically. There is also a decrease in the proportion of neutrophil able to
pass through a 8pm pore filter, indicating an increase in neutrophil activation. Other,
indirect indicators of increased neutrophil activation including serum lysozyme levels
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have been shown to rise in claudicants following exercise. Recently, more specific
markers of neutrophil activation have become available such as flow cytometry. This is
able to detect neutrophil expression of activation-specific surface markers (CD1 lb).
Using this technique, Turton showed that exercise in patients with IC is associated with
an increase in CD1 lb expression on neutrophils, which is not seen in healthy controls -
even with exhaustive exercise.78
Table 3.1 The systemic consequences of exercise in claudicants.
Taken from references 76; 79;80
Rise in neutrophil count
Neutrophil activation
Rise in thromboxane
Rise in von Willebrand Factor
Rise in microalbuminuria (glomerular
endothelial cell injury)
Fall in antioxidants
In addition to the activation of neutrophils directly by the ischaemic/reperfused muscle,
there is also indirect evidence of systemic activation of neutrophils. Patterson used
plasma taken from patients undergoing aortic surgery following clamp release, and
showed that it was capable of activating neutrophils.81 This 'circulating neutrophil
activator' has been proposed to be Interleukin 8, but has not been confirmed.
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In summary then, it appears that exercise in claudicants, leads to an increase in the
number of activated neutrophils, originating in the affected limb, and in response a
number of systemic effects.
Platelets.
Platelets may also be affected by exercise in claudicants, but the data regarding this are
conflicting depending on the methods used to measure platelet activation. Kirkpatrick,
showed that exercise in claudicants was associated with a rise in soluble P selectin
levels (a putative marker of platelet activation) when compared to controls. However,
Lewis, using flow cytometry, did not show any difference in platelet activation between
claudicants and controls.83 These studies, and the methods of assessing platelet
activation are discussed in more detail in a subsequent chapter. As yet therefore, it is
not clear, if and how platelets are affected by the IRI seen when patients with IC
exercise.
Non-cellular effects
Aside from the activation of neutrophils, there are marked biochemical effects of
ischaemia-reperfusion.(Figure 3.1) In the presence of ischaemia, xanthine
dehydrogenasse is converted to xanthine oxidase. Reperfusion provides the oxygen that
xanthine oxidase requires as a co-factor for the metabolism of hypoxanthine (which
accumulates in muscle ischaemia) to xanthine, with the generation of superoxide ion -
the source of oxygen derived free radicals (ODFR). These ODFR, which can also be
produced by activated neutrophils, result in numerous harmful effects which are
discussed below.
There is a substantial amount of data to suggest that ODFR are produced during
exercise in claudicants. Because of the very short half-lives ofODFR, they are difficult
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to measure, but their levels can be assessed by measuring their stable metabolites, such
as malondialdehyde (MDA), and/or a decrease in the amount of free-radical scavengers,
such as glutathione peroxidase, and selenium. Hickman et al showed that exercise in
claudicants results in an increase in MDA,84 while Edwards et al showed that at rest,
85claudicants have reduced free-radical scavenging.
Consequences of ischaemia reperfusion in IC
The production of activated neutrophils and ODFR in the exercising claudicant has a
number of potentially harmful effects.(Figure 3.1)
• Lipid peroxidation. ODFR lead to peroxidation ofcell membrane
phospholipids, damaging vascular EC.
• EC basement membrane damage. This is caused by elastase from activated
neutrophils, leading to an increase in vascular permeability.
• Neutrophil chemotaxis. ODFR activate phospholipase A2 in the EC membrane,
which produces arachidonic acid (AA) from cell membrane phospholipids. AA
is the precursor of important eicosanoids such as Thromboxane A2 (TXA2),
Leukotreine B4 (LTB4) and PGI2. Both TXA2 and LTB4 are chemotactic for
neutrophils, further increasing the inflammatory, and potentially damaging
process.
There is evidence ofEC injury following exercise in claudicants from numerous studies.
The majority of these use a measurement ofmicroalbuminuria as an indication ofEC
damage, which has been validated by experimental work in animals. This has shown
that following exercise, claudicants have an increase in urinary microalbuminuria,
which is not seen in non-claudicants.86 Further evidence of systemic cellular damage
was seen in a study by Iwata et al, who assessed intestinal permeability pre and post-
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exercise by measuring the differential absorption of lactulose and mannitol. Mannitol is
relatively well absorbed from the intestine, while in normal conditions, lactulose
remains largely unabsorbed (the basis for its use as a laxative). However, if the
intestinal mucosal cells are damaged, then lactulose may be absorbed across widened
cellular tight junctions. Therefore, systemic damage is seen as a rise in lactulose
absorption, with respect to mannitol absorption. In Iwata et al's study of 11 claudicants,
lactulose absorption rose significantly following exercise in claudicants, an effect not
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seen in a control group.
Figure 3.0 The consequences of ischaemia-reperfusion
Ischaemia-reoerfusion






Increase in vascular permeability
Edwards, in the study mentioned previously, also assessed EC damage, using vWF.
This EC product is thought to be released into the circulation following EC damage, and
has been widely used as a marker ofEC disruption - although this is not universally
accepted since it is also released from platelets. Edwards seemed to confirm that
exercise in claudicants, unlike in controls, is accompanied by EC damage as evidenced
or
by a significant rise in serum vWF levels.
What, if any, are the potential consequences of such systemic cellular damage? One
possibility is the progression of atherosclerosis. EC damage is one of the first events in
the development of atherosclerotic plaque. EC function (as indicated by decreased NO
production) is known to be poorer in patients with atherosclerotic risk factors but no
overt signs of vascular disease. To date however, there are no published studies which
have directly studied the effect of IRI in claudication on EC function, or the progression
of atherosclerosis, so this remains as a hypothesis.
It may also be speculated, that with the central role of the EC in haemostasis (Chapter




Thrombophilia in Peripheral Arterial Disease
Introduction
In addition to well-established risk factors such as smoking, diabetes,
hypercholesterolaemia and hypertension, an increasing number of novel humoral and
endothelial factors have recently been implicated in the aetiology and progression of
vascular disease. Thrombophilia may be defined as a propensity to thrombosis
QO
secondary to abnormalities in haemostasis. Thrombophilia has long been recognised
as contributing to venous thrombosis, but is increasingly associated with arterial
disease. It is important because screening may identify patients at high risk of
thrombosis who may then be offered prophylaxis. This chapter will focus on the
prevalence and significance of thrombophilic states associated with PAD and discuss
possible strategies for screening and treatment.
Prevalence of thrombophilia
General coagulation activation
If thrombophilia is important in PAD then there
should be evidence of activation of coagulation in
affected patients. Thrombin and fibrinogen, and
products of their metabolism, including thrombin-
antithrombin (TAT) complexes, prothrombin
fragments (PF) 1+2 and fibrin degradation
products (FbDPs) can be used to measure



























longitudinal93 epidemiological studies have demonstrated an association between
activation of coagulation and PAD. Furthermore, in 1988, Boneu showed that PAD was
associated with inhibition of fibrinolysis.94 In young patients (<51 years old)
undergoing lower limb revascularisation, as many as 76% may have a hypercoagulable
state (increased platelet aggregation or coagulation abnormality).95
Hey
A mild elevation of hey levels (hyperhomocysteinaemia) affects 5% or more of the
population and is increasingly recognised as an independent risk factor for
atherosclerosis and thrombosis.96 Hyperhomocysteinaemia can cause increased Factor
V activity, possibly via a decrease in thrombomodulin cell surface activity and a
corresponding decrease in APC.97"100 The prevalence of hyperhomocysteinaemia in
PAD may be between 50 and 60%101"103and many cross-sectional studies have
demonstrated a clear association between plasma homocysteine levels and PAD.104
AT
AT is an endogenous anti-coagulant,
produced by the liver, which inactivates
thrombin and Factor Xa. Deficiency ofAT is
inherited in an autosomal dominant fashion.
In a population-based study of 7983 subjects
over 55 years old 3.1% had deficiency of AT,





























Fibrinogen is the substrate on which the end-
product of the coagulation cascade, thrombin,
acts to produce fibrin, and ultimately, a blood
clot. Its effects are diverse and include
increases in blood viscosity, red cell
aggregation, platelet aggregation and
































arterial intima may also lead to smooth
muscle cell proliferation and leukocyte
migration.107"110 Flyperfibrinogenaemia has
long been associated with cardiovascular disease and is present in more than 50% of
patients with PAD.111"113
Antiphospholipid antibodies
Antiphospholipid antibodies (aPL) are a
group of auto antibodies originally thought
to be targeted towards negatively charged
phospholipid, although recent work
suggests that they are directed against P2-
glycoprotein I.114 aPLs are of two types,
detected by different laboratory methods:
the anticardiolipin antibody (aCL) enzyme






































anticoagulant (LAC) coagulation assay. Although the lupus assay relies on the in-vitro
effect of aPL to prolong coagulation assays, the in-vivo effect is procoagulant, the
mechanism for which is uncertain. Antiphospholipid antibodies may inhibit protein C
and protein S, and have prothrombotic effects via enhanced platelet reactivity or
endothelial cell surface molecules such as heparan sulphate and tissue factor.114
Cross-sectional studies have shown that the prevalence of aPL amongst patients with
PAD requiring intervention varies between 26% and 45%.I15"117 This mostly comprises
patients with aCL who constitute 84%-94% the total. A small proportion of patients
with aPL have both LAC and aCL (2%-3%).115,117; 118 No studies have yet compared
the prevalence of aPL in PAD with the prevalence in the general population, and no
large cross-sectional studies have been performed to give a population prevalence of
aPL.
PC deficiency
PC is a vitamin K dependent protein
which, when activated by the
thrombin-thrombomodulin complex,
inactivates factors Va and Villa. PC
deficiency is established as a risk
factor for venous thrombosis, but its
role in arterial pathology is less
clear. Few studies have investigated
the prevalence of PC deficiency in







































claudicants, deficiency of PC was found in 2 (1.7%).118 Other studies have shown the
prevalence of PC deficiency to be between 2.5 and l5°/° in PAD patients, but no
comparisons were made with control groups.95'119-121
APC Resistance /Factor VLeiden
APC resistance is the most common inherited
risk factor for thrombosis. The prevalence
varies in different ethnic populations; in UK
it is 3.5-4.9%, Africans 0% and in Cyprus
13%.122'123 The most common cause ofAPC
resistance is a mutation in the factor V gene
leading to the replacement of Arginine 506
with Glutamine, (Factor V Leiden, [FVL])
which renders it more resistant to degradation
by PC. This is responsible for 90-95% of
APC resistance, the remainder of which is
made up of acquired conditions such as aPL, pregnancy and the oral contraceptive
pill.124-127 APC resistance is measured using a plasma assay and exogenous APC, and is
indicated by a lowering of the APC ratio (normal range 2.2 to 2.6). This will identify
the majority, but not all of patients with FVL. FVL may also be identified directly
using genomic analysis, but not all mutations lead to lowering of the APC ratio. FVL is
thought to underlie 18%-30% of venous thromboses, but its importance in arterial
disease is less well defined.
Both APC resistance and FVL have been demonstrated to be more common in patients
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FVL and APC resistance (defined as ratio <2.6) to be higher (26.4%) in 359 patients
with PAD than in 278 controls (12.2%).128 A smaller study by Foley in patients who
had undergone lower limb arterial bypass surgery reported a 17.8% prevalence ofFVL,
compared with a local population prevalence of 3.5%.122 Evans only reported one
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positive APC resistant patient in 116 claudicants . Variations in these reported figures
may be explained by the preferential use ofDNA analysis or APC ratio to define FVL;
variations in the lower end of the normal range for defining the normal APC ratio and

























PS is a vitamin K dependent plasma protein
and an essential co-factor for the anticoagulant
and profibrinolytic effect of APC.129 PS
deficiency has been identified as a cause of
venous thrombosis, and more recently has
been proposed as a factor in arterial disease.
The prevalence of PS deficiency in the general
population is thought to be around 0.7%.
130There are only a few small studies
investigating the prevalence of PS deficiency
in PAD. Allart in 1990 showed PS deficiency to be present in 3 out of 45 patients (8%)
less than 45 years old who required surgical treatment for PAD.129. A study of 33
patients undergoing arterial surgery, and 10 controls found a prevalence of PS
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A G to A transition at position 2021OA of
the prothrombin gene is associated with
an increased risk of venous thrombosis,
although the underlying mechanism is
not clear. The prevalence of this
mutation is 1.2% to 4.3% in patients with
venous thrombosis, 5.7% in patients with
PAD, and 0.7% in controls.1321 133
However, no specific studies have been
performed investigating the association
between prothrombin 2021OA and
arterial disease.
Despite studies screening for different states, using a variety of methods, in patients
with a range of disease severity, it is clear that there is an increased prevalence of
thrombophilic states in PAD, perhaps as high as 60%. Although common, the clinical







Studies ofgeneral coagulation activation
There is a correlation between the level of coagulation activation and the severity of
PAD as determined by walking distance91, ankle-brachial pressure index (ABPI)134'135,
duplex ultrasonography, angiography136 and clinical symptoms112. For example, Ray
reported the prevalence of thrombophilia (PC deficiency, PS deficiency, AT deficiency,
LAC) to be 11% in controls, 27% in claudicants and 40% in patients who had received a
revascularisation.121
The importance of a hypercoagulable state in PAD has also been revealed through the
association between coagulation abnormalities and the progression of PAD. In the
Edinburgh Artery Study, whole blood viscosity, plasma viscosity and fibrinogen levels
were predictive of the requirement for vascular intervention,137 or fall in ABPI,93 over a
six year follow-up period. Furthermore, whole blood viscosity, and fibrinogen levels
have been shown to be predictive for the progression ofPAD as determined by walking
distance.138
Thrombophilic states may also be important causes of failure of arterial interventions.
In 1994, Ray studied 124 patients undergoing arterial reconstruction and reported 75
graft occlusions after a mean follow up of 44 months.121 Almost half (49%) of these
were subsequently identified as having a thrombophilia, compared with 27% of patent
reconstructions. Abnormalities identified in the graft occlusion group were: PC
deficiency (21% of occlusions), PS deficiency (17%), LAC (25%) and multiple
abnormalities (12%). A subsequent prospective study, investigated the presence of a
thrombophilia prior to arterial reconstruction in 60 patients with one-year follow up. 139
A pre-operative thrombophilia was identified in 65% of patients whose graft
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subsequently occluded within one year, compared with 20% of those with a patent graft
(P < .05). The presence of thrombophilia was particularly significant in early graft
failures, where 11 of the 12 occlusions within one month had a pre-operative
hypercoagulable abnormality. A prospective study of 137 patients undergoing a
mixture of arterial reconstructions identified 14 patients (10%) with a hypercoagulable
state.120. Three of these patients (27%) suffered a graft thrombosis within 30 days,
compared with two of 123 patients with a normal thrombophilia screen (1.6%). Eldrup
Jorgensen studied 20 young (<51years old) patients undergoing aorto-iliac (7) or infra-
inguinal (13) vascular surgery.95 Four patients suffered an early (<30 days) post¬
operative thrombosis, all of who had thrombophilia identified pre-operatively. Patients
with multiple coagulation abnormalities appear to be at special risk. Thus, of 124
patients undergoing revascularisation studied by Ray, 11 had multiple thrombophilias,
all of whom had had a previous revascularisation. Nine of these patients had a further
occlusion during the follow-up period.121
Hey
Hyperhomocysteinaemic patients have an increased rate of vein graft stenosis and
increased failure of bypass grafts and angioplasty. ,03; 140 Patients undergoing peripheral
arterial bypass surgery with elevated homocysteine have evidence of pre-existing
intimal hyperplasia in saphenous vein biopsies.102 A prospective study investigating
hyperhomocysteinaemia and progression of PAD, with mean follow-up of 37 months
found a trend towards an association, but this was not statistically significant.141 This
may, however, represent a type II error as only a relatively small number of patients
(22) were judged to have progression ofPAD during follow-up.
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Fibrinogen
Fibrinogen levels correlate with the severity of PAD, higher levels being associated
with more severe disease, as determined by claudication distance,112 angiography,142; 143
and ABPI.134' 136; 144 Hyperfibrinogenaemia has been shown to be predictive for the
progression of PAD, as measured by change in claudication distance,138 or the
requirement for intervention.137
Given that hyperfibrinogenaemia is associated with the development and progression of
PAD, it is unsurprising that high levels of fibrinogen are predictive of failure of
interventions for PAD.145 Prospective studies have shown that hyperfibrinogenaemia is
associated with failure of vein and prosthetic femoral popliteal bypass grafts. In
additon, associations have been demonstrated between raised fibrinogen levels and graft
stenosis, implying that it is not simply an increased thrombotic tendency underlying the
failure of such interventions.145"147 Data regarding fibrinogen and patency following
percutaneous angioplasty are conflicting. Two prospective studies have shown that
hyperfibrinogenaemia is associated with poorer patency rates, while another prospective
study showed that high fibrinogen levels measured prior to angioplasty were associated
with improved patency rates.148"150
At present there are no selective treatments available to lower fibrinogen and
consequently no reported trials confirming benefit in treating hyperfibrinogenaemia.
While there is a great deal of evidence associating fibrinogen levels and PAD, it is
difficult to conclude that this relationship is causal until such trials are available.
Fibrinogen is an acute phase protein, and its increased levels in arterial disease may
merely be representative of an underlying low-grade inflammatory process.
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aPL
No studies to date have demonstrated an association between the prevalence of aPL and
the progression of PAD. However, aPL and the antiphospholipid syndrome are
associated with an increased risk of thrombotic complications of vascular surgery,
although the majority of these studies are retrospective.151"154 Ahn retrospectively
identified seven patients with aPL who underwent a total of 18 vascular procedures.155
Three of these patients, none of whom were anticoagulated developed multiple post¬
operative thrombotic complications and all eventually required amputation. The
remaining four vascular patients in this study were taking steroids, anticoagulants, or
vitamin K at the time of the initial operation. A similar study found that 16 of 19
patients with aPL undergoing a vascular procedure suffered a thrombosis, 12 of who
died.156 In a retrospective report of 234 patients undergoing vascular surgery, aPLs
were associated with a shorter bypass patency period (17 v 58 weeks) and a risk of
occlusion that was 5.6 times greater than patients without aPLs.152
The only prospective study to investigate the association between aPL and the outcome
of vascular intervention, showed a trend towards the presence of aPL and failure of
arterial bypass surgery, but this did not reach statistical significance.157 This result is
unfortunately confounded by the fact that, significantly more of the aPL group were
anticoagulated post-operatively thus diminishing any likely difference between the
groups.
AFC resistance /FVL
Ouriel prospectively monitored 76 patients who underwent lower limb revascularisation
for a mean of 47 months. 60% of those with APC resistance (defined as APC ratio
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<2.0) had an occlusion of their graft, while only 24% of those without APC resistance
suffered a graft failure (P < .02).158 A similar finding was seen in Sampram's study in
which 32% of those with fVL and 49% of those with APC resistance suffered a graft
occlusion (both P < .001).159 A study from Foley et al reported no association between
fVL and graft occlusion, but excluded patients whose graft occluded within six weeks
of surgery, a time that others have reported as important in graft occlusion associated
with thrombophilia160.
PS deficiency
Although the prevalence of PS deficiency is higher in patients with PAD, its
significance is unknown. Allart investigated the families of young (<45 years old) PAD
patients who were found to be heterozygotes for PS deficiency, but no association was
found between likelihood of PS deficiency, and arterial thrombosis.161 This finding
corroborated a previous study, which showed that relatives of PS deficient individuals
did not have an increased incidence of arterial thrombosis.162
Deficiency of PS was identified in 4 of 20 patients (20%) whose arterial reconstruction
failed compared with 6 of 40 (15%) of those with a successful reconstruction at 30 days
post surgery, although this difference did not reach statistical significance.161
AT deficiency
In Van der Bom's population study, examination of 7983 subjects revealed a complex
relationship between level ofAT and ABPI.163 In men, mild PAD was associated with a
high level of AT, while severe PAD was associated with lower levels ofAT. Whilst in
women, there was in an inverse relationship between ABPI and AT level. The authors
suggest that levels of AT rise in the presence of cardiovascular disease as a protective
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mechanism, but as vascular disease progresses, AT becomes consumed, leading to
lower levels. The reason for the difference between the sexes is not clear.
The poor results of intervention in patients with thrombophilias, in terms of intervention
failure and mortality, reinforce the clinical importance of these states in patients with
PAD. The presence of two or more co-existent thrombophilias, seems to have an
additive effect, and be particularly dangerous clinically. However, many thrombophilic
states may be asymptomatic for many years and the 'two-hit' hypothesis suggests that
thrombophilic states only become apparent when a subject is exposed to some other




The British Committee for Standards in Haematology identified 10 groups of patients
who should be screened for thrombophilia (Table l).164 The treatment of thrombophilic
abnormalities is complex, and the decision for treatment, which may be lifelong
anticoagulation, should only be made after careful consideration of the patient, the
individual thrombophilia and any triggering factors that may have precipitated a
previous thrombosis. It is our recommendation that such patients are referred to a
haematologist.
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Table 4.1 Patients to be investigated for thrombophilia.
1 Venous thromboembolism before the age of 40-45 years
2 Recurrent venous thrombosis or thrombophlebitis
3 Thrombosis in an unusual site, eg mesenteric vein, cerebral vein etc
4 Unexplained neonatal thrombosis
5 Skin necrosis, particularly if on coumarins
6 Arterial thrombosis before the age 30 years
7 Relatives of patients with thrombophilic abnormality
8 Patients with clear family history of venous thrombosis
9 Unexplained prolonged activated partial thromboplastin time
10 Patients with recurrent foetal loss, idiopathic thrombocytopaenia or
SLE
For patients with PAD who do not fall into one of the groups in Table 4.1,
thrombophilia screening is still likely to reveal an abnormality in approximately 30 -
60% of patients. In those who are not undergoing a vascular intervention, there is no
evidence to suggest that treatment of the thrombophilia will alter the progression of
arterial disease. There is evidence however, that patients with a thrombophilia
undergoing a vascular intervention have a poor prognosis, with increased risk of graft
occlusion, limb loss and death, and this can be partially offset by treatment. It is
therefore recommended that all patients undergoing a vascular intervention should be
screened for a thrombophilic tendency.
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Testing for thrombophilia should depend on the individual abnormality.
Antiphospholipid antibodies, activated protein C resistance, and
hyperhomocysteinaemia are the commonest abnormalities, and should form the basis of
a thrombophilia screen. Screening for PC and PS deficiency, prothrombin 2021OA, and
AT deficiency may be useful, but likely to yield less positive results, although no less
significant.
Assays for hey have previously been difficult to perform, due to the requirement for
immediate cooling of the sample and separation within 1 hour. New techniques are
being developed to improve the stability of blood samples for hey analysis, increasing
the ease by which homocysteine assays can be performed.165; 166
The cost of thrombophilia screening is used as an argument against its use. However, if
screening were targeted to high-risk groups, such as those in Table 4.1, or those
undergoing intervention, the cost of screening may be offset against the reduced risk of
failure of vascular intervention. The treatment of intervention failure may include
prolonged hospital stay, repeated intervention, or amputation, all with significant costs.
A more detailed cost-benefit analysis is beyond the scope of this article, and would be
difficult to perform given that the lack of trials in this area means the true benefit of
screening and/or treatment cannot be quantified.
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Treatment
Although numerous different treatments are available for thrombophilias, they have not
been formally studied in patients with PAD to determine whether improved outcomes
can be attained.
Hyperhomocysteinaemia.
Patients with hyperhomocysteinaemia, who are undergoing a vascular intervention,
should be treated with hey lowering therapy prior to surgery if there is sufficient time.
If the surgery is urgent, consideration should be given to formally anticoagulating these
patients until the level of hey can be reduced. Hyperhomocysteinaemia may be
corrected simply with folic acid, and vitamins B]2 and/or B6, although it has yet to be
demonstrated whether such treatment will lead to a reduction in cardiovascular risk or
improvement in patency rates. Trials are presently being undertaken to determine
whether lowering homocysteine levels is beneficial in terms of outcome for vascular
patients both in PAD and in cardiac and cerebrovascular disease. It seems sensible in
the absence of current evidence however, to lower homocysteine levels in PAD patients
undergoing intervention.
Anticoagulation.
Anticoagulation in non-thrombophilic patients is of benefit in femoro-popliteal bypass
grafts when compared with no treatment, but when compared to aspirin, the data are
conflicting. 167 The largest study was a multicentre, randomised controlled trial
investigating the effectiveness of oral anticoagulation (to maintain an INR 4.0-4.5)
against aspirin (80mg daily) in 2690 patients undergoing infrainguinal bypass
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surgery,168 which showed no overall benefit of either treatment in preventing graft
occlusion. Patients with aPL who are anticoagulated (with heparin and subsequently
warfarin) when they underwent vascular surgery were noticed to suffer fewer
complications155. No studies to date have prospectively investigated the use of
anticoagulation in PAD patients with a thrombophilia. However, Khamashita et al
retrospectively studied the effectiveness of anticoagulation in patients with
antiphospholipid syndrome.169 They showed that anticoagulation with warfarin to an
international normalised ratio (INR) of >3 was significantly more effective in
preventing recurrent thrombosis than anticoagulating to an INR < 3, or aspirin. This
study was not confined to patients with PAD, but is significant in demonstrating a
benefit of aggressive anticoagulation in thrombophilia.
Steroids.
Whilst the thrombophilias discussed previously are not thought to be associated with a
vasculitis, patients with the lupus anticoagulant who are taking steroids seem to have a
reduced thrombotic risk.155 The protective effect of steroids in conjunction with aspirin
has been demonstrated previously in obstetric patients, and leads to a decrease in lupus
anticoagulant levels.170 There are no data on the use of steroids for PAD patients with
thrombophilia.
Anti-platelet agents.
Aspirin is beneficial in obstetric patients with the lupus anticoagulant.171 The use of
aspirin has not been investigated in PAD with a thrombophilia, but it is suggested that it
be used in patients with aPL, with no history of thrombosis. Patients with aPL
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undergoing surgery, or with a history of thrombosis should be formally anticoagulated,
as these patients are at high risk of thrombosis.
Factor replacement.
An alternative treatment for patients with PC and PS deficiency undergoing surgery is
the use of peri-operative fresh frozen plasma or PC concentrate. In the case of
peripheral vascular surgery, patients will usually require formal anticoagulation to
ensure the patency of the graft.
Nucleic acid therapy.
Recently, oligonucleotides have been shown to have in-vitro anticoagulant effects
through specific protein binding.172 It remains to be seen whether this will translate into
improved outcomes in thrombophilias.
Summary
The evidence to date supports an association between certain thrombophilias and
peripheral vascular disease. Hyperhomocysteinaemia, hyperfibrinogenaemia, APC
resistance and aPL syndrome are more common in PAD, but there is no clear evidence
for the other thrombophilias.
Thrombophilic states in general are associated with an increased failure rate of vascular
reconstruction. This is particularly marked when considering patients with multiple
thrombophilias, and early intervention failures. No conclusive evidence yet exists to
show that treatment of these thrombophilic states can lead to an improvement in the
course of PAD, or the results of intervention. While it may be appropriate to
anticoagulate patients identified with a thrombophilia who are undergoing a vascular
intervention, it cannot yet be justified to recommend screening of all patients with PAD
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for thrombophilia. There is a pressing need for well-designed trials of therapeutic




The excess number of deaths suffered by patients with IC can only be partly explained
by the presence ofwidespread atherosclerotic disease.2 Most of this higher than
expected morbidity is due to the thrombotic complications of systemic atherosclerosis.
It therefore seems plausible that claudicants may suffer from a prothrombotic tendency.
As one of the main differentiating factors between patients with IC, and patients with
other manifestations of atherosclerosis is the repeated ischaemia-reperfusion of a large
muscle mass, this could be the source of any haemostatic disturbance.
From the literature reviewed in Chapter 4, it can be that patients with peripheral arterial
disease have a higher prevalence of thrombophilia than the general population.
However, the majority of these were inherited abnormalities, and are unlikely to be
secondary to IR.
It would seem to be biologically plausible that IR in claudicants could lead to
disturbances in haemostasis. The studies presented in Chapter 3 show that IC is
accompanied by a significant systemic response, much ofwhich leads to EC
disturbance. As the EC plays such a pivotal role in haemostasis (Chapter 2), it is
entirely probable that such a disturbance could have effects on the coagulation system.
Further coagulation disturbance could occur via platelet involvement - which may also
be affected by IR in claudication (Chapter 2).
In summary, therefore, the hypothesis is that the ischaemia-reperfusion seen during
exercise in patients with IC, is associated with disturbances in haemostasis, which may
contribute to the excess number of deaths seen in this population.
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Chapter 5
Thrombin Production in Intermittent Claudication.
Introduction
In general terms, the haemostatic system can be thought of as a balance, with fibrin
production on one side and fibrin breakdown (fibrinolysis) on the other. Thrombin is
the enzyme which converts fibrinogen to fibrin, and therefore anything which increases
thrombin production may contribute to the high number of thrombotic events
claudicants are known to suffer.
As exercise in claudicants is associated with a well described systemic inflammatory
response, it would perhaps be surprising if the coagulation system were unaffected. We
therefore studied the effect of exercise in claudicants on the coagulation system. This
chapter will examine thrombin production, and the next chapter will investigate the
effect on fibrinolysis.
Hypothesis
Exercise in patients with IC, leads to an increase in the production of thrombin, and
fibrin, when compared to a non-claudicant population.
Aim
To compare the production of thrombin, using several biomarkers, in claudicants, and




40 male subjects were recruited, 20 patients with intermittent claudication, all current
cigarette smokers; 20 patients with no evidence ofperipheral arterial disease, 10
smokers and 10 non-smokers. Every alternate claudicant was age matched +/- 3 years
to a smoking, and non-smoking control. Inclusion and exclusion criteria are presented
in Tables 5.1 and 5.2.
Table 5.1 Inclusion and exclusion criteria for claudicants.
Inclusion criteria Exclusion criteria
Male
Claudicant, as defined by Edinburgh
Claudication Questionnaire, for > 6
months
Resting ankle-brachial pressure index
<0.8
Diabetes mellitus
Haemoglobin concentration < llg/dl
Current viral infection
Absolute claudication distance 25-300m Current therapy with: warfarin
Walking unrestricted by co-morbidity
other than claudication
Smoker of equivalent of at least 20
cigarettes per day, for >10 years
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Table 5.2 Inclusion and exclusion criteria for smoking and non-smoking controls.
(* smoking controls only, f non-smoking controls only)
Inclusion criteria Exclusion criteria
Male
No history of peripheral arterial disease
Palpable pedal pulses, and resting ante¬
brachial pressure index >1.0
Walking unrestricted by co-morbidity
*Smoker of equivalent of at least 20
cigarettes per day, for >10 years
jNon-smoker for > 15 years
Diabetes mellitus
Haemoglobin concentration < 1 lg/dl
Current viral infection
Current therapy with: warfarin
Methods
The study was approved by the Local Research and Ethics Committee. All subjects
signed a written consent form (Appendix 1).
Subjects attended the Vascular Studies Unit on two occasions: a screening visit and an
assessment visit. All studies were conducted in a quiet, temperature controlled room,
maintained at 25°C to 28°C.
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Screening visit. Subjects were screened to ensure they fulfilled the inclusion and
exclusion criteria. This consisted of:
• History and examination, including documentation of lower limb pulses.
• For claudicants, completion of the Edinburgh Claudication Questionnaire.5
• Calculation ofABPI as follows:
o Measurement of systolic blood pressure in both arms,
o Measurement of systolic blood pressure in posterior tibial, and dorsalis
pedis arteries, in both feet,
o ABPI was calculated for each leg by dividing the highest pressure for
that limb, by the highest arm pressure.
• Treadmill test, with recording ofmaximum walking distance as follows:
o Subjects walked on a motorised treadmill, at 3.5 km/h, at a gradient of
12°
• Blood sampling, for measurement of full blood count.
If subjects fulfilled all inclusion and exclusion criteria, they returned for an assessment
visit, within 3 weeks of screening.
Assessment visit. Subjects were transported to the hospital by taxi, and transferred from
the drop off-point to the vascular laboratory by wheelchair to avoid walking. During
the whole visit, subjects did not exercise other than on the treadmill. Those requiring to
visit the toilet were taken by wheelchair. Subjects were asked to abstain from smoking,
or eating heavy meals for 1 hour prior to arrival, and were told to avoid unaccustomed
exercise in the preceding 24 hours.
Upon arrival, the subject was seated in a quiet area, and an 18 gauge cannula inserted in
the right ante-cubital fossa, which was kept patent with boluses of 0.9% saline. After
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60 minutes, and 90 minutes, blood was drawn through the cannula. Details of blood
collection at each time point are presented below (Table 5.3). After sitting for a total of
120 minutes, subjects underwent a standard treadmill exercise. Subjects walked at
3.5km/hr, at a gradient of 12° until maximum claudication distance (claudicants), or for
3 minutes (controls). The subject then returned to his seat, and blood was collected at
the following times following the end of exercise: 1 minute, 5 minutes, 20 minutes, 40
minutes, 60 minutes and 120 minutes.(Figure 5.1) Following the last blood sample,
subjects were given something to eat and drink, had their pulse and blood pressure
checked, and were allowed to leave ifwell.
Figure 5.1 Outline of blood sampling protocol
Exercise
I * UJL I Iz
-60 -30 20 40 60 120
Times refer to minutes prior to the start of exercise, and minutes post-cessation of
exercise (not to scale).
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Table 5.3 Details ofblood collected at each time point
Sample
No
Tube(s) Tube type For measurement of:





D-dimer, PF 1+2, Fibrinogen, PT,
APTT
3 lx 4.5ml Stabilyte tPA activity/ antigen, PAI-1
activity/ antigen, APC-PCI
4 lx 10ml SCAT-2 FbDP, PAP, TPAPAI-1, TAT
5 lx 4.5ml EDTA Tube ESR
All blood was drawn without venous occlusion. PT = prothrombin time; APTT =
Activated partial thromboplastin time; APC-PCI = Activated Protein C-Protein C




Five samples were taken at each time point, they are detailed in Table 5.3. Each tube
was gently inverted five times, and then placed immediately on ice. Subsequent
handling was as follows;
• Tube 1. Discarded
• Tube 2. Kept in ice-water for 10 minutes, then centrifuged at 2000g for 15
minutes at 4°C. The supernatant (platelet-free plasma) was then aliquoted into
cryovials for storage at -80°C and later batch analysis. 100pi of sample was
used for measurement ofprothrombin time (PT) and activated partial
thromboplastin time (APTT) (detailed below).
• Tube 3. Kept in ice-water for 10 minutes, then centrifuged at 2000g for 15
minutes at 4°C. The supernatant was then aliquoted into cryovials for storage at
-80°C and later batch analysis.
• Tube 4. Kept in ice-water for 10 minutes, then centrifuged at 2000g for 15
minutes at 4°C. The supernatant was then aliquoted into cryovials for storage at
-80°C and later batch analysis.




Full blood count. These were performed in the Department ofHaematology,
Birmingham Heartlands Hospital using a Bayer Advia 120 (Bayer, UK).
PT and APTT. This was performed using near patient-testing equipment (Rapidpont
Coag, Bayer, UK), within 30 minutes of sampling. Each analysis required the transfer
of 50pl of citrated plasma onto the appropriate test card, placed in the analyser. Quality
control specimens were run at the start and end of each day.
Fibrinogen, PF1+2, TAT. These assays were all performed using commercially
available kit assays as detailed in Table 5.4.
ActivatedProtein C-Protein C Inhibitor (APC-PCI). This assay was performed using
the method of Stenflo.173
ESR. Samples were batch analysed at the end of each day using a Starsted Automatic
ESR analyser in the Department ofHaematology, Birmingham Heartlands Hospital.
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Table 5.4 Summary of assays.
Biomarker Manufacturer Reference range Lower limit of
quantification
Fibrinogen Dade-Behring (IL,USA) 180-400mg/dl 17mg/dl
TAT Dade-Behring (IL,USA) 0-5ng/ml 0 ng/ml
PF 1+2 Dade-Behring (IL,USA) 0.4-1.8nmol/l 0 nmol/1
Statistical methods
Summary variables for each biomarker were calculated for the periods pre and post-
exercise by calculating the area under the curve (AUC).(Figure 5.2). Groups were
compared pre, and post-exercise with the Kruskal-Wallis test. Where this returned a
value ofP<0.05, the Mann-Whitney U test was used to identify the groups which had
significantly different values. A value of P<0.05 was taken to be statistically
significant.
SPSS version 11.0.0 package (Statistical Package for Social Sciences Inc, Chicago, IL,
USA) was used for all statistical analysis.
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Total AUC — area ofA+B+C+D+E+F+G+H.
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Results
All data are presented as median and interquartile range (IQR) unless otherwise stated.
Preliminary analysis revealed subject 007 (claudicant) had very high levels ofAPC-
PCI, D-dimer and FbDP. This individual was known to have a small abdominal aortic
aneurysm (AAA), which was thought to be the cause for the coagulation abnormalities.
Therefore, it was decided to exclude other subjects who were known to have an AAA
(subject 103, and subject 111 - both smoking controls).
Subjects.
Details of the remaining subjects for analysis in the three groups are shown in Table 5.5.
There was no significant differences between the groups with regards to age or body
mass index. There was a higher prevalence of chronic obstructive airways disease in
the claudicants compared to the control groups and claudicants were also more likely to
be taking aspirin. There was no significant difference in cholesterol levels between the
three groups.
83
Table 5.5 Subject details
Controls
Claudicants Smokers Non-smokers P=
a\Ite n=8 n=10
Age, years (IQR) 63 (57-70) 65 (60-70) 66 (58-70) 0.742*
Body mass index, kg/m2 23.6 24.5 25.4 0.137*
(IQR) (21.7-26.0) (23.4-26.7) (23.4-28.5)
Smoking
pack years 44 45 0 <0.001*
Medical history
CAD 4 0 1 0.320f
CVD 0 0 0
HT 4 2 0 0.260f
COAD 6 0 0 0.034t
Medication
Aspirin 13 1 1 0.002f
B-blocker 1 0 1 0.647f
Nitrate 1 0 0 0.615f
Ca blocker 3 0 0 0.213f
ACEI 2 1 1 0.984f
PAD
Lowest ABPI 0.56 1.09 1.12 <0.001*
Walking distance, m, 82 174 174 <0.001*
(IQR) (64-174) (170-174) (174-174)
Cholesterol, mmol/1 4.7(4.1-5.6) 5.2 (4.8-6.6) 4.5 (4.4-5.1) 0.274*
(IQR)
CAD = coronary artery disease (angina, myocardial infarction or coronary bypass
surgery); CVD = cerebrovascular disease (transient ischaemic attack or stroke); HT
hypertension; COAD = chronic obstructive airway disease; Ca blocker = calcium
channel blocker. *=Kruskal-Wallis Test. f=Fisher's Exact Test.
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ESR
(Figure 5.3) ESR was significantly higher in claudicants compared to controls before
and after exercise.












Data are presented as medians with interquartile ranges. *=Tntermittent claudicants vs




(Figures 5.4, 5.5) PT was slightly higher in both smoking groups (claudicants and
smoking controls) than non-smokers. All groups showed a prolongation of the PT after
exercise, but this was more marked, and lasted longer in the smokers. APTT was
similar in all groups with no obvious effect of exercise.
Figure 5.4 Plot ofPT with time for the three subject groups
Data are presented as medians with interquartile ranges. *=Kruskal-Wallis Test
comparing all three groups.
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Figure 5.5 Plot ofAPTT with time for the three subject groups
Time (Minutes)
Data are presented as medians with interquartile ranges. *=Kruskal-Wallis Test
comparing all three groups.
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Fibrinogen.
(Figure 5.6). This was significantly higher at baseline in claudicants compared to non-
smokers, but similar to smoking controls. Smoking controls had significantly higher
levels than non-smoking controls. Exercise had no perceptible effect on fibrinogen
levels in claudicants or controls.









-60 -40 -20 20 40
Time points
60 80 100 120
Data are presented as medians with interquartile ranges. *=Intermittent claudicants vs




(Figures 5.7 and 5.8) TAT and PF 1+2 are formed when thrombin is produced. Levels
were similar in all three groups prior to exercise, but following exercise, TAT was
significantly higher in the claudicants compared to controls, although PF1+2 levels
were not significantly different
Figure 5.7 Plot ofTAT with time for the three subject groups
.Data are presented as medians with interquartile ranges. *=Intermittent claudicants vs
Smoking controls, f= Intermittent claudicants vs Non-smoking controls. Both Mann-
Whitney U Test.
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(Figure 5.9) When formed, thrombin is bound to thrombomodulin on the endothelial
cell surface. This complex activates Protein C, an important mediator in negative
feedback in the coagulation cascade, and also the activator of thrombin-activable
fibrinolysis inhibitor (TAFI). Protein C, is quickly bound by its specific inhibitor
(Protein C inhibitor), and it is this complex which was assayed. Levels of APC-PCI
were similar between the groups at baseline, but were higher in the claudicants
following exercise, but this failed to reach statistical significance.
Figure 5.9 Plot ofAPC-PCI with time for the three subject groups.
Time points
Data are presented as medians with interquartile ranges. *=Kruskal-Wallis Test
between all three groups.
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Discussion
This study has, shown that exercise in claudicants is accompanied by increased
generation of levels ofTAT and APC-PCI when compared to matched controls,
suggesting increased fibrin formation. We did not show a difference in PF1+2 levels
between groups, before or after exercise, and we are unable to explain this. PF1+2 have
a longer half life than TAT (90 minutes vs 15 minutes), so may be less responsive to
acute events such as the exercise in this study. However, given the findings that
claudicants seem to have increased levels of thrombin production, we might expect to
have found elevated levels ofPF1+2 in the claudicants at rest, which was not the case.
Three previous studies have examined thrombin production in exercising claudicants
(Table 5.6). Two of these studies showed that in contrast to our data, levels of thrombin
generation (as indicated by TAT and PF 1+2) were higher at baseline in claudicants
compared to controls.90'91 In addition, they did not demonstrate a response to exercise.
The baseline differences in these two studies are probably accounted for by the controls
and claudicants being poorly matched. De Buyzere does not mention smoking or
diabetic status in his paper. Herren's claudicant and control groups were poorly
matched for smoking status (50% current smokers vs 8%), hyperlipidaemia (36% vs
9%) and hypertension (50% vs 38%). As these conditions have all previously been
shown to influence levels ofPF 1+2 and TAT, this could explain the baseline
differences between the two groups.174 176 This is confirmed by the study by Mustonen,
who compared claudicants and controls who were well matched for all these factors.177
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He demonstrated that levels of thrombin generation were similar at baseline in
claudicants and controls, and that claudicants, but not controls had a rise in thrombin
generation following exercise - the same as our findings.
Table 5.6 Previous studies of thrombin generation in claudicants
Author and Subjects Sampling Baseline Effect of Notes
year time points differences exercise
De Buyzere 34 30 minutes rest TAT, PF No change No mention made of
199391 claudicants before sampling higher in in either number of diabetics,
30 age, sex- Sampled 'before claudicants group with smokers, or
matched and after'. exercise hypertensives
controls
Herren 22 3 minutes TAT, PF No change Groups poorly
199490 claudicants before and after higher in in either matched for smoking,
13 age, sex- exercise. No claudicants group with hypertension,
matched mention of rest exercise hyperlipidaemia.
controls prior to
sampling
Mustonen 15 15 minute rest. TAT levels Increase in Matched for smoking,
1997177 claudicants Sampling equal in TAT in hypertension,
15 age, sex before, and claudicants claudicants, hyperlipidaemia and
matched immediately and controls no change diabetes mellitus
controls after exercise. in controls
There is no clear reason why both the De Buyzere and Herren study did not show an
effect of exercise on thrombin production. Our data have demonstrated that the increase
in thrombin production can persist for up to 2 hours. De Buyzere's patients were only
rested for 30 minutes prior to exercise, and no mention is made of the rest period in
Herren's paper; compared to over two hours in our study. If patients are studied
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without sufficient rest to allow a true ' baseline', then it will be difficult to detect a rise
in thrombin production following exercise.
These findings support our hypothesis that exercise in claudicants is accompanied by a
procoagulant state, however, they do not suggest why this occurs. A number of areas in
the coagulation cascade might be susceptible to the systemic effects of claudication.
• Thrombomodulin (TM) is a protein bound to the surface ofEC's. Following the
production of thrombin, it binds to TM, and activates PC, which in turn inhibits
the formation of further thrombin. EC disturbance is known to occur following
• • 178
exercise in claudicants, and this could reduce the effectiveness of this
feedback system, resulting in excessive thrombin formation.
• In addition, it is know that cytokines can result in the release of tissue factor
from EC's. IL 1 and TNF, which are released in ischaemia-reperfusion, can lead
to thrombin production via the extrinsic coagulation pathway.179'180
• Work with cultured EC's has shown that in hypoxic conditions, certain
membrane proteins are upregulated, including Factor X, which might also
increase thrombin production.181
• Catecholamines have been shown to increase levels ofTAT, possibly by platelet
activation.182 It may be that the pain of exercise in claudication induces
catecholamine release, which leads to activation of the coagulation cascade.
However, in Mustonen's study, catecholamine levels were similar in the
claudicant and controls groups, despite differing responses to exercise.177
Our study does not point to any particular mechanism, and further work would be
required to try and clarify this.
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Conclusion
We have provided evidence that exercise in claudication is associated with increased
production of thrombin. This state may contribute to the high cardiovascular morbidity
and mortality in this patients group.
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Chapter 6
Fibrinolysis in Intermittent Claudication.
Introduction
As discussed in the previous chapter, thrombin production is only one side of the
balance when considering the coagulation system. If the excess thrombin production
seen in claudicants is accompanied by an increase in fibrinolysis, then the net effect on
thrombus formation could be cancelled out. In theory, fibrinolysis may be more
susceptible to the effects of exercise in the claudicant. The main source of tissue
Plasminogen Activator (tPA) is the endothelial cell - which is known to be affected in
exercising claudicants.80 It is known that the normal increase in fibrinolytic activity
seen following exercise is reduced in both CAD183 and diabetes mellitus.184
Furthermore, a reduction in fibrinolytic activity is becoming increasingly recognised as
a risk factor for coronary events,185 which claudicants are known to be at increased risk
of.186
Hypothesis
Exercise in patients with IC, leads to a reduced fibrinolytic response when compared to
subjects without claudication.
Aim.
To compare fibrinolysis, using several biomarkers, in claudicants, and age and sex
matched controls, before and after exercise.
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Methods
The study was conducted as part of the study outlined in Chapter 5. Briefly, claudicants
and controls underwent a standardised treadmill exercise in the middle of a four hour
rest period. Blood samples were taken pre-exercise, and post-exercise to study the
effect on fibrinolysis and fibrin turnover. The assays performed to study fibrinolysis,
and fibrin turnover are detailed in Table 6.1.
Table 6.1 Fibrin turnover and fibrinolysis assays
Assay Manufacturer Reference range Lower limit of
quantification
FbDP Organon Teknika (Belgium) 0-310 ng FE/ml 50 ng FE/ml
D-dimer American Diagnostica (CT, USA) 0-100 ng/ml 32 ng/ml
tPA activity Biopool (CA, USA) 0-1.2 IU/ml 0.2 IU/ml
tPA antigen Biopool (CA, USA) 0.5-14 ng/ml 0 ng/ml
PAP DRG Diagnostics, Germany Not available 0 ng/ml
PAI-1 Chromogenix, Italy Not available 2 IU/ml
activity
PAI-1 Biopool (CA, USA) 4-43 ng/ml 0 ng/ml
antigen
TAFI DRG Diagnostics, Germany Not available 0.3 pg/ml
antigen
FbDP=Fibrin degradation products; FE=fibrinogen equivalents; tPA=tissue
plasminogen activator; PAP=plasmin-antiplasmin complexes; PAI=plasminogen




(Figures 6.1,6.2) These are both products of the action of plasmin on fibrin. As such,
they are a product of both thrombus formation, and fibrinolysis. Overall, levels ofD-
dimer and FbDP in claudicants were consistently higher than the control groups, but this
did not reach statistical significance. D-dimer increased with exercise in claudicants
and the smoking controls, with no appreciable rise in non-smoking controls.
Figure 6.1 Plot of FbDP with time for the three subject groups.
20 40
Time points
Data are presented as medians with interquartile ranges. *=Intermittent claudicants vs
Smoking controls, f= Intermittent claudicants vs Non-smoking controls. Both Mann-
Whitney U Test.
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Figure 6.2 Plot of d-dimer with time for the three subject groups
Data are presented as medians with interquartile ranges. *=Kruskal-Wallis Test
comparing all three groups. **=Tntermittent claudicants vs Smoking controls, f=
Intermittent claudicants vs Non-smoking controls. Both Mann-Whitney U Test.
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tPA antigen /activity
(Figures 6.3,6.4) Claudicants had higher levels of tPA antigen at baseline, although the
amount of tPA activity was similar in the three groups. All three groups had an increase
in tPA antigen with exercise, which was similar in magnitude. All three groups showed
a large rise in tPA activity following exercise, which reached the highest level in the
smoking controls, although there was no overall difference in the groups post-exercise.
Figure 6.3 Plot of tPA antigen with time for the three subject groups
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Data are presented as medians with interquartile ranges. *=Kruskal-Wallis Test
comparing all three groups.
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PAI-1 antigen.
(Figure 6.5) Claudicants had consistently higher levels ofPAI-1 compared to controls.
Claudicants seem to have an increase in levels ofPAI-1 antigen with exercise, but this
quickly returns to pre-exercise levels.
Figure 6.5 Plot ofPAI antigen with time for the three subject groups
Data are presented as medians with interquartile ranges. *=Kruskal-Wallis Test
comparing all three groups.
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PAI-1 activity.
(Figure 6.6) No difference was detected in PAI-1 activity levels between the three
groups, pre, or post-exercise. There is a trend for PAI-1 activity in the claudicants to
decrease with exercise.
Figure 6.6 Plot ofPAI-1 activity with time, for the three subject groups
Data are presented as medians with interquartile ranges. *=Kruskal-Wallis Test
comparing all three groups.
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tPA-PAI-1 complexes
(Figure 6.7) Claudicants have slightly higher levels of tPA-PAI-1 complexes compared
to the control groups pre-exercise, which persists until 40 minutes post-exercise.
Figure 6.7 Plot of tPA-PAI-1 complexes with time for the three subject groups
tPA-PAI-1 = tissue plasminogen activator - plasminogen activator inhibitor complexes.
Data are presented as medians with interquartile ranges. *=Kruskal-Wallis Test
comparing all three groups.
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PAP
(Figure 6.8) Claudicants have similar levels ofPAP, an indicator of plasmin
production, as the smoking controls, but higher levels than the non-smokers.
Claudicants and the non-smoking controls have a small rise with exercise.






Data are presented as medians and interquartile ranges. *=Intermittent claudicants vs




(Figure 6.9) TAFI antigen levels were higher at baseline in the smoking control group
compared to the claudicants pre, but no significant differences were present between the
groups post exercise.






Data are presented as medians and interquartile ranges. *=Intermittent claudicants vs
Smoking controls, f= Intermittent claudicants vs Non-smoking controls. Both Mann-
Whitney U Test. **=Kruskal-Wallis Test comparing all three groups.
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Discussion
Our data show that despite an increase in thrombin production, claudicants do not have
a corresponding increase in fibrinolytic activity following exercise as shown by similar
levels ofPAP when compared to the smoking controls. Indeed, some of the results
point to a possible reduction in fibrinolysis:
• Fibrin turnover, as measured by D-dimers and FbDP is a function of thrombin
production and fibrinolysis. Given claudicants greater production of fibrin, if
their fibrinolytic capacity were similar to controls, we may expect that they
should have higher levels ofFbDP and D-dimers. As these levels were similar
in all three groups, we may speculate this reflects an actual deficiency in the
fibrinolytic response of claudicants.
• Following exercise, tPA activity levels in claudicants are slightly less than in
smoking controls, but the wide interquartile ranges of the data prevent this from
becoming statistically significant.
Our data provide some explanation ofwhy the fibrinolytic response may be blunted in
the claudicant group:
• As mentioned above, there may be a reduction in tPA activity following
exercise. This is despite there being significantly more tPA antigen present in
the claudicant group
• This study shows that at baseline, claudicants have an excess of PAI-1 antigen
compared to controls. It is likely that any tPA produced in claudicants is
therefore more likely to be 'mopped up' by this excess PAI-1. This is supported
by the fact that all three groups had similar rises in tPA antigen, but the controls
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had greater rises in tPA activity. However, if this were the case, we might
expect to see a greater rise in tPA-PAI-1 complexes in the claudicants, which we
do not.
• As Protein C is the activator of TAFI, and given the increased levels ofAPC-
PCI seen in the claudicants, we could speculate that fibrinolysis may be reduced
by this pathway in the claudicants. Unfortunately, our assay for TAFI measures
only TAFI antigen, not activity, and no differences were found in TAFI levels
between the groups.
• The main source of inducible tPA release is from EC's. It may be that the EC's
in claudicants are unable to respond to exercise in the same way as EC's in non-
claudicants in terms of the magnitude of tPA release. This may be due to two
reasons:
o Patients with PAD are known to have chronic, systemic EC dysfunction,
as determined by reduced brachial artery reactivity.187 This simply reflects
the systemic nature of atherosclerosis, and the involvement of EC's in the
early development of atherosclerotic plaque. The data from patients with
CAD are conflicting. One study which used venous occlusion to measure
tPA release showed a reduced response in patients with CAD compared to
controls. In studies measuring the fibrinolytic response to exercise, some
have shown a significant 'blunting' of the response in CAD patients,188"191
while another showed no significant difference between groups.192
However, even in this final study, there was a marked trend towards a
reduced tPA activity response in the CAD group compared to matched
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controls, and this may represent a type II error, despite the author's
assertion it was adequately powered.
oEC dysfunction may be exacerbated by ischaemia-reperfusion. As
discussed earlier, exercise in claudicants leads to demonstrable systemic
EC disturbance.178
A number of previous studies have examined different aspects of fibrinolysis in
claudicants. In contrast to our findings, Killewich found baseline levels of tPA activity
were lower in claudicants, but in this study, the claudicant groups (divided into mild and
severe claudicants) had more diabetics ([mild claudicants vs severe claudicants vs
controls] 49% vs 55% vs 0%) and smokers (44% vs 45% vs 0%), both of which are
known to have reduced fibrinolytic activity.185'193; 194 Furthermore, no mention is made
in the paper of how long the patients were rested prior to blood sampling. As the
fibrinolytic response can last up 20 minutes, it is important to ensure subjects are
sufficiently rested prior to baseline blood sampling. Womack examined the effect of
exercise on fibrinolysis in claudicants, and concluded they had a substantial rise in
fibrinolytic activity (tPA activity rose by 180%), but did not have a control group.195
Strengths and weaknesses.
The major strengths of this study are the uniform population, and the well-matched
nature of the controls. All of our claudicants were male, smoking, non-diabetics. This
was chosen to represent a 'typical' claudicant, while minimising variation. Claudicants
were age matched, to a smoking, and non-smoking control each, again all non-diabetic.
As might be expected, claudicants were more likely to have other co-morbidities, and be
taking more medication, particularly aspirin. The issue of aspirin, and its influence on
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the fibrinolytic response to exercise has been studied, and was not found to be
significant.196 However, it is impossible to exclude that the co-morbidities and
concomitant medications did not have an effect, although we think this is unlikely to
have a significant influence. Unfortunately, with the small number of subjects we
studied, formal statistical modelling to control for these factors was not possible.
An inescapable drawback is the differing duration of exercise in the claudicants, and
controls. Perhaps, if the control group had walked to exhaustion, then they may have
had a different response. Studies in CAD patients have tried to standardise exercise
between subjects and controls using VO2, heart rate rises, or inability to keep up with a
graded treadmill test, but in each of these, the CAD patients walked less far than the
controls.
Conclusion
In conclusion, this study has shown that despite the excess thrombin that is produced




Cellular Responses to Exercise in Claudicants
Introduction
The previous chapters have demonstrated how exercise in patients with claudication
affects the non-cellular components of the coagulation system. However, cells within
the blood may also be affected by exercise in claudicants. Platelets and neutrophils,
which have both inflammatory and prothrombotic influences, are possible candidates
which may be involved.
Platelet activation.
Platelets play a pivotal role in haemostasis, by helping to promote, and localise the
coagulation cascade. Platelet activation is one of the initial events in the coagulation
process, and some of the subsequent coagulation reactions take place on the platelet
surface. (Figure 7.1) Furthermore, because of the inflammatory mediators which can be
released by platelets (such as thromboxane A2), they may be an important link between
the low-grade inflammatory reaction seen following exercise in claudicants, and any
coagulation changes seen.
There are a large number ofmethods of measuring platelet activation, most ofwhich
suffer from significant shortcomings. (Table 7.1) Plasma separation prior to assays of
secreted proteins can lead to ex-vivo platelet activation. P-selectin is commonly used as
a marker of platelet activation, but it is also released from EC - cells which are known
to be affected by atherosclerosis and ischaemia-reperfusion raising further doubts about
its usefulness.197
111
Figure 7.1 Role of platelets in coagulation.

























Table 7.1 Common methods for assessing platelet function
Information from Ref 201
Bleeding time
Platelet aggregation studies
Expressed / secreted platelet proteins
Plasma P-selectin
Plasma 13-thromboglobulin
Plasma Platelet Factor 4
Flow cytometry
Measurement of platelet-bound activation-specific proteins
Measurement of platelet-leukocyte complexes
Measurement of the bleeding time can detect platelet abnormalities, however the test is
difficult to standardise and is not sensitive enough to detect small changes in platelet
function. Platelet aggregation studies, monitoring the formation of platelet aggregates
following deliberate stimulation, is also subject to standardisation difficulties, and are
not widely used.198
Flow cytometry.
This technique passes single particles through a laser beam, and can measure a variety
of parameters based on particle size and granularity. In addition, by detecting the
binding of fluorochrome-bound monoclonal antibodies to individual cells, the
expression of specific cell markers can be assessed. In the assessment of platelets, flow
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cytometry has the advantage that it is performed in the more physiologic environment of
whole blood, with less pre-assay manipulation. Flow cytometry can measure platelet
activation in two ways:
• Measurement of the number of platelets which are expressing activation-specific
proteins (ie P-selectin [CD 62P]).
• Measurement of leukocyte-platelet complexes. Platelet activation in-vivo leads
to the formation of platelet-monocyte, and platelet-neutrophil complexes and
measurements of these can be used to assess in-vivo platelet activation.198
Previous studies have shown that measuring the number ofmonocyte-platelet
complexes is a more sensitive marker of in-vivo platelet activation than other
flow-cytometry methods.199; 200
Platelet activation in intermittent claudication.
A number of studies have demonstrated that at rest, subjects with intermittent
claudication have more activated platelets, and their unactivated platelets are more
reactive when compared to healthy controls.201"203
The evidence regarding the effect of exercise on platelet activation is more equivocal.
In a comparison of exercise in 34 claudicants and 12 matched controls, it was found that
soluble P-selectin levels rose after exercise in the claudicant group, but not in the
control group.82 However, the rise only reached statistical significance at one time
point, and only after a second period of exercise. A similar study, using flow cytometry
to assess platelet-bound P-selectin expression found no change with exercise in 16
claudicants.83 Therefore, the question of the effect of exercise on platelet activation in
patients with claudication remains unanswered.
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Neutrophil activation.
The white cell count (WCC) has been shown to be predictive of future coronary,
cerebrovascular and peripheral vascular events.204 Neutrophils are the commonest
white cell type, whose primary function is the removal of bacteria and dead tissue.
Previous research has shown that ischaemia-reperfusion leads to neutrophil activation,
which in turn can have significant systemic effects on the circulation:204
• Activation of neutrophils increases their stiffness, slowing their travel through
capillaries, and possibly blocking them.
• Activated neutrophils increase their adhesion to EC, and other blood cells,
further increasing the chance of becoming trapped in the microcirculation.
• Following activation, neutrophils release a number of toxic agents, including
highly reactive oxygen-derived free radicals. These can interact with EC,
having deleterious effects on their function. (Figure 7.2)
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Figure 7.2 Prothrombotic effects of neutrophil activation
Activation of neutrophil
I





















Altered endothelial cell function
(TXA2=Thromboxane A2, LTB4=:Leukotreine B4) Data taken from Ref 207
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Claudicants are known to have higher neutrophil counts than matched controls,85 and
exercise in claudicants leads to further rise in neutrophil counts, while even with
exhaustive exercise, no such rise is seen in non-claudicants.78'205 The rise in neutrophil
numbers is thought to be due to the release of neutrophils, from ischaemic muscle, into
the draining blood, as demonstrated by comparing neutrophil counts in the femoral
artery and vein of exercising claudicants.76 This release of inflammatory cells is
accompanied by a decrease in plasma antioxidant levels (indicating release of free
radicals), and EC damage.84 As discussed in the previous chapters, it may be EC
damage that mediates the coagulation changes associated with exercise in claudication.
A number of indirect markers of neutrophil activation have been used previously (Table
7.2), but more recently, flow-cytometry detection ofCD1 lb expression has been used as
a more direct marker of neutrophil activation.78,83 CD1 lb is an adhesion molecule with
is uniquely expressed on the surface of activated neutrophils,206 and can be targeted by
fluorochrome-linked monoclonal antibodies.








Exercise in claudicants is associated with activation of platelets and neutrophils, which
may mediate, and contribute to the coagulation changes seen in these patients.
Aim.
The aim of our study was to assess platelet and neutrophil activation following exercise




The first 21 subjects recruited into the study detailed in Chapter 5 were recruited into
this sub-study, consisting of 10 claudicants, and 11 control subjects (6 smokers and 5
non-smokers). As we had no previous data regarding platelet or neutrophil activation,
we were unable to perform a power calculation to determine sample size.
Methods.
Full details of the methodology are presented in Chapter 5. Briefly, subjects
(claudicants, or controls) undertook a standard treadmill exercise, with blood sampling
prior to, and following the exercise. Blood was taken 60 and 30minutes prior to
exercise, and 1, 5, 20, 40, 60 and 120 minutes following exercise. For this sub-study, an
additional 2 blood samples were taken at each time point. (Table 7.3)
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Table 7.3 Additional blood samples taken for flow cytometry analysis
Sample Tube(s) Tube type For measurement of:
No
1 lx 1.8ml 0.105M Platelet activation
citrate
2 lx 3ml ACD-B CDllb expression
Samples were prepared as follows:
• Tube 1 (platelet analysis). 1ml of blood immediately transferred to a chilled
cryovial containing 1 ml of 2% paraformaldehyde (Esoterix Cell Oncology,
Holland), and gently inverted five times. Samples were then incubated with the
following fluorochrome-bound monoclonal antibodies:
o Anti-CD41 (GP lib) which allows unique identification of platelets,
o Anti-CD62P (P-selectin) to identify activated platelets.
• Tube 2 (neutrophil analysis). Kept in ice-water for 30 minutes. lOOpl of chilled
blood was added to 50pl of anti-CDl lb antibody (Esoterix Cell Oncology,
Holland), and 100pi of blood added to 50pi of control antibody (Esoterix Cell
Oncology, Holland). Following incubation for 2 hours in ice water, 1 ml of 2%
paraformaldehyde was added to each vial to fix the samples.
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Flow cytometry.
Flow cytometry was performed within 24 hours on a Becton Dickinson FACscaliber
(Becton Dickinson Biosciences, CA, USA). Cell types were identified on the basis of
forward and side scatter and further analysed for the binding of fluorochrome-bound
monoclonal antibodies.
Statistical methods
Pre-exercise values were calculated by taking the average of the results of the two pre-
exercise samples. For samples taken post-exercise, the area under the curve (AUC) was
calculated for each individual. Groups were compared pre, and post-exercise with the
Kruskal-Wallis test, or ANOVA where the data were distributed normally. Where this
returned a value ofP<0.05, the Mann-WhitneyU test (or T-test) was used to identify the
groups which had significantly different values. A value of P<0.05 was taken to be
statistically significant.
SPSS version 11.0.0 (Statistical Package for Social Sciences Inc, Chicago, IL, USA)
was used for all statistical analysis.
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Results
All results are presented as median (interquartile range) unless otherwise stated.
Details of the patients recruited into this sub-study are detailed in Table 7.4. The blood
cell counts at screening were similar for the three groups, (Table 7.5) although non¬
smoking controls had a higher platelet count than the smoking controls. (P=0.004
Mann-Whitney U).
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Age (median), years (IQR) 61 69 69 0.408*
(58-69) (60-70) (58-70)
Body mass index, kg/m 23.5 24.5 27.4 0.214*
(IQR) (21.8-25.0) (23.4-26.7) (23.5-31.7)
Smoking 0.875f
pack years 42 45 0
Medical history
CAD 0 0 1
CVD 0 0 0
HT 0 0 0
COAD 0 0 0
Medication
Aspirin 9 2 1
fi-blocker 0 0 1
PAD
Lowest ABPI (median) 0.72 1.09 1.12 0.232tf
Walking distance
(median) ,m 169 174 174 1.0tr
Cholesterol (mmol/1) 187 204 180 0.875*
*=Kruskal-Wallis between all 3 groups. f=Mann-Whitney U claudicants v smoking
controls. ff=Mann-Whitney U smoking v non-smoking controls.
CVD=cerebrovascular disease, COAD=chronic obstructive airways disease,
HT=hypertension, ABPI=ankle-brachial pressure index.
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Table 7.5 Blood cell counts at screening
Controls
Claudicants Smokers Non-smokers P=
n=10 n=6 n=5
White cell count (xl09/l) 9.8 8.4 7.7 0.111*
(IQR) (8.8-10.7) (7.6-9.7) (7.0-9.3)
Neutrophils (xl09/l) 6.8 5.1 5.1 0.111*
(5.0-7.8) (4.7-6.2) (3.8-5.6)
Lymphocytes (xl09/l) 2.0 2.6 2.4 0.695*
(1.7-3.2) (2.2-2.8) (1.6-3.3)




Two measures of platelet activation were used, total P-selectin expression (expressed as
molecules of equivalent soluble fluorochrome [MESF]), and monocyte-platelet
complexes (% monocytes bound to platelets).
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P-selectin expression.
(Figure 7.3) At baseline, the overall P-selectin expression was greater in the control
groups compared to the claudicants. Following exercise, all groups showed a rise in
platelet P-selectin expression, but overall there was no significant difference between
the groups post-exercise.






























Points represent median values. Error bars show interquartile ranges. *=Intermittent
claudicants vs Smoking controls, f= Intermittent claudicants vs Non-smoking controls.
Both Mann-Whitney U Test. **=Kruskal-Wallis comparing all three groups.
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Monocyte-platelet complexes (MPC).
(Figure 7.4) Results are expressed as the percentage ofmonocytes bound to platelets.
These data were normally distributed, therefore means, standard errors and parametric
significance tests were used. Some negative values were obtained because of the
compensation used by the flow cytometer. At all time points, the % ofMPC's was
highest in the claudicant group, although this did not reach statistical significance
Figure 7.4 Monocyte platelet complexes before and after exercise (%MPC)




(Figure 7.5). At baseline, there was no difference in the expression ofCD1 lb by
granulocytes between the three groups. Following exercise, all groups showed an
increase in CD1 lb expression, which reached the highest level in the smoking controls.
By 60 minutes post- exercise, CD1 lb expression had returned to baseline values in all
groups.
Figure 7.5 CD1 lb expression in granulocytes before and after exercise.
Points represent median values. Error bars show interquartile ranges. *=Kruskal-




Previous studies have shown that patients with peripheral arterial disease have increased
activation, and reactivity of platelets, although the evidence regarding the response to
exercise is equivocal. Our study, using a robust measure of platelet activation, platelet
P-selectin expression measured by flow cytometry, has shown that our patients with
claudication had less platelet activation than age and sex-matched controls. This
discrepancy may be due to the fact that all of the subjects with claudication were taking
aspirin, compared to three of the 11 control subjects. Previous studies have not
attempted to control for antiplatelet agent usage, and it would have been unethical to
discontinue it in the claudicants, or to start it in the control subjects without a suitable
indication. In the study by Koksch et al which found an increase in platelet activation in
PAD, measured by a similar method to ours, only 40% of the PAD subjects were taking
aspirin.202 From Figure 7.3, it appears that exercise may have some effect in activating
platelets, particularly at five minutes. However, in no group was the 5 minute P-selectin
expression significantly greater than baseline levels.
Although the use of monocyte-platelet complexes as a marker of platelet activation is
thought to be robust and useful, it did not point to any clear effect in this study.
In summary, the high prevalence of aspirin use in our PAD patients seems to have
reduced the amount of platelet activation in our patients, both at rest, and after exercise.
Although this may have prevented us from making a meaningful comparison with our
control groups, it is perhaps reassuring that the high platelet activity noted by other
studies in this population, is reduced by aspirin.
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Neutrophil activation
Our data have shown that although claudicants have an increase in neutrophil activation
following exercise, this is less marked than the increase in controls matched for age, sex
and smoking status. These findings are contrary to previous studies which have found
higher increases in neutrophil activation in claudicants compared to controls, whether
*70. QO 90S
assessed by CD lib expression, ' or more indirect measures. There is a marked
effect of smoking as illustrated by comparing the two control groups, which leads to an
enhanced response to exercise in the smoking controls. It is known that activation of
neutrophils leads to them becoming stiffer, increasing the time it takes them to pass
through the microcirculation. It may be that in patients with peripheral arterial disease,
these activated neutrophils are becoming adherent to a damaged endothelium, and
becoming trapped - in a similar manner to the white-cell trapping seen in chronic
venous disease.207 However, if neutrophils were trapped in the microcirculation, we
might expect to see a late 'wash-out' of activated neutrophils - which we do not.
Previous investigation of the effect of smoking on neutrophil activation has yielded
seemingly conflicting results.208 Although soluble markers of neutrophil activation
were higher in smokers compared to non-smokers, the number of activated neutrophils
in systemic blood was not higher in the smokers. Incubation of unactivated neutrophils
with smoker's plasma led to neutrophil activation, which was not seen with the non-
smokers plasma. The conclusion from this study is that smoking leads to neutrophil
activation, and sequestration in the microcirculation, with 'leakage' of neutrophil
secretion products into the systemic circulation.
The reason for the lower number of activated neutrophils in our claudicants may be
explained by the combination of:
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1. sequestration of neutrophils, activated by smoking and possibly claudication.
2. a microcirculation lined by endothelial cells affected by atherosclerosis +/-
ischaemia-reperfusion.
If neutrophils are becoming trapped in the microcirculation, what implications does this
have? We can speculate that this would lead to further localised endothelial damage,
and possible the progression of atherosclerosis. Endothelial damage is likely to lead to
prothrombotic effects, and further white cell activation (Figure 7.2). Ultimately, these
may lead to progression of disease, both locally and systemically. It must be borne in
mind, that there is unequivocal evidence of benefit of exercise therapy in claudication.
However, if ways can be developed of reducing the potentially deleterious effects, such
as neutrophil sequestration, this may enhance the benefit achieved.
Conclusions
The high prevalence of antiplatelet agent use in our claudicant population has prevented
us making definite conclusions about the effect of exercise on platelet activation in this
study. However, it would appear that the use of flow-cytometry to detect platelet P-
selectin expression is a useful technique, and could be used for further work in this area.
Following exercise, claudicants have an attenuated increase in systemic neutrophil
activation compared to matched controls, possibly reflecting sequestration of activated




The effect ofwalking distance on the fibrinolytic response
Introduction
A possible explanation for the lack of an enhanced fibrinolytic response in patients with
claudication may be related to the amount of time spent walking. If the fibrinolytic
response depends on the duration of exercise, the response in claudicants would be
expected to be reduced as they spent less time, on average, walking than the controls.
This hypothesis was tested using the data available from the study in Chapter 6.
Hypothesis.
The lack of an enhanced fibrinolytic response in claudicants is due to the reduced
walking time during their exercise period.
Aim.
To examine the influence ofwalking distance on the fibrinolytic response in
claudicants.
Methods.
The data from the study in Chapter 6 were analysed. The preferable method of studying
the influence ofwalking time on the fibrinolytic response would be to construct a
logistic regression model. However, as only a relatively small number of subjects with
complete data sets were available, this was not possible. It was therefore decided to
divide the claudicants into two groups: those walking less than three minutes at the
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assessment visit, and those walking more than three minutes. Three minutes was
chosen as the cut-off, as this was the duration of exercise in the control groups. This
allowed comparison between the two groups of claudicants, and also between the
claudicants able to walk for more than three minutes, and the control groups. The
biomarkers studied were APC-PCI, tPA activity, tPA antigen, and PAP complexes.
Graphs similar to those in Chapters 5 and 6 were plotted, and the area under the curve
calculated for each group pre and post-exercise. Data for the non-smoking control
group are not plotted for clarity.
Results
Subjects
8/19 subjects walked for longer than 3 minutes at their assessment visit (Table 8.1). It
can be seen that there is a considerable 'learning' effect with treadmill walking for some
individuals. The group that walked longer than three minutes at the assessment visit,
walked a median of 82m at the screening visit, which increased to 174m at the
assessment visit. Other than the differences in walking distance, the groups are similar.
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Age, years (IQR) 61 (58-68) 62 (56-68) 0.968*
Body mass index, kg/m2 23 24 0.600*
(IQR) (22-26) (23-27)
Smoking
pack years 47 47 <0.904*
Medical history
CAD 1 2 0.603f
HT 1 3 0.603f
COAD 2 4 l.Of
Medication
Aspirin 6 7 l.Of
PAD
Lowest ABPI 0.59 0.51 0.116*
Walking distance, m, 93 82 0.322*
(IQR) [screening] (66-116) (64-118)
Walking distance, m, 66 174 <0.001*
(IQR) [assessment] (60-92) (172-184)
Cholesterol, mmol/1 (IQR) 5.3 (4.6-6.1) 4.8(4.1-5.21) 0.186*
IQR = interquartile range; CAD = coronary artery disease (angina, myocardial
infarction or coronary bypass surgery); CVD = cerebrovascular disease (transient
ischaemic attack or stroke); HT = hypertension; COAD = chronic obstructive airway
disease; Ca blocker = calcium channel blocker; ACEI = ACE inhibitor. *=Mann-
Whitney U Test. t=Fisher's Exact Test
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tPA antigen
(Figure 8.1) From Chapter 6, tPA antigen levels were higher both pre and post exercise
in claudicants than in controls. There seems to be no difference in tPA antigen levels
when the claudicant group are categorised according to walking distance.
Figure 8.1 tPA antigen for claudicants categorised by walking ability, and smoking
controls.
Data presented as medians and interquartile ranges. *=Claudicants walking <3 minutes




(Figure 8.2) There was no statistically significant difference between the claudicant
group as a whole and the control groups with respect to tPA activity. However, when
the claudicants who walked further than three minutes are taken as a separate group,
they are seen to have higher tPA activity pre and post exercise when compared to the
smoking controls, although not reaching statistical significance.
Figure 8.2 . tPA activity for claudicants categorised by walking ability, and smoking
controls.
Time points
Data presented as medians and interquartile ranges. *=Claudicants walking <3 minutes




(Figure 8.3) Complete data is only available for two claudicants who walked for longer
than three minutes and therefore no error bars are shown, or formal statistics calculated.
With the obvious cautions about interpreting these data, it appears that the subjects with
longer walking distance have a considerable increase in PAP when compared to the
other claudicant group, and the smoking controls.
Figure 8.3 PAP for claudicants categorised by walking ability, and smoking controls.




(Figure 8.4) Levels ofAPC-PCI were similar at baseline, but the claudicants who
walked for longer than 3 minutes had a larger rise than the other groups, indicating
greater thrombin generation.
Figure 8.4 APC-PCI for claudicants categorised by walking ability, and smoking
controls.
Time points
Data presented as medians and interquartile ranges. *=Claudicants walking <3 minutes




The data from the previous chapters appeared to show that claudication was associated
with increased thrombin generation, without a corresponding increase in fibrinolytic
response. However one of the main differences between the groups was the distance
they walked at the assessment visit (claudicants 82m, controls 174m). It could therefore
be argued that the lack of an enhanced fibrinolytic response in the claudicants is due to
the shortened duration of exercise, and not to the claudication itself. Our data would
seem to confirm this hypothesis. When compared to the smoking controls, and the
claudicants walking less than three minutes, the longer walking claudicants had higher
levels of tPA activity at rest and post exercise, and possibly higher levels of tPA
antigen, and larger increase in PAP - indicating total fibrinolysis. The improved
response of the longer walking claudicants, however does not seem to simply be a
function of their increased walking distance, as they also have increased levels at rest.
This may reflect that they have less damaged endothelium - capable of releasing more
tPA, although it is not clear why tPA activity levels are higher than in the smoking
controls. It is tempting to speculate this is a physiological attempt to counteract the
increased thrombin generation, but the mechanism responsible for this is obscure.
Do these findings alter the significance of the data from the previous chapters? It is
difficult to quantify the net effect of increased thrombin generation against the enhanced
fibrinolytic response seen in the claudicants. Although claudicants who have a longer
walking distance seem to have improved fibrinolysis, they also have the most marked
increase in thrombin generation.
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Caution needs to be exercised when interpreting the data from this chapter. It is likely
that walking distance in the claudicants is not a completely independent variable, and it
may be representing the effect of another variable, for example disease severity. In
addition, once the claudicant group was divided on the basis of walking ability, the
small numbers have hindered formal statistical analysis. However, the graphs presented
show consistent trends which we feel merit cautious acceptance.
Conclusion.
The previous finding that increased thrombin generation in claudicants is left unchecked
by increased fibrinolysis is over simplistic. Claudicants who walk further, generate




Normal Variability of Thrombin Generation and Fibrinolysis
Introduction
The previous chapters have suggested that exercise in patients with intermittent
claudication (IC) leads to thrombin generation and relative hypofibrinolysis. However,
the reproducibility of the measurement of, and the longitudinal variation in, markers of
thrombin generation and fibrinolysis in resting and exercising claudicants has yet to be
established. The aim of this study, therefore, was to examine the reproducibility of
coagulation markers measured before and after exercise, and on two separate occasions
two weeks apart, in individuals with IC and age matched controls.
Patients and Methods
22 subjects from the study in Chapters 5 and 6 returned for a second assessment visit,
which was conducted in the same manner as assessment visit 1. The number of subjects
chosen to assess reproducibility was arbitrary, and was dictated by financial constraints.
Blood samples were collected at the same time points, for a selected number of
biomarkers. (Table 9.1) AUC's were calculated for pre and post-exercise periods in the
same manner as previously. AUC's were then converted into time-controlled values by
dividing the pre-exercise values by 30, and the post-exercise values by 119 to produce
clinically relevant results. (Figure 9.1)
In order to test the reproducibility of baseline biomarker levels, pre-exercise AUC's
were compared between visits. Calculating the difference between time-controlled pre
and post-exercise AUC's, and comparing this value for visits 1 and 2 tested the
reproducibility of the effect of exercise. The method of Bland and Altman,209 which
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plots the mean of the results from visits one and two on the x-axis, against the
difference between the results from the two visits on the y-axis, was used to compare
data from the two visits.
Table 9.1 Markers measured at each time point. ; PT = prothrombin time; APTT =
activated partial thromboplastin time; tPA = tissue plasminogen activator; PAI-1 =
plasminogen activator inhibitor 1; APC = Activated Protein C; PCI = Protein C
Inhibitor.
*=commercially available assay kit.
Marker Method
PT Bayer, Rapidpoint coag,
APTT UK*
Thrombin-antithrombin
complexes Dade-Behring, IT, USA*
tPA activity Biopool, CA,USA*
PAI-1 activity Biopool, CA,USA*
APC-PCI complexes Stenflo.173
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Figure 9.1. Calculation of time controlled AUC
Post-exercise AUC = C+D+E+F+G+H / (d-c)
Results
The details of the subjects studied are presented in Table 9.2. Bland-Altman plots for
each of the measured parameters are presented in Figures 9.2 to 9.13. Complete data
were not available for all subjects, as sufficient sample volume was not obtained at
every time point for every parameter at both visits on all subjects. Subjects with
incomplete data sets are not plotted. Coefficients of variation for the assays at baseline
have also been calculated (Table 9.3), which demonstrates relatively low variability for
APTT, PT, APC-PCI complexes, tPA activity and PAI activity, with higher variability
for TAT complexes.
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Table 9.2 Patient details. IQR = interquartile range; IHD = ischaemic heart disease
(angina, myocardial infarction or coronary bypass surgery); CVD = cerebrovascular
disease (transient ischaemic attack or stroke); HT = hypertension; COAD = chronic
obstructive airway disease; Ca blocker = calcium channel blocker; *=Kruskal-Wallis.
f= Fishers Exact Test
Controls
Claudicants Smokers Non-smokers P=
n=10 n=6
n=6
Age, years (IQR) 59 (58-67) 69 (60-70) 69 (58-70) 0.378*
Body mass index, kg/m 24 23 27 0.760*
(IQR) (22-25.0) (23-25) (24-32)
Smoking
pack years 44 45 0 0.005*
Medical history
CAD 2 0 1 0.320f
CVD 0 0 0
HT 2 0 0 0.325f
COAD 2 0 0 0.325f
Medication
Aspirin 8 1 1 0.017f
B-blocker 0 0 1 0.252f
Nitrate 1 0 0 0.615f
PAD
Lowest ABPI 0.56 1.11 1.12 <0.001*
(IQR) (0.51-0.62) (1.06-1.13) (1.09-1.16)
Walking distance, m, 108 174 174 <0.001*
(IQR) (64-174) (170-174) (174-174)
Cholesterol, mmol/1 (IQR) 4.9(4.3-6.1) 4.9 (4.8-6.6) 4.6(4.3-5.1) 0.794*
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Figure 9.2 Reproducibility of baseline APTT measurements
Mean difference = 2.Is
Mean APTT (s) (visit 1, visit 2)
= 95% prediction intervals of difference between measurements at visit 1 and
visit 2.
Figure 9.3 Reproducibility of the effect of exercise on APTT measurements.
8.0
*6.0
Mean difference =0.7 s
-6.0
Mean change in APTT with exercise (s) (visit 1, visit 2)
visit 2.
•••= 95% prediction intervals of difference between measurements at visit 1 and
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Figure 9.4 Reproducibility ofbaseline PT measurements
2.5
Mean difference = 0.1S
£
H "° 5
Mean PT (s) (visit 1, visit 2)
visit 2.
-= 95% prediction intervals of difference between measurements at visit 1 and
Figure 9.5 Reproducibility of the effect of exercise on PT measurements.
1.0
0.5
Mean difference = -0.1 s
0.2
Mean change in PT with exercise (s) (visit 1, visit 2)
visit 2
= 95% prediction intervals of difference between measurements at visit 1 and
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Figure 9.6 Reproducibility ofbaseline TAT measurements.
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M«an TAT (ng/ml) (visit 1, visit 2)
= 95% prediction intervals of difference between measurements at visit 1 and
visit 2.














Mean change in TAT with exercise (ng/ml) (visit 1, visit 2)
= 95% prediction intervals of difference between measurements at visit 1 and
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Mean difference = 0 ng/ml
Mean APC-PCI (nglml) (Visit 1, visit 2)
visit 2.
95% prediction intervals of difference between measurements at visit 1 and












Mean difference = -0.1 ng/ml
Mean APC-PCI (ng/ml) (Visit 1, visit 2)
visit 2.
= 95% prediction intervals of difference between measurements at visit 1 and
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Mean difference = 0 ng/ml
Mean tPA activity (lU/mi) (Visit 1, visit 2)
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••= 95% prediction intervals of difference between measurements at visit 1 and










Mean change in tPA activity with exercise (lU/ml) (Visit 1, visit 2)
95% prediction intervals of difference between measurements at visit 1 and
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Mean PAH activity (lU/ml) (visit 1, visit 2)
= 95% prediction intervals of difference between measurements at visit 1 and
visit 2.
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Mean change in PAi-1 activity with exercise (lU/ml) (visit 1, visit 2)
visit 2.
95% prediction intervals of difference between measurements at visit 1 and
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Table 9.3. Co-efficient of variation for pre-execise AUC values.








This study has shown that the normal variability of coagulation parameters can be
significantly high.
Bland-Altman graphs can be interpreted quantitatively or qualitatively. If a variable's
clinically relevant (or normal) range is known, then one can determine whether the 95%
prediction limits for estimation of the difference lie within this range. If that range is
not known and it is not, therefore, possible to define exactly what level of variation
between measurements is clinically acceptable or meaningful, then it is necessary to
simply assess the graphs pragmatically on a variability spectrum. When the difference
between the two measurements is small in comparison to the mean of the two
measurements then variability is low and/or reproducibility is high. If the difference
approaches the mean then the variability is high and reproducibility is low. It is
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important to point out that although the mean of the differences often approaches zero,
this is to be expected statistically, and does not indicate that the variability is low.
Baseline
At baseline, all the markers except PT and APTT, exhibited differences between the two
visits approached the mean of the measurements between the two visits in a large
number of subjects, indicating significant variability over time with the same subject
and/or low assay reproducibility.
Effect ofexercise.
These data are calculated by subtracting pre-exercise, from post-exercise AUCs and
some of the points have negative x-values, representing a fall in the variable with
exercise. Again, APTT, and PT, show reasonable consistency between visits, but most
of the other markers vary widely, suggesting that the same individual responds to the
similar levels of exercise in different ways on different days and/or the assay lacks
reproducibility. There are a number of possible reasons fore this inter-visit variation:
• The method of blood collection varied from visit to visit. This is not a likely
source of visit to visit variation, as the method, timing and processing of all
samples was standardised before the study started. All samples were taken from
a pre-placed venous cannula, without a tourniquet, and placed immediately on
ice. No changes were made during the study to the tubes the blood was
collected in, or the method of processing.
• The assays themselves lack reproducibility. Again, this seems unlikely, as
assays were performed to strict protocols, in accredited laboratories (except the
PT and APTT) according to Good Laboratory Practice. This ensures adequate
quality control checks are performed prior to and at the end of each assay run.
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In the case of PT and APTT, quality control specimens were run at the
beginning and end of each day to ensure correct calibration of the analyser.
• There are significant actual variations in the levels of these markers in
individuals from visit to visit. Although visits occurred at the same time of the
day, and influences known to affect these biomarkers (exercise, smoking, eating
and drinking) were controlled as far as possible, this would seem to be the most
likely explanation of the intra-visit variation.
The variation in coagulation parameters over time has been studied previously in
various patient groups, although not in those with PAD or IC. A study of 26 healthy
volunteers showed even greater variation in coagulation markers that observed in the
present study (coefficients ofvariation [CV's]: tPA antigen 15%, TAT 25%, PAP 20%,
PAI activity 30% and PAI antigen 47%). The results from these studies are difficult to
compare as a variety of statistical methods have been used - including correlation
coefficients,210 coefficients of variation (CV),211;212 and reliability coefficients213'214.
The use of these summary variables is attractive, as it gives a single figure that attempts
to describe the spread of the data. But, such figures can be highly misleading. For
example, the CV's of the some of the markers in this study were low (Table 9.3) despite
the Bland-Altman plots showing that levels varied widely between visits.
CV's also allow the construction of a power calculation to give the number of subjects
(or repeated measures) likely to be required to achieve a statistically meaningful result
in longitudinal studies. For example with a within-subject CV of 30%, six
measurements must be made for each sample in order to be reasonably sure (a=0.05,
(3=0.10) of detecting a true halving, or doubling of the marker211. For the markers
measured in our study: 2 measurements would be required to detect a doubling, or
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halving of APTT, or PT; 3 measurements for APC-PCI, tPA activity, or PAI activity;
and the high variability of baseline TAT measurements (CV 40%) means that the
marker would have to be measured 12 times to be likely O=0.10, a=0.05) of detecting a
true halving or doubling.
On the basis of present and previous data, one can state with some confidence that
coagulation parameters can vary significantly in the same individual (healthy and
diseased) over time in response to a range of (often unidentified and unrecognised)
stimuli such as intercurrent illness. Those undertaking basic science investigations and
clinical trials that use biomarkers must be aware of this variability and the important
implications it has for study design and interpretation.
Conclusion
It is likely that longitudinal studies investigating coagulation parameters will be
undertaken in patients with claudication. Before groups embark upon such
investigations, pilot data needs to be collected to allow the calculation of an appropriate
power calculation. It appears from our data that markers show significant intra-
individual variation with time, despite careful attempts to minimise this. The
implication is that large numbers ofmeasurements need to be made, or methods of




The overriding conclusion of the work presented in this thesis is that research in this
area is fraught with difficulties. The data from Chapter 9 regarding variability; the wide
error bars from the other chapters; along with the lack of any firm conclusions which
can be drawn about fibrinolysis, neutrophil response and platelet response; all stem
from the difficulty in study this subject.
Undoubtedly, some of these difficulties could have been reduced by changes to the
study design which are more apparent in retrospect.
• A more homogenous control group, for example entirely smokers would have
increased the power of the study, reducing the chance ofmissing possibly
significant differences between the groups (ie reducing Type 2 errors).
• As all of the subjects with claudication were taking aspirin, and most of the
controls were not, it was unrealistic to expect to see an increase in platelet
activation in the claudicant group. It could be argued that the control group
could have been given a course of aspirin, so that at least the two groups were
comparable. If this were not considered ethical, then a comparison between the
groups is probably meaningless.
• It was not anticipated that patients with abdominal aortic aneurysms (AAA)
would have obvious coagulation abnormalities. The very high levels ofD-dimer
found in one of our patients with a AAA may or may not have been due to his
AAA, but we felt it merited excluding patients with aneurysms from the study.
Future studies should exclude patients with a AAA.
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Despite the above reservations, some tentative conclusions can be drawn.
'
i
• Walking in patients with inferpiittent claudication is associated with ah increase
in thrombin generation, which could,pf6dtide!a pro-coagulant state'if l£ff''"
unchecked by a corresponding enhanced fiBrihd lytic response. ' *'• " ;m
• There is evidence of a reduction in the number of activated neutrophils in the
systemic circulation of patients with intermittent claudication.
What then are the implications of these findings? It is accepted that walking exercise
improves walking distance, and it seems that walking to the point ofmaximal
claudication produces larger increases in walking distance than walking for shorter
distances.44'45 Although it is a widely held belief that exercise is generally beneficial,
this is largely based on studies with healthy volunteers, or cardiac rehabilitation
programmes.52 No studies to date have yet examined the effect of exercise therapy on
total morbidity ormortality in claudicants. Given the findings of the studies in this
thesis, it would be reassuring to know that the advice given to claudicants regarding
exercise therapy is not harmful in terms of cardiovascular morbidity and mortality.
However, it is known that exercise therapy can reduce some of the systemic
consequences of exercise in claudicants,215 so in the absence of firm data regarding total
morbidity and mortality, there is no good reason not to encourage claudicants to
exercise as before.
As with most research, the research in this thesis has raised many questions with
possible areas for future work.
• Is the prothrombotic state seen in claudicants following exercise due to
ischaemia-reperfusion as postulated, or is it the effect of exercise in the presence
ofwidespread atherosclerosis? This question could be answered by studying
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claudicants exercising without ischaemia-reperfusion - arm exercises for
example.
• What is the effect of treatment of claudication on the coagulation response, by
exercise therapy, or percutaneous balloon angioplasty for example? There is
evidence that exercise therapy can reduce the systemic inflammatory response in
91 S
claudicants.
• If, as seems likely, the procoagulant state is mediated by cytokines, can this be
ameliorated medically by anti-inflammatory drugs?
• It may be that some of the more subtle effects of exercise in claudicants are not
detected because we were sampling from the systemic circulation, and some
markers / cells may be too diluted to detect changes, or become trapped in the
peripheral circulation, or the pulmonary capillaries. Taking blood samples from
the femoral vein would answer these issues.
In conclusion, the work presented in this thesis has shown that research in this area is
often not straightforward. Whilst it appears that patients with intermittent claudication
may generate more thrombin when compared to a control group, it is not clear whether
this is related to ischaemia-reperfusion. Furthermore, the clinical relevance of these
findings has not been demonstrated and would require further work. Any additional
conclusions based on this work are difficult to draw, largely because of the variability of
the parameters, and the relatively small numbers of subjects studied.
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Appendix 1
Consent Form and Information Sheet
Study Title: A pilot study to measure biochemical markers of coagulation and
fibrinolysis in blood taken from healthy subjects and subjects with intermittent
claudication, pre- and post-standardised exercise
You are being invited to take part in a research study. Before you decide it is
important for you to understand why the research is being done and what it will
involve. Please take as much time to read the following information carefully
and discuss it with friends, relatives and your doctor if you wish. Ask us if there
is anything that is not clear or if you would like more information.
We appreciate you taking the time to read (or have read to you), inquire about,
and understand the following information.
What is the purpose of the study?
Pfizer is doing this research study to look at certain naturally occurring chemicals
(biochemical markers) in your blood. This study will measure blood coagulation
(clotting) chemicals and blood fibrinolysis (clot-breaking) chemicals. By
measuring these chemicals it will help further understand the way that the blood
coagulates (clots) and then how these clots are normally broken down within the
body.
We will be taking blood samples before and after you have walked on a treadmill
in order to examine the changes in these chemicals on exercise.
We will be studying: (a) 20 subjects who smoke and are diagnosed with
intermittent claudication (pain on walking), (b) 10 healthy volunteers who smoke
and (c) 10 healthy volunteers who are lifelong non-smokers.
Why have I been chosen?
You are being asked as you have intermittent claudication or are a healthy male
who can be matched to a patient with intermittent claudication.
We require smokers who have a chronic smoking habit ( □ 20 cigs/day for □ 1
year): we require healthy volunteers who are lifelong non-smokers.
40 subjects at this centre will be involved in the study and your participation will
last for a period of about 3 weeks.
Do I have to take part?
It is up to you to decide whether or not to take part. You will be given this
information sheet to keep. If you do decide to take part you will be asked to sign
a consent form, and you will receive a copy ofyour signed form. If you decide
not to take part this will not affect your medical care. You are free to withdraw
from the study at any time without giving a reason. This will not affect your
medical care.
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What will happen to me if I take part?
During the study you will be seen in the outpatient department, for 3 visits. Your
travelling expenses between the Birmingham Heartlands Hospital and home will
be paid. On completion of the study, you will receive £125 to compensate you
for your time and inconvenience.
At the start of the study (Screening Visit) you will have a vascular examination
and medical. Your blood pressure and pulse rate will be measured and a blood
and urine sample (for laboratory safety tests) will be taken. A small finger-prick
blood sample will also be taken to measure your blood glucose and cholesterol.
If you are a patient with intermittent claudication, you will undergo an exercise
test (walking on a treadmill) if no treadmill assessment has been performed in the
last 2. months. You will be asked to walk until the pain in your leg makes you
want to stop. A blood sample will be taken at this visit for genetic analysis: we
wish to check the variation in your genes for some of the blood chemicals being
measured in the study. No other type of genes will be tested for.
If you are suitable for the study, you will be asked to return for Study Visit 1
about 7-14 days after the Screening Visit. Following Study Visit 1, you will be
asked to return 7-14 days later for Study Visit 2. (Study Visit 2 is the last visit.)
Transport via taxi will be arranged for you at each study visit. On arrival, you
will be asked to sit down in a wheelchair as we aim to minimise body movement
as much as possible. You will be asked questions about your health and a small
finger-prick blood sample will be taken to measure your blood glucose and
cholesterol.
A cannula (a small plastic tube used for blood sampling) will be put into your
arm for standard blood sampling. Blood samples will be taken to measure the
levels of blood clotting chemicals in your blood, both before and after an exercise
test. The exercise test is performed on a treadmill. If you have claudication you
will be asked to walk on the treadmill until the pain in your leg makes you want
to stop. If you are a normal volunteer you will be asked to walk on the treadmill
until you want to stop because of tiredness, or for 3 minutes, whichever is the
shorter. Once you have completed the exercise, you will again be asked to sit.
The times at which samples will be taken are: 60 minutes before exercise, 30
minutes before exercise, and then 1 minute, 5 minutes, 20 minutes, 40 minutes,
60 minutes and 120 minutes after the exercise test.
Once the final blood sample has been taken, at 120 minutes after exercise, the
doctor will check you are fine before you leave.
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What do I have to do?
If you are suitable for the study and agree to take part, there are certain
restrictions on what you can and cannot do:
• Smokers must not smoke for 1 hour before arriving for each study visit.
• Please eat any main meal, e.g. breakfast or lunch, over an hour before
arriving.
• For 48 hours before each study visit you should not make any changes to
your normal lifestyle e.g. unaccustomed exercise.
• Drugs which are used to treat intermittent claudication e.g. Prazilene®,
Trental® and Hexopal® should not be taken for 48 hours before the study
visits.
• You should continue taking all other medications during the whole time you
are taking part in the study, but should ensure that you tell the doctor in
charge of the study what drugs you are taking.
If you feel unwell during the study you should inform the study doctor, as he/she
will need to record details of this as part of the study.
What are the possible risks of taking part?
The treadmill exercise and the blood sampling procedure may cause some minor
discomfort. For example, there may be light bruising around the needle-puncture
site of the cannula for blood sampling. Participants with claudication will
develop their normal leg pain when they are asked to walk on the treadmill.
What are the possible benefits of taking part?
There is no intended clinical benefit from taking part in this study.
All study tests, examinations and medical care required as part of this study are
provided free.
What are my rights if something goes wrong?
Whilst Pfizer does not expect you to suffer any health problems by taking part in
this study, Pfizer may compensate anyone whose health suffers as a result of
participation in this study. You do not have to prove it was anyone's fault; if the
health problem arose because of your participation in the study you will be
compensated.
Pfizer accepts that this study is being conducted subject to the Association of the
British Pharmaceutical Industry (ABPI) guidelines entitled "Clinical Trial
Compensation Guidelines", relating to compensation for injury arising in the
course of clinical trials, under which any compensation will be considered: a
copy of the guidelines are available on request.
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Will my taking part in this study be kept confidential?
Your family doctor (General Practitioner) will usually be told that you have
decided to take part in this study.
Your records obtained while you are in this study as well as related health records
will remain strictly confidential at all times. However, these will need to be
made available to others working on Pfizer's behalf and possibly the independent
ethics committee members.
By signing the consent form you agree to this access for the current study and
any further research that may be conducted in relation to it (even if you
withdraw). The information disclosed will remain confidential.
What will happen to the results of the research study?
The results of this study are likely to be published in a medical journal.
You will not be identified in any report/publication.
Who has reviewed the study?
The East Birmingham Ethics Committee has reviewed the study.
If you have any problems with the conduct of the study, you can telephone the
secretary of the Ethics Committee on 0121 424 0594, who will arrange for your
worries to be investigated.
Data Protection: What use will be made of data collected from this study?
Personal data, which may be sensitive, (e.g. date of birth) will be collected and
processed but only for research purposes in connection with this study.
The study data will be sent around the world but you will not be referred to by
name or identified in any report or publication nor could the data be traced back
to you.
By taking part in this study you agree not to restrict the use of any data even if
you withdraw.
Pfizer Limited (who will control the use of the data) will take steps to ensure
your personal data is protected.
By agreeing to take part in this study you agree to the transfer of your personal
data to other Pfizer companies and to medicines regulatory authorities both
within and outside Europe where some data protection laws may not be as good
as in Europe.
192
Contact for further information
Thank you for taking the time to read (or have read to you) the information about
this study. If you have any questions or concerns now or at any time about the
study, your safety or your rights, please ask your doctor, his/her study staff or the
contact person(s) indicated below.
If you enter this study, you can contact the following people listed below if you
have any questions or worries.
Contact Details
• Study co-ordinator: Paul Burns
. Tel: 0121 424 2115 - during office hours
• Tel: 0121 424 2000 (switchboard) - outside office hours
• The East Birmingham Ethics Committee
. Tel: 0121 424 0594
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CONSENT FORM
AGREEMENT TO PARTICIPATE IN A CLINICAL STUDY
Subject Initials: Subject Name:
Date ofBirth: *Study doctor's name:
1 I confirm that I have read and understand the information
sheet dated 29 June 2001 for the above study and have had
the opportunity to ask questions.
2 I understand that my participation is voluntary and that I am
free to withdraw at any time, without giving any reason,
without my medical care or legal rights being affected.
3 I understand that others working on Pfizer's behalf and the
independent ethics committee will need my permission to
look at my health records both in respect of the current study
and any further research that may be conducted in relation to
it, even if I withdraw. I agree to this access.
4 I consent to the collection, processing, reporting and transfer
within and outside Europe of my personal and sensitive data
for healthcare and/or medical research purposes.
5 I agree not to restrict the use of any data or results, which
arise from this study.
6 I consent to the collection of a blood sample for targeted
genetic analysis (TAFI and related genes).
7 I agree to take part in the above study.
Signed by subject: Date:
Subject Name:
[Print please] please date your own signature at time of signing**
Signed by doctor: Date: / /
Study Doctor's Name:
[Print please]






















1 -60 122 112 92 113 119 127 101 129 206 150
1 -30 125 107 98 115 126 107 97 119 134 179
1 1 139 111 97 123 138 123 104 138 178 137
1 5 140 733 101 122 129 100 116 134 176 160
1 20 115 96 104 111 NA 107 99 122 159 214
1 40 154 110 94 112 131 152 100 141 149 150
1 60 119 116 97 115 138 164 117 180 151 162
1 120 119 167 100 112 140 148 143 140 211 181
2 -60 95 111 121 166 125 108 126 117 NA NA
2 -30 113 111 119 118 121 128 143 NA NA NA
2 1 100 117 125 140 136 120 151 132 NA NA
2 5 121 110 116 129 159 150 144 148 NA NA
2 20 98 135 101 133 130 144 137 NA NA NA
2 40 128 119 129 155 123 150 127 124 NA NA
2 60 109 113 114 130 132 149 135 138 NA NA
2 120 113 151 146 158 156 244 127 127 NA NA
NA=no sample received / unsuitable for analysis
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Assay: Flow cytometry - Platelet MESF (CD62)





1 -60 144 130 120 126 134 117 152 166 146 125 176
1 -30 165 159 117 138 134 121 143 148 159 139 164
1 1 151 135 123 135 143 123 146 162 151 125 135
1 5 186 129 133 129 156 120 144 207 162 148 167
1 20 142 141 131 141 163 123 138 193 140 136 142
1 40 144 146 126 146 157 131 139 178 157 136 166
1 60 161 148 120 137 170 120 133 161 135 128 163
1 120 170 113 115 133 184 115 133 176 179 159 353
2 -60 136 134 138 137 159 120 144 123 132 131 111
2 -30 135 123 149 138 177 132 146 116 130 171 137
2 1 139 136 155 134 141 124 166 122 126 115 120
2 5 143 143 161 292 157 127 167 127 131 120 130
2 20 138 149 123 130 142 123 175 129 126 136 115
2 40 147 151 150 132 152 133 171 118 190 146 122
2 60 148 146 133 132 128 135 NA 126 144 123 123
2 120 149 127 165 156 141 139 NA 120 175 139 120
NA=no sample received / unsuitable for analysis
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1 -60 3 1 3 3 0 0 0 -1 -3 0
1 -30 3 2 2 1 0 1 1 -2 -1 0
1 1 8 1 2 1 1 1 -2 -1 2 1
1 5 1 6 2 0 0 1 -2 0 0 0
1 20 9 -2 1 4 NA 3 0 -1 2 1
1 40 # 3 2 3 1 2 3 -1 0 1
1 60 0 1 2 2 0 2 -1 0 -2 1
1 120 5 2 3 6 0 3 -2 -1 -2 1
2 -60 1 1 0 0 0 -1 -2 6 NA NA
2 -30 5 2 2 -2 3 1 0 NA NA NA
2 1 -2 0 1 1 2 0 1 8 NA NA
2 5 0 0 1 2 -3 1 -1 5 NA NA
2 20 -3 2 0 0 1 0 0 NA NA NA
2 40 -2 1 0 -1 -1 0 1 -1 NA NA
2 60 3 5 0 1 -3 1 0 5 NA NA
2 120 -7 2 -3 -2 1 1 0 4 NA NA
NA^no sample received / unsuitable for analysis
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Assay: Flow cytometry - % monocyte-platelet complexes
g- Smoking Controls Non-smoking Controls
n>
2.5"
1 -60 -3 0 2 0 0 2 0 -1 -2 -1 0
1 -30 -5 1 0 0 0 0 1 -2 2 2 2
1 1 -3 0 1 0 1 2 1 0 0 2 1
1 5 -2 0 1 1 0 1 0 2 3 1 -1
1 20 -6 3 1 0 0 1 0 0 1 -2 1
1 40 -2 0 1 -1 0 3 -1 -2 -1 1 -1
1 60 -5 1 0 2 0 1 -8 -5 3 3 2
1 120 -2 -1 2 0 1 1 -1 -1 3 -1 -2
2 -60 1 1 0 -1 -1 1 6 -4 0 0 -1
2 -30 -1 0 0 2 -4 0 1 0 2 0 0
2 1 0 1 2 1 3 4 1 0 0 1 1
2 5 1 1 -1 3 0 0 0 0 1 0 0
2 20 0 -1 -2 0 -1 0 0 0 0 4 0
2 40 1 1 -1 1 -1 0 0 0 2 2 0
2 60 1 1 3 0 1 0 NA 0 0 0 2
2 120 -2 2 1 2 0 1 NA 2 0 1 2
NA=no sample received / unsuitable for analysis
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Assay: Flow cytometry - CDllb expression on lymphocytes
Claudicants
1 -60 2434 1670 2283 1914 2194 3059 2243 2702 3285 2369
1 ©fO1 2354 1641 2198 1956 2043 3115 2414 2576 2928 2361
1 1 2554 2148 2654 2173 2971 3673 2553 2621 3116 3014
1 5 2551 1933 2402 2115 2796 3224 2419 2543 2807 2743
1 20 2453 1722 2210 1978 2530 3339 2306 2469 3014 2727
1 40 2406 1671 2241 1939 2389 2778 2285 2579 2886 2494
1 60 2346 1666 2000 1941 2437 2768 2276 2597 2972 2542
1 120 2351 1566 1485 1880 2178 2574 1988 2386 2614 2477
2 -60 2797 1599 2163 1960 2604 2620 3445 3684 8455 NA
2 -30 2913 1714 2006 2046 2343 2714 3235 3373 8059 NA
2 1 3673 2312 2059 2349 4169 3174 3384 3579 9001 NA
2 5 3266 2167 1988 2226 3999 3125 3048 3646 9287 NA
2 20 3228 2037 2022 2073 3064 3052 3077 3528 8963 NA
2 40 3098 1926 1870 2044 2559 2688 2940 3304 7993 NA
2 60 2946 1846 1933 2139 2339 2837 2642 3237 7075 NA
2 120 3051 1905 1869 1946 2020 2715 2922 3271 8152 NA
NA=no sample received / unsuitable for analysis
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Assay: Flow cytometry - CDllb expression on lymphocytes




1 -60 2899 2335 2907 3165 3334 2900 NA 2053 2423 3203 4051
1 -30 2800 2192 3048 3157 3035 2720 NA 2119 2761 3447 3595
1 1 3121 2520 3586 5348 8478 3810 NA 2644 5119 5486 6272
1 5 2718 2286 3371 3993 6829 3186 NA 2538 4448 4221 5144
1 20 2629 2318 3150 4547 4875 3104 NA 2506 3133 4434 4445
1 40 2751 2375 2793 3715 3714 3294 NA 2343 3642 3082 4116
1 60 2657 2143 2688 3452 3442 2856 NA 2300 2830 3837 4396
1 120 2569 2164 2651 3123 3109 2651 NA 2394 2784 4457 4006
2 -60 2667 2491 2629 2685 2956 3054 2586 2567 2801 3112 4385
2 -30 2621 2442 2973 2862 2884 3230 2975 2544 2511 2746 4727
2 1 3047 2621 3397 4510 8534 3637 5484 3131 4948 4625 6876
2 5 3069 2488 3058 3680 6432 3147 4584 2791 4117 3987 6079
2 20 2746 2371 2943 3527 4519 3135 3656 2679 3412 3789 5144
2 40 2568 2398 2716 3248 3282 3310 3153 2524 2908 4203 4383
2 60 2640 2322 2671 3137 NA 3077 2976 2458 2638 3355 4573
2 120 2410 2253 2439 2706 NA 3190 3145 2570 2616 3070 4736












© § § § ©© S § ©© § o
w £ to © -J oe vc ©
1 -60 14.1 13.7 13.1 18.9 13.2 13.9 14.4 12.5 14 15
1 -30 13 13.8 13.5 14.2 13.2 13.9 14.4 12.7 13.4 15.4
1 1 12.9 15.5 13.2 14.9 13.8 13.3 14.7 13.3 13.1 15.5
1 5 13 NA 15.4 14.5 13.8 14.4 13.9 13.2 13.4 15.6
1 20 13.2 14.1 15.6 19.6 13.8 14.2 14.3 13 13.2 15.2
1 40 12.6 13.9 16.2 15 14.9 14.6 14.5 12.9 13.2 14.9
1 60 12.8 14.3 13.6 19 13.4 13.7 14.8 12.6 12.7 15.1
1 120 12.9 14 13.6 14.7 13.2 14.2 14.1 12.7 13.8 14.8
2 -60 12.8 13.7 13 14.8 13.7 13.4 13.8 13.6 13.1 NA
2 -30 12.3 13.5 12.9 14.5 13.8 13.6 16.1 13.7 NA NA
2 1 12.4 13.9 13 15.3 13.1 13.9 14.3 13.4 13.8 NA
2 5 12.4 13.8 12.9 14.5 13.8 13.3 14.3 13.4 13 NA
2 20 12.9 13.4 13 14.1 13.7 13.4 16.4 13.5 13.2 NA
2 40 12.6 13.8 13.5 14.4 13.6 13.4 13.7 13.7 13.4 NA
2 60 12.5 14.8 12.9 14.2 13.7 13.8 12.8 13.4 13.6 NA
















101 103 105 107 109 111 113 115 117 119 201 203 205 207 209 211 213 215 217 219
1 -60 14.3 14.7 13.7 14.2 13.6 NA NA NA NA NA 14 13.2 13.6 NA 13.7 12.8 NA NA NA NA
1 -30 13.9 14.3 13.8 14 13.4 NA NA NA NA NA 13.4 13.6 14.3 NA 13.4 12.7 NA NA NA NA
1 1 14.5 15.7 13.9 14.3 13.7 NA NA NA NA NA 13.1 13.2 15 NA 13.2 13 NA NA NA NA
1 5 14.1 15.7 14 14.1 14.2 NA NA NA NA NA 13.4 13.5 14.9 NA 13.3 13.1 NA NA NA NA
1 20 13.8 15.5 14 14.1 13 NA NA NA NA NA 13.2 13.4 14.6 NA 13.2 12.8 NA NA NA NA
1 40 14.7 16.6 13.6 13.6 13.7 NA NA NA NA NA 13.2 13.1 14.1 NA 13.1 12.7 NA NA NA NA
1 60 13.6 15.4 13.7 13.6 13.8 NA NA NA NA NA 12.7 13.4 14.3 NA 13.2 12.8 NA NA NA NA
1 120 14.1 15.6 13.9 14.5 13.3 NA NA NA NA NA NA 13.4 14.3 NA 12.9 13.3 NA NA NA NA
2 -60 13.8 NA 12.9 13.8 13 13 NA NA NA NA 13.2 13.6 14.4 NA 13 13.4 NA NA NA NA
2 -30 14.3 NA 14.2 13.9 13.2 12.8 NA NA NA NA 12.7 13.5 13.7 NA 12.8 12.6 NA NA NA NA
2 1 14 NA 14.1 13.2 14.1 13.2 NA NA NA NA 13.6 13 14.3 NA 12.9 13 NA NA NA NA
2 5 15.2 NA 14.1 12.9 14.2 13.4 NA NA NA NA 13.4 15 14.5 NA 13.1 13.1 NA NA NA NA
2 20 14.2 NA 13.8 13.3 15.7 13.4 NA NA NA NA 12.9 13 14.2 NA 12.9 12.5 NA NA NA NA
2 40 13.8 NA 13.4 13.3 14 13 NA NA NA NA 13.4 13.4 14.4 NA 13.2 12.7 NA NA NA NA
2 60 14.6 NA 16.4 13.4 13.2 13.9 NA NA NA NA 12.7 12.9 14.5 NA 12.9 13 NA NA NA NA
2 120 14.1 NA 13.6 13.6 13.8 13 NA NA NA NA 13.4 13.4 13.8 NA 13.3 12.6 NA NA NA NA
NA=no sample received / unsuitable for analysis
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001 002 003 004 005 900 007 008 009 010 Oil oK» ow o 9tfl oa\ o-j oX o9 oe
1 -60 14.1 13.7 13.1 18.9 13.2 13.9 14.4 12.5 14 15 NA NA NA NA NA NA NA NA NA NA
1 -30 13 13.8 13.5 14.2 13.2 13.9 14.4 12.7 13.4 15.4 NA NA NA NA NA NA NA NA NA NA
1 1 12.9 15.5 13.2 14.9 13.8 13.3 14.7 13.3 13.1 15.5 NA NA NA NA NA NA NA NA NA NA
1 5 13 NA 15.4 14.5 13.8 14.4 13.9 13.2 13.4 15.6 NA NA NA NA NA NA NA NA NA NA
1 20 13.2 14.1 15.6 19.6 13.8 14.2 14.3 13 13.2 15.2 NA NA NA NA NA NA NA NA NA NA
1 40 12.6 13.9 16.2 15 14.9 14.6 14.5 12.9 13.2 14.9 NA NA NA NA NA NA NA NA NA NA
1 60 12.8 14.3 13.6 19 13.4 13.7 14.8 12.6 12.7 15.1 NA NA NA NA NA NA NA NA NA NA
1 120 12.9 14 13.6 14.7 13.2 14.2 14.1 12.7 13.8 14.8 NA NA NA NA NA NA NA NA NA NA
2 -60 12.8 13.7 13 14.8 13.7 13.4 13.8 13.6 13.1 NA NA NA NA NA NA NA NA NA NA NA
2 -30 12.3 13.5 12.9 14.5 13.8 13.6 16.1 13.7 NA NA NA NA NA NA NA NA NA NA NA NA
2 1 12.4 13.9 13 15.3 13.1 13.9 14.3 13.4 13.8 NA NA NA NA NA NA NA NA NA NA NA
2 5 12.4 13.8 12.9 14.5 13.8 13.3 14.3 13.4 13 NA NA NA NA NA NA NA NA NA NA NA
2 20 12.9 13.4 13 14.1 13.7 13.4 16.4 13.5 13.2 NA NA NA NA NA NA NA NA NA NA NA
2 40 12.6 13.8 13.5 14.4 13.6 13.4 13.7 13.7 13.4 NA NA NA NA NA NA NA NA NA NA NA
2 60 12.5 14.8 12.9 14.2 13.7 13.8 12.8 13.4 13.6 NA NA NA NA NA NA NA NA NA NA NA
2 120 13.7 14.5 13 14 13.7 13.6 13.9 13.3 13.4 NA NA NA NA NA NA NA NA NA NA NA
NA=no sample received / unsuitable for analysis
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Assay: Activated partial thromboplastin time
Units: Seconds





101 103 105 107 109 111 115 117 119 201 203 205 207 209 211 213 215 217 219
1 -60 14.3 14.7 13.7 14.2 13.6 NA NA NA NA NA 14 13.2 13.6 NA 13.7 12.8 NA NA NA NA
1 -30 13.9 14.3 13.8 14 13.4 NA NA NA NA NA 13.4 13.6 14.3 NA 13.4 12.7 NA NA NA NA
1 1 14.5 15.7 13.9 14.3 13.7 NA NA NA NA NA 13.1 13.2 15 NA 13.2 13 NA NA NA NA
1 5 14.1 15.7 14 14.1 14.2 NA NA NA NA NA 13.4 13.5 14.9 NA 13.3 13.1 NA NA NA NA
1 20 13.8 15.5 14 14.1 13 NA NA NA NA NA 13.2 13.4 14.6 NA 13.2 12.8 NA NA NA NA
1 40 14.7 16.6 13.6 13.6 13.7 NA NA NA NA NA 13.2 13.1 14.1 NA 13.1 12.7 NA NA NA NA
1 60 13.6 15.4 13.7 13.6 13.8 NA NA NA NA NA 12.7 13.4 14.3 NA 13.2 12.8 NA NA NA NA
1 120 14.1 15.6 13.9 14.5 13.3 NA NA NA NA NA NA 13.4 14.3 NA 12.9 13.3 NA NA NA NA
2 -60 13.8 NA 12.9 13.8 13 13 NA NA NA NA 13.2 13.6 14.4 NA 13 13.4 NA NA NA NA
2 -30 14.3 NA 14.2 13.9 13.2 12.8 NA NA NA NA 12.7 13.5 13.7 NA 12.8 12.6 NA NA NA NA
2 1 14 NA 14.1 13.2 14.1 13.2 NA NA NA NA 13.6 13 14.3 NA 12.9 13 NA NA NA NA
2 5 15.2 NA 14.1 12.9 14.2 13.4 NA NA NA NA 13.4 15 14.5 NA 13.1 13.1 NA NA NA NA
2 20 14.2 NA 13.8 13.3 15.7 13.4 NA NA NA NA 12.9 13 14.2 NA 12.9 12.5 NA NA NA NA
2 40 13.8 NA 13.4 13.3 14 13 NA NA NA NA 13.4 13.4 14.4 NA 13.2 12.7 NA NA NA NA
2 60 14.6 NA 16.4 13.4 13.2 13.9 NA NA NA NA 12.7 12.9 14.5 NA 12.9 13 NA NA NA NA
2 120 14.1 NA 13.6 13.6 13.8 13 NA NA NA NA 13.4 13.4 13.8 NA 13.3 12.6 NA NA NA NA










-60 7 6 18 13 14 4 10 25 8 NA NA NA NA NA NA NA NA NA NA NA
-30 9 4 18 13 14 4 10 25 10 NA NA NA NA NA NA NA NA NA NA NA
1 9 4 18 13 16 4 10 27 12 NA NA NA NA NA NA NA NA NA NA NA
5 9 6 21 13 16 4 10 23 10 NA NA NA NA NA NA NA NA NA NA NA
20 11 6 18 13 16 4 10 24 12 NA NA NA NA NA NA NA NA NA NA NA
40 11 6 18 15 16 4 10 27 12 NA NA NA NA NA NA NA NA NA NA NA
60 11 6 18 13 16 4 10 19 12 NA NA NA NA NA NA NA NA NA NA NA
120 11 6 21 15 16 4 12 27 12 NA NA NA NA NA NA NA NA NA NA NA
2 -60 8 4 27 16 35 17 12 23 13 NA NA NA NA NA NA NA NA NA NA NA
2 -30 10 4 29 16 33 17 12 22 11 NA NA NA NA NA NA NA NA NA NA NA
2 1 10 6 29 16 34 17 12 25 13 NA NA NA NA NA NA NA NA NA NA NA
2 5 10 6 29 16 34 17 14 23 13 NA NA NA NA NA NA NA NA NA NA NA
2 20 10 6 29 14 33 19 14 23 13 NA NA NA NA NA NA NA NA NA NA NA
2 40 10 6 29 16 34 17 14 22 13 NA NA NA NA NA NA NA NA NA NA NA
2 60 10 6 29 16 37 17 16 23 11 NA NA NA NA NA NA NA NA NA NA NA
2 120 8 6 29 16 37 20 14 20 13 NA NA NA NA NA NA NA NA NA NA NA




g- Smoking Controls Non-smoking Controls
n>
3
101 103 SOI 107 109 111 113 115 117 119 201 203 205 207 209
K>
213 215 LU 219
1 -60 4 NA 16 4 NA NA NA NA NA NA 8 4 9 NA 4 NA NA NA NA NA
1 -30 4 NA 16 4 NA NA NA NA NA NA 6 7 9 NA 4 13 NA NA NA NA
1 1 4 NA 16 4 NA NA NA NA NA NA 8 7 9 NA 4 11 NA NA NA NA
1 5 6 6 16 4 NA NA NA NA NA NA 6 7 9 NA 4 11 NA NA NA NA
1 20 6 4 16 4 NA NA NA NA NA NA 8 7 11 NA 10 13 NA NA NA NA
1 40 4 4 16 6 NA NA NA NA NA NA 8 7 9 NA 6 13 NA NA NA NA
1 60 4 4 20 4 NA NA NA NA NA NA 8 7 11 NA 6 13 NA NA NA NA
1 120 NA 2 18 4 NA NA NA NA NA NA 8 7 NA NA 4 13 NA NA NA NA
2 -60 6 NA 11 4 11 NA NA NA NA NA NA NA 2 NA 4 10 NA NA NA NA
2 -30 6 NA 11 4 11 NA NA NA NA NA NA NA 8 NA 7 4 NA NA NA NA
2 1 4 NA 6 4 10 NA NA NA NA NA NA NA 6 NA 4 12 NA NA NA NA
2 5 6 NA 10 4 11 NA NA NA NA NA NA NA 2 NA 4 12 NA NA NA NA
2 20 4 NA 11 6 11 NA NA NA NA NA NA NA 6 NA 2 10 NA NA NA NA
2 40 6 NA 12 4 11 NA NA NA NA NA NA NA 6 NA 4 12 NA NA NA NA
2 60 6 NA 12 4 11 NA NA NA NA NA NA NA 8 NA 7 10 NA NA NA NA
2 120 6 NA 14 6 11 NA NA NA NA NA NA NA 8 NA 4 6 NA NA NA NA









































































1 -30 407 332 482 637 366 331 462 567 375 382 405 480 317 408 350 350 412 631 334 496
1 1 636 338 480 428 388 348 478 571 383 412 NA NA NA NA NA NA NA NA NA NA
1 5 416 304 514 484 381 390 522 523 383 419 NA NA NA NA NA NA NA NA NA NA
1 20 418 351 474 444 372 368 499 537 353 403 NA NA NA NA NA NA NA NA NA NA
1 40 414 307 492 441 355 346 494 574 364 401 NA NA NA NA NA NA NA NA NA NA
1 60 646 298 511 406 381 388 450 593 356 393 381 501 309 421 347 359 401 463 309 495
1
12
419 363 471 630 350 371 456 593 372 387 413 418 294 406 344 349 382 458 303 462
2 -60 400 319 583 441 659 727 598 602 360 369 NA NA NA NA NA NA NA NA NA NA
2 -30 393 326 582 560 699 605 542 539 325 365 345 503 329 630 283 381 637 506 332 447
2 1 402 345 532 492 529 627 547 556 377 361 NA NA NA NA NA NA NA NA NA NA
2 5 400 317 525 529 572 640 592 526 387 381 NA NA NA NA NA NA NA NA NA NA
2 20 511 322 522 489 548 698 530 533 368 377 NA NA NA NA NA NA NA NA NA NA
2 40 412 322 542 404 561 654 539 549 362 390 NA NA NA NA NA NA NA NA NA NA
2 60 387 331 546 491 545 665 527 536 358 383 NA NA NA NA NA NA NA NA NA NA
2
12
399 274 529 424 524 667 504 536 353 337
NA NA NA NA NA NA NA NA NA NA








o 103 105 107 109 111 113 115 119 201 203 205 207 209 211 213 215 217 219
1 -60 342 416 381 356 488 492 446 544 246 647 364 359 324 221 291 317 251 252 340 245
1 -30 333 420 380 344 495 480 338 721 269 528 480 293 328 191 296 322 297 264 324 250
1 1 362 429 421 367 460 480 NA NA NA NA 365 375 340 258 309 327 NA NA NA NA
1 5 341 404 411 364 464 509 NA NA NA NA 522 365 344 231 315 328 NA NA NA NA
1 20 329 409 371 351 474 520 NA NA NA NA 631 360 312 224 308 316 NA NA NA NA
1 40 335 406 380 336 424 525 NA NA NA NA 409 352 334 235 296 305 NA NA NA NA
1 60 326 414 384 355 408 520 338 555 309 560 397 362 326 204 297 309 248 242 290 269
1 120 346 390 369 357 412 417 361 627 298 561 389 370 328 216 318 300 241 253 275 268
2 -60 342 381 378 354 338 466 NA NA NA NA 462 368 324 250 279 NS NA NA NA NA
2 -30 324 379 377 282 369 458 662 461 321 496 418 353 334 252 283 277 267 408 350 252
2 1 344 422 383 511 393 467 NA NA NA NA 487 383 346 280 267 NS NA NA NA NA
2 5 336 417 371 360 408 638 NA NA NA NA 450 379 348 263 282 NS NA NA NA NA
2 20 332 391 368 401 402 452 NA NA NA NA 429 378 332 258 259 NS NA NA NA NA
2 40 335 365 368 457 358 440 NA NA NA NA 424 381 331 264 278 NS NA NA NA NA
2 60 324 398 351 397 362 449 NA NA NA NA 382 371 328 260 276 NS NA NA NA NA
2 120 337 386 358 386 347 635 NA NA NA NA 376 372 326 260 275 NS NA NA NA NA
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1 -60 2.4 11.3 5.6 13.1 1.3 11.4 14.2 16.3 18.7 20.1 NA NA NA NA NA NA NA NA NA NA
1 -30 38.9 32.4 50.4 17.7 1.8 14.6 17.8 56.0 26.0 18.0 10.9 17.5 20.5 15.3 8.9 7.7 11.4 3.0 35.0 18.9
1 1 78.1 78.4 54.0 52.0 18.0 12.7 31.6 45.4 20.5 42.5 NA NA NA NA NA NA NA NA NA NA
1 5 40.2 >60 101 34.8 4.1 11.0 37.9 41.7 14.7 15.0 NA NA NA NA NA NA NA NA NA NA
1 20 46.1 43.0 35.6 58.5 5.6 15.7 32.2 56.8 12.1 30.1 NA NA NA NA NA NA NA NA NA NA
1 40 266 53.3 35.5 28.1 8.6 52.5 33.5 149 12.2 15.2 NA NA NA NA NA NA NA NA NA NA
1 60 34.6 27.3 40.5 48.3 7.0 28.0 39.7 426 29.0 32.8 NA NA NA NA NA NA NA NA NA NA
1 12 NA NA NA NA NA NA NA NA NA NA
30.2 38.0 12.5 17.4 4.0 21.3 30.3 47.5 13.2 29.9
2 -60 8.7 3.0 17.0 15.7 7.9 11.6 10.6 7.2 34.9 10.5 NA NA NA NA NA NA NA NA NA NA
2 -30 11.4 21.0 22.6 12.5 3.0 23.8 25.8 38.7 39.9 16.1 NA NA NA NA NA NA NA NA NA NA
2 1 13.4 42.1 12.4 7.6 10.1 30.5 45.9 40.7 24.0 17.4 NA NA NA NA NA NA NA NA NA NA
2 5 18.5 50.2 11.4 9.6 3.9 21.1 47.2 22.6 19.0 22.7 NA NA NA NA NA NA NA NA NA NA
2 20 13.1 96.2 9.6 25.8 8.6 40.0 44.8 15.0 37.9 22.3 NA NA NA NA NA NA NA NA NA NA
2 40 11.9 56.9 10.8 22.6 7.7 229 47.0 18.2 30.8 19.4 NA NA NA NA NA NA NA NA NA NA
2 60 18.2 178 15.1 23.3 11.8 42.1 37.6 46.1 34.5 17.8 NA NA NA NA NA NA NA NA NA NA
2 12 NA NA NA NA NA NA NA NA NA NA
8.0 103 7.2 16.4 9.3 52.4 33.2 15.7 34.6 12.8








101 103 105 107 109 ** 113 115 117 119 201 203 205 207 209 211 213 215 217 219
1 -60 2.1 20.6 6.0 12.2 5.7 6.8 NA NA NA NA 1.9 1.4 8.7 4.6 1.7 14.6 NA NA NA NA
1 -30 2.1 33.2 9.3 14.7 17.7 3.0 30.1 9.7 12.3 15.3 6.8 26.9 18.4 7.8 3.8 7.4 7.3 5.4 7.6 17.5
1 1 5.0 16.0 11.1 42.7 12.6 42.2 NA NA NA NA 8.1 4.3 25.2 29.9 3.4 14.2 NA NA NA NA
1 5 3.2 19.2 4.1 18.5 8.1 10.5 NA NA NA NA 8.7 7.7 9.0 23.1 3.9 6.0 NA NA NA NA
1 20 6.4 10.2 4.9 18.9 18.1 8.1 NA NA NA NA 7.5 27.5 15.0 32.5 5.2 7.2 NA NA NA NA
1 40 3.2 8.8 3.2 27.2 15.7 20.7 NA NA NA NA 5.8 27.6 35.7 27.7 6.0 16.9 NA NA NA NA
1 60 7.9 8.3 5.1 29.0 21.3 7.1 NA NA NA NA 11.5 4.6 18.4 18.0 8.5 5.1 NA NA NA NA
1 120 5.5 8.9 3.8 22.9 6.5 22.3 NA NA NA NA 3.3 22.5 4.9 17.2 4.9 26.6 NA NA NA NA
2 -60 2.2 9.5 20.9 206 7.6 50.5 NA NA NA NA 2.2 9.5 20.9 206 7.6 50.5 NA NA NA NA
2 -30 6.5 16.4 12.8 323 5.5 12.7 NA NA NA NA 6.5 16.4 12.8 323 5.5 12.7 NA NA NA NA
2 1 10.0 21.0 9.2 44.3 9.2 17.9 NA NA NA NA 10.0 21.0 9.2 44.3 9.2 17.9 NA NA NA NA
2 5 13.0 18.7 4.2 187 7.4 7.0 NA NA NA NA 13.0 18.7 4.2 187 7.4 7.0 NA NA NA NA
2 20 13.3 17.7 6.0 47.2 8.4 40.0 NA NA NA NA 13.3 17.7 6.0 47.2 8.4 40.0 NA NA NA NA
2 40 13.5 16.0 3.5 32.2 11.2 14.6 NA NA NA NA 13.5 16.0 3.5 32.2 11.2 14.6 NA NA NA NA
2 60 4.9 16.3 55.1 26.5 11.3 8.7 NA NA NA NA 4.9 16.3 55.1 26.5 11.3 8.7 NA NA NA NA
2 120 4.3 15.4 4.2 7.3 5.7 8.4 NA NA NA NA 4.3 15.4 4.2 7.3 5.7 8.4 NA NA NA NA
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1 -60 0.80 0.70 0.70 0.70 0.70 1.10 1.60 1.00 0.90 0.90 NA NA NA NA NA NA NA NA NA NA
1 -30 1.00 0.80 1.20 0.70 0.70 1.50 2.50 1.50 1.00 1.00 1.10 0.90 0.50 0.90 0.80 0.60 0.60 0.60 0.90 0.50
1 1 1.40 1.40 1.20 1.20 0.60 1.00 2.30 1.80 0.90 1.30 1.00 0.50 0.60 0.90 0.60 0.80 0.80 0.60 0.70 0.50
1 5 1.30 0.90 1.10 0.80 0.70 1.30 2.40 3.10 0.90 0.90 0.90 0.60 0.40 0.70 0.50 0.90 0.70 0.80 0.70 0.50
1 20 1.30 1.10 1.00 1.00 0.80 1.40 2.30 2.20 0.80 1.10 0.90 0.40 0.70 1.10 0.50 0.70 1.10 0.50 0.80 0.60
1 40 3.70 1.20 0.80 0.80 0.90 1.60 2.50 3.30 0.80 0.80 0.90 0.50 0.70 1.10 0.40 1.00 0.50 0.70 1.80 0.60
1 60 1.10 0.70 1.00 1.00 0.90 1.80 2.60 2.80 0.90 1.00 1.00 0.50 0.40 0.90 0.40 0.80 1.10 0.40 0.70 0.60
1 120 1.10 0.90 0.70 0.60 0.70 1.40 1.90 1.60 0.80 1.00 1.10 0.50 0.40 0.90 0.30 1.00 0.70 0.40 0.60 0.70
2 -60 0.90 0.70 0.70 0.60 0.80 1.10 1.30 1.00 1.50 0.50 NA NA NA NA NA NA NA NA NA NA
2 -30 0.90 0.70 1.00 0.80 0.90 1.40 2.00 1.40 1.60 0.60 NA NA NA NA NA NA NA NA NA NA
2 1 0.60 1.00 0.60 0.60 0.70 1.10 2.40 2.30 1.30 0.70 NA NA NA NA NA NA NA NA NA NA
2 5 0.90 2.10 0.80 0.90 1.00 1.50 2.60 1.40 1.60 0.80 NA NA NA NA NA NA NA NA NA NA
2 20 0.70 1.40 0.70 1.00 1.10 2.00 2.00 1.30 1.40 0.90 NA NA NA NA NA NA NA NA NA NA
2 40 0.70 1.30 0.50 1.00 1.20 2.80 2.60 1.30 1.00 0.60 NA NA NA NA NA NA NA NA NA NA
2 60 0.80 2.20 0.60 1.10 1.00 2.10 2.20 1.80 1.20 0.70 NA NA NA NA NA NA NA NA NA NA
2 120 0.70 1.40 0.60 0.90 1.10 2.20 2.00 1.10 1.10 0.60 NA NA NA NA NA NA NA NA NA NA





g Smoking Controls Non-smoking Controls
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1 -60 0.80 0.80 0.70 1.00 0.90 0.70 NA NA NA NA 0.40 0.60 0.90 0.50 0.80 1.40 NA NA NA NA
1 -30 0.80 1.20 0.70 1.00 1.00 0.60 0.60 0.70 0.90 1.00 0.50 0.80 1.20 0.60 0.90 1.30 0.40 0.60 0.40 1.20
1 1 0.90 0.90 0.80 1.30 0.80 1.00 0.90 0.60 1.10 0.90 0.50 0.50 1.50 0.80 0.80 1.30 0.40 0.50 0.50 0.70
I 5 0.80 0.90 0.70 1.00 0.80 0.80 0.70 0.40 0.90 0.60 0.60 0.70 0.70 0.70 0.90 1.10 0.50 0.60 0.60 0.80
1 20 0.80 0.70 0.80 1.00 0.90 0.80 1.00 0.60 1.40 1.00 0.60 1.00 0.80 0.80 1.10 1.00 0.50 0.50 0.60 0.90
1 40 0.60 0.60 0.80 1.10 0.80 0.90 0.60 0.40 1.30 0.90 0.60 1.10 1.50 0.90 1.00 1.50 0.40 0.60 0.90 0.70
1 60 0.80 0.60 0.90 1.20 0.80 0.80 0.50 0.40 3.70 0.50 0.70 0.80 1.10 0.80 1.10 1.20 0.50 0.50 1.20 0.70
1 120 0.70 0.70 0.70 1.10 0.70 0.90 0.80 0.50 1.40 0.50 0.50 1.00 0.80 0.60 1.10 1.60 0.30 0.50 0.50 0.90
2 -60 1.20 1.10 0.90 3.00 0.50 1.40 NA NA NA NA 0.50 0.60 1.20 0.70 0.60 NS NA NA NA NA
2 -30 1.40 0.70 0.70 3.40 0.50 0.70 NA NA NA NA 0.60 0.70 1.10 0.70 0.60 NS NA NA NA NA
2 1 1.30 1.20 0.60 1.80 0.60 0.80 NA NA NA NA 0.50 0.70 1.50 0.90 1.20 NS NA NA NA NA
2 5 1.30 0.60 0.60 2.80 0.60 0.70 NA NA NA NA 0.60 0.70 1.50 0.60 0.50 NS NA NA NA NA
2 20 1.00 1.00 0.70 1.60 0.60 1.30 NA NA NA NA 0.70 0.70 1.10 0.70 0.60 NS NA NA NA NA
2 40 1.00 0.60 0.70 1.70 0.50 1.00 NA NA NA NA 0.80 0.70 1.20 0.60 0.50 NS NA NA NA NA
2 60 0.90 0.70 1.50 1.50 0.40 0.90 NA NA NA NA 0.70 0.60 0.90 0.90 0.70 NS NA NA NA NA
2 120 1.10 0.60 0.60 1.30 0.40 0.90 NA NA NA NA 0.70 0.50 0.80 0.60 0.50 NS NA NA NA NA

























1 -60 0.19 0.11 0.16 0.13 0.15 0.16 3.80 0.13 0.18 0.26 NA NA NA NA NA NA NA NA NA NA
1 -30 0.13 0.14 0.17 0.18 0.16 0.21 3.90 0.14 0.17 0.36 NA NA NA NA NA NA NA NA NA NA
1 1 0.23 0.09 0.18 0.15 0.17 0.23 4.30 0.14 0.23 0.39 NA NA NA NA NA NA NA NA NA NA
1 5 0.23 0.11 0.24 0.40 0.18 0.26 4.25 0.13 0.17 0.53 NA NA NA NA NA NA NA NA NA NA
1 20 0.37 0.76 0.17 0.39 0.22 0.33 4.25 0.40 0.22 0.55 NA NA NA NA NA NA NA NA NA NA
1 40 0.31 1.33 0.35 0.51 0.25 0.39 4.20 NA 0.24 0.71 NA NA NA NA NA NA NA NA NA NA
1 60 0.41 1.13 0.12 0.27 0.26 0.41 4.10 0.35 0.25 0.92 NA NA NA NA NA NA NA NA NA NA
1 120 0.33 0.32 0.31 0.32 0.43 0.25 4.00 0.18 0.28 0.67 NA NA NA NA NA NA NA NA NA NA
2 -60 0.25 0.16 0.15 0.11 0.13 0.12 2.55 0.10 0.12 NA NA NA NA NA NA NA NA NA NA NA
2 -30 0.22 0.16 0.16 0.19 0.17 0.17 2.55 0.14 0.15 NA NA NA NA NA NA NA NA NA NA NA
2 1 0.33 0.25 0.16 0.17 0.13 0.17 3.20 0.15 0.23 NA NA NA NA NA NA NA NA NA NA NA
2 5 0.33 0.40 0.18 0.16 NA 0.21 3.05 0.17 0.19 NA NA NA NA NA NA NA NA NA NA NA
2 20 0.33 0.66 0.19 0.20 0.15 0.21 3.15 0.20 0.19 NA NA NA NA NA NA NA NA NA NA NA
2 40 0.36 0.65 0.16 0.15 0.16 0.21 3.25 0.13 0.23 NA NA NA NA NA NA NA NA NA NA NA
2 60 0.38 0.50 0.21 0.27 0.23 0.27 3.05 0.13 0.24 NA NA NA NA NA NA NA NA NA NA NA
2 120 0.33 0.45 0.18 0.21 0.18 0.32 3.45 0.12 0.18 NA NA NA NA NA NA NA NA NA NA NA








o 103 105 107 109 111 113 Ul 117 119 201 203 205 207 209 211 213 215 217 219
-60 0.10 0.21 0.15 0.23 0.10 0.14 NA NA NA NA 0.14 NA NS 0.16 NA 0.22 NA NA NA NA
-30 0.12 0.25 0.14 0.27 0.13 0.13 NA NA NA NA 0.14 NA 0.15 0.37 NA 0.28 NA NA NA NA
1 0.13 0.32 0.15 0.20 0.12 0.21 NA NA NA NA 0.14 NA 0.18 0.40 NA 0.31 NA NA NA NA
5 0.13 0.35 0.15 0.32 0.12 0.24 NA NA NA NA 0.15 NA 0.19 0.38 NA 0.33 NA NA NA NA
20 0.14 0.33 0.18 0.41 0.14 0.29 NA NA NA NA 0.17 NA 0.22 0.56 NA 0.37 NA NA NA NA
40 0.12 0.31 0.16 0.40 0.21 0.29 NA NA NA NA 0.16 NA 0.17 0.56 NA 0.35 NA NA NA NA
60 0.12 0.43 0.15 0.42 0.22 0.28 NA NA NA NA 0.16 NA 0.13 0.47 NA 0.37 NA NA NA NA
120 0.13 0.63 0.15 0.69 0.13 0.37 NA NA NA NA 0.13 NA 0.14 0.36 NA 0.46 NA NA NA NA
-60 0.14 NA NS 0.16 NA 0.22 NA NA NA NA 0.14 0.16 0.08 NA NA NA NA NA NA NA
-30 0.14 NA 0.15 0.37 NA 0.28 NA NA NA NA 0.15 0.14 0.13 NA NA NA NA NA NA NA
1 0.14 NA 0.18 0.40 NA 0.31 NA NA NA NA 0.14 0.15 0.09 NA NA NA NA NA NA NA
5 0.15 NA 0.19 0.38 NA 0.33 NA NA NA NA 0.16 0.14 0.12 NA NA NA NA NA NA NA
20 0.17 NA 0.22 0.56 NA 0.37 NA NA NA NA 0.17 0.19 0.14 NA NA NA NA NA NA NA
40 0.16 NA 0.17 0.56 NA 0.35 NA NA NA NA 0.17 0.18 0.18 NA NA NA NA NA NA NA
60 0.16 NA 0.13 0.47 NA 0.37 NA NA NA NA 0.21 0.20 0.17 NA NA NA NA NA NA NA
120 0.13 NA 0.14 0.36 NA 0.46 NA NA NA NA 0.18 0.19 0.19 NA NA NA NA NA NA NA






































































1 -30 46 30 39 39 51 45 629 63 244 246 84 21 3 124 0 18 15 26 11 5
1 1 109 47 37 64 56 47 468 71 150 232 NA NA NA NA NA NA NA NA NA NA
1 5 60 14 35 42 29 47 555 54 245 182 NA NA NA NA NA NA NA NA NA NA
1 20 57 42 21 28 59 36 398 45 214 302 NA NA NA NA NA NA NA NA NA NA
1 40 48 57 32 62 32 37 659 76 248 338 NA NA NA NA NA NA NA NA NA NA
1 60 35 18 33 24 40 63 585 52 232 320 76 23 10 105 1 15 25 20 5 4
1 120 57 46 53 35 63 45 607 69 250 345 91 26 6 132 0 9 24 23 15 10
2 -60 38 28 37 26 84 58 679 50 323 177 NA NA NA NA NA NA NA NA NA NA
2 -30 44 19 32 28 84 64 666 41 285 132 52 24 5 90 2 20 19 8 42 20
2 1 49 18 46 32 81 61 798 39 338 163 NA NA NA NA NA NA NA NA NA NA
2 5 56 22 35 26 84 62 497 63 321 131 NA NA NA NA NA NA NA NA NA NA
2 20 35 22 49 28 64 56 776 45 304 144 NA NA NA NA NA NA NA NA NA NA
2 40 46 31 33 30 64 62 863 52 321 148 NA NA NA NA NA NA NA NA NA NA
2 60 39 18 21 12 70 61 686 58 298 172 NA NA NA NA NA NA NA NA NA NA
2 120 52 72 42 39 72 62 639 97 311 150 NA NA NA NA NA NA NA NA NA NA
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1 -60 37 164 25 135 36 80 9 5 4 16 22 44 44 6 12 72 0 27 0 0
1 -30 45 162 41 123 24 76 2 10 0 26 9 20 21 5 39 56 0 27 7 24
1 1 37 142 29 128 30 71 NA NA NA NA 12 20 13 14 11 66 NA NA NA NA
1 5 45 114 29 125 65 90 NA NA NA NA 15 15 21 12 72 88 NA NA NA NA
1 20 0 108 27 118 15 80 NA NA NA NA 8 13 19 9 12 34 NA NA NA NA
1 40 47 128 33 116 66 92 NA NA NA NA 11 19 26 8 27 82 NA NA NA NA
1 60 29 154 23 95 23 56 0 2 2 22 6 15 37 0 36 65 0 23 3 23
1 120 45 172 41 121 11 92 17 10 6 35 12 26 37 27 40 55 0 64 16 18
2 -60 35 93 49 161 9 59 NA NA NA NA 2 20 34 5 NA NA NA NA NA NA
2 -30 37 88 55 114 1 76 2 4 4 29 27 20 24 24 19 33 0 59 18 6
2 1 47 103 53 238 9 64 NA NA NA NA 16 23 45 8 6 NA NA NA NA NA
2 5 39 100 37 87 9 70 NA NA NA NA 16 16 34 9 31 NA NA NA NA NA
2 20 33 83 35 142 19 70 NA NA NA NA 9 22 26 6 21 NA NA NA NA NA
2 40 39 110 96 169 11 58 NA NA NA NA 20 32 21 23 7 NA NA NA NA NA
2 60 37 102 29 161 14 63 NA NA NA NA 11 19 30 2 11 NA NA NA NA NA
2 120 58 119 61 135 19 70 NA NA NA NA 29 36 29 114 7 NA NA NA NA NA
NA=no sample received / unsuitable for analysis
216
Assay: FbDP



































































1 -30 308 269 367 354 254 340 2655 475 836 1303 815 544 374 1728 284 217 259 355 257 224
1 1 359 276 360 150 214 346 2542 461 800 1323 NA NA NA NA NA NA NA NA NA NA
1 5 399 ns 357 342 257 361 2695 450 807 1263 NA NA NA NA NA NA NA NA NA NA
1 20 332 288 385 354 138 390 2851 486 801 1165 NA NA NA NA NA NA NA NA NA NA
1 40 358 327 369 364 262 354 2659 497 894 1132 NA NA NA NA NA NA NA NA NA NA
1 60 347 294 360 334 276 349 2683 488 875 1268 809 582 396 2034 298 232 261 366 262 224
1 120 348 335 395 350 267 363 2728 4104 903 1359 864 651 378 19113 313 266 294 384 277 249
2 -60 336 239 357 363 496 455 21034 337 1059 1297 NA NA NA NA NA NA NA NA NA NA
2 -30 324 237 378 357 519 442 2566 357 1019 1295 651 538 492 1003 263 220 261 295 363 3113
2 1 347 259 144 156 521 479 2483 359 977 1178 NA NA NA NA NA NA NA NA NA NA
2 5 358 276 346 367 545 469 2641 369 976 1213 NA NA NA NA NA NA NA NA NA NA
2 20 374 290 372 364 589 485 2844 300 1056 1087 NA NA NA NA NA NA NA NA NA NA
2 40 325 276 331 360 549 471 2452 358 1110 1119 NA NA NA NA NA NA NA NA NA NA
2 60 323 306 141 357 478 503 2459 367 1015 1134 NA NA NA NA NA NA NA NA NA NA
2 120 305 303 337 351 447 465 2635 370 1029 1301 NA NA NA NA NA NA NA NA NA NA
NA=no sample received / unsuitable for analysis
217
Assay: FbDP
Units: ng fibrinogen equivalents /ml
H
g Smoking Controls Non-smoking Controls
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O
s 103 105 107 109 111 113 115 117 119 201 203 205 207 209 211 213 215 h«*—1 219
-60 377 847 204 476 309 301 154 231 305 448 150 181 236 256 186 348 241 366 166 233
-30 416 640 232 4114 340 288 176 282 205 446 157 1104 252 237 203 362 276 442 158 291
1 402 812 215 4104 352 307 NA NA NA NA 158 1104 237 274 198 NA NA NA NA NA
5 388 617 222 484 363 298 NA NA NA NA 161 175 248 262 211 NA NA NA NA NA
20 356 891 243 519 374 281 NA NA NA NA 157 172 253 285 190 NA NA NA NA NA
40 3103 704 211 505 344 299 NA NA NA NA 151 180 1113 271 220 NA NA NA NA NA
60 336 953 210 463 351 315 162 222 280 449 158 178 166 263 196 349 238 437 207 288
120 356 943 220 479 320 330 179 207 267 377 150 190 1104 244 196 336 294 391 148 292
-60 356 991 236 568 346 2103 NA NA NA NA 180 186 129 277 216 NA NA NA NA NA
-30 366 1056 231 607 316 2103 170 237 300 258 189 198 148 278 214 361 201 536 214 221
1 352 9113 279 604 329 260 NA NA NA NA 184 194 177 303 219 NA NA NA NA NA
5 344 1012 255 633 342 279 NA NA NA NA 184 202 173 305 225 NA NA NA NA NA
20 333 869 258 684 323 2104 NA NA NA NA 173 188 230 289 214 NA NA NA NA NA
40 326 888 238 664 339 268 NA NA NA NA 1104 182 166 300 221 NA NA NA NA NA
60 335 982 242 615 337 265 NA NA NA NA 180 178 180 284 215 NA NA NA NA NA








































Oil 012 013 014 015 016 017 018 019 020
1 -30 20.2 6.6 11.4 13.3 7.5 20.7 9.1 10.8 27.4 10.2 11.0 12.8 14.7 12.9 18.4 16.1 16.2 14.8 8.0 9.9
1 ■ 11.9 15.7 10.6 13.9 8.2 20.8 10.60 13.3 34.2 11.6 14.8 13.8 17.8 15.2 18.7 18.7 17.2 15.3 10.4 11.7
1 5 13.6 12.7 10.0 12.0 7.2 20.2 8.6 10.2 29.9 11.4 13.7 13.7 17.0 14.0 19.3 16.8 14.7 15.0 10.9 10.6
1 20 12.1 9.9 10.6 13.7 5.7 20.4 7.8 9.4 29.2 10.4 12.5 12.8 14.4 13.7 13.5 16.3 15.6 14.3 9.0 9.6
1 40 9.7 9.5 10.5 13.6 4.7 18.3 7.5 9.8 30.9 8.5 12.3 11.8 14.2 13.6 16.9 14.8 14.7 12.2 8.8 9.8
1 60 13.6 9.1 10.3 15.0 4.5 15.5 8.7 8.8 27.2 10.2 11.9 12.9 14.0 13.3 18.1 15.7 16.1 12.1 8.1 9.8
1 120 12.1 6.7 9.4 13.6 6.9 14.9 7.9 11.9 24.8 9.0 11.8 12.7 13.4 11.4 15.0 14.9 14.9 8.8 7.6 9.1
2 -60 17.0 9.2 10.8 14.1 8.1 13.3 7.9 9.1 25.4 11.8 NA NA NA NA NA NA NA NA NA NA
2 -30 16.0 9.5 10.9 12.0 7.2 13.2 6.5 10.5 21.1 12.2 NA NA NA NA NA NA NA NA NA NA
2 1 13.3 12.0 10.4 10.6 7.7 15.4 7.1 14.2 25.5 15.8 NA NA NA NA NA NA NA NA NA NA
2 5 14.0 9.8 9.7 13.1 7.8 13.2 6.2 14.7 25.1 13.3 NA NA NA NA NA NA NA NA NA NA
2 20 17.8 8.1 9.7 10.5 6.0 11.9 6.0 13.3 24.8 13.6 NA NA NA NA NA NA NA NA NA NA
2 40 13.7 7.2 9.3 11.0 4.7 12.1 6.9 12.8 22.2 13.1 NA NA NA NA NA NA NA NA NA NA
2 60 10.7 6.9 9.0 14.1 6.7 14.6 6.2 11.4 22.4 13.2 NA NA NA NA NA NA NA NA NA NA
2 120 12.5 6.8 9.1 12.1 5.3 11.0 7.3 11.8 21.6 12.1 NA NA NA NA NA NA NA NA NA NA









101 103 105 107 109 111 113 115 -4 119 201 203 205 207 209
N
*- 213 215 217 219
1 -60 5.1 8.9 6.2 6.0 4.7 10.3 11.0 8.7 9.7 6.8 5.8 6.5
1 -30 4.5 8.6 7.0 5.9 4.7 10.7 4.0 6.8 11.1 13.4 11.0 8.6 9.7 6.1 5.4 8.0 8.2 10.5 7.7 15.3
1 1 6.2 9.7 7.9 8.2 11.4 10.9 7.9 8.4 11.4 18.9 12.8 8.9 12.0 NA 7.3 10.3 9.4 13.0 9.9 14.3
1 5 3.1 9.2 7.3 8.5 13.4 10.6 6.5 7.4 12.0 18.7 12.2 9.4 12.6 11.3 7.5 9.2 8.8 11.4 9.9 13.9
1 20 4.4 8.2 6.9 6.8 6.4 10.1 5.4 6.5 10.8 13.9 12.3 7.8 8.8 7.9 7.1 7.8 9.0 7.8 8.4 14.0
1 40 5.0 7.7 6.8 6.1 5.9 9.6 5.6 6.3 10.9 14.7 8.4 7.5 7.6 7.5 6.5 7.7 8.8 12.2 8.3 12.3
1 60 4.6 10.3 6.7 6.2 6.9 8.8 4.3 6.8 11.2 14.2 10.2 8.9 5.5 7.3 6.6 7.8 8.5 10.5 8.3 11.5
1 120 5.9 7.0 5.0 6.0 4.9 9.3 5.0 6.2 10.0 13.0 10.6 8.7 6.6 7.4 6.5 6.4 7.2 9.7 8.2 10.8
2 -60 7.6 12.5 7.6 4.5 9.4 11.4 NA NA NA NA 11.2 13.6 7.2 8.5 9.4 NA NA NA NA NA
2 -30 8.9 10.3 6.7 3.6 8.5 10.3 NA NA NA NA 10.9 8.2 8.5 8.2 6.6 NA NA NA NA NA
2 1 9.1 13.5 8.7 6.2 18.0 12.3 NA NA NA NA 12.7 8.9 13.4 14.0 8.2 NA NA NA NA NA
2 5 10.0 12.9 7.2 4.1 15.4 11.6 NA NA NA NA 9.3 7.8 7.5 11.8 7.6 NA NA NA NA NA
2 20 8.9 10.1 6.7 6.1 6.4 11.3 NA NA NA NA 10.5 6.8 5.6 9.1 7.1 NA NA NA NA NA
2 40 7.8 9.9 6.7 6.8 8.3 11.2 NA NA NA NA 10.3 6.6 4.2 8.3 6.8 NA NA NA NA NA
2 60 8.9 10.0 6.5 5.4 7.2 10.3 NA NA NA NA 11.0 7.4 5.2 7.5 6.1 NA NA NA NA NA
2 120 8.1 9.0 5.4 4.9 7.6 10.5 NA NA NA NA 10.7 5.5 4.5 8.1 4.7 NA NA NA NA NA









































































1 -30 0.70 0.50 0.40 0.30 0.70 0.40 0.90 0.30 0.40 1.10 0.60 0.20 0.60 1.20 1.60 0.30 1.00 1.30 1.40 1.30
1 1 1.40 3.00 0.70 0.70 1.50 1.50 1.10 0.80 1.00 2.50 1.70 0.70 1.40 1.90 3.00 1.10 2.00 2.50 2.00 2.00
1 5 NS 0.90 0.60 0.70 1.50 1.10 1.00 0.40 0.50 3.00 1.60 0.60 1.10 1.60 2.50 0.60 2.00 1.80 2.00 1.50
1 20 0.80 0.60 0.30 0.60 1.00 0.70 0.90 0.60 0.80 1.50 1.00 0.30 0.70 1.30 1.90 0.50 1.40 1.40 1.60 1.30
1 40 0.80 0.80 0.50 0.80 1.00 0.70 1.10 0.40 1.00 1.60 1.00 0.40 0.80 1.30 1.90 0.50 1.30 1.30 1.50 1.50
1 60 0.80 0.70 0.30 0.80 1.10 0.60 1.10 0.50 0.90 1.80 0.90 0.40 0.80 1.50 3.00 0.60 1.40 1.30 1.60 1.50
1 120 1.00 1.00 0.50 0.90 1.20 0.50 1.30 0.80 0.90 1.30 0.90 0.40 0.60 1.30 2.50 0.60 1.40 1.20 1.50 1.50
2 -60 0.50 0.50 BLQ 0.60 1.10 0.20 0.70 0.30 0.30 0.70 NA NA NA NA NA NA NA NA NA NA
2 -30 0.50 0.50 BLQ 0.70 1.10 0.30 0.70 0.40 0.40 0.80 NA NA NA NA NA NA NA NA NA NA
2 1 1.00 3.00 0.20 2.00 2.50 1.30 0.90 1.10 1.10 3.50 NA NA NA NA NA NA NA NA NA NA
2 5 0.80 1.30 BLQ 1.40 2.50 0.90 0.50 0.70 0.80 3.00 NA NA NA NA NA NA NA NA NA NA
2 20 0.70 1.10 BLQ 1.10 1.30 0.60 0.60 0.70 0.80 1.40 NA NA NA NA NA NA NA NA NA NA
2 40 0.70 0.80 BLQ 0.90 1.20 0.50 0.90 0.70 0.80 1.30 NA NA NA NA NA NA NA NA NA NA
2 60 0.80 0.70 0.20 1.10 1.90 0.60 0.90 0.80 0.80 1.30 NA NA NA NA NA NA NA NA NA NA
2 120 1.00 1.00 0.40 1.00 1.10 0.50 1.00 1.00 0.70 1.10 NA NA NA NA NA NA NA NA NA NA









h- *>* M f-J N> K» N>
H- s tn s M tn \e w l/l -J \s — W Ul -4 3
1 -60 0.8 0.5 0.4 0.3 1.0 0.2 1.0 0.9 BLQ 0.7 BLQ 0.2 0.6 0.8 0.5 0.3 0.2 0.4 0.3 0.9
1 -30 0.7 0.6 0.6 0.3 0.9 0.3 1.1 1.0 BLQ 0.7 BLQ 0.2 0.7 0.9 0.6 0.3 0.3 0.5 0.3 0.8
1 1 1.6 1.8 1.3 1.2 10.0 1.3 2.5 1.8 0.5 2.5 BLQ 1.0 5.0 6.0 1.6 1.1 0.8 1.5 0.9 1.6
1 5 1.0 1.0 0.9 0.8 9.0 0.8 1.8 1.6 BLQ 2.5 BLQ 0.5 3.0 3.5 1.2 0.7 0.6 1.1 0.7 1.3
1 20 0.7 0.8 0.6 0.5 1.5 0.5 1.1 1.1 BLQ 1.2 BLQ 0.3 1.1 1.6 0.8 0.4 0.5 0.7 0.4 1.1
1 40 0.7 0.8 0.8 0.6 1.1 0.5 1.3 1.3 BLQ 1.0 BLQ 0.3 0.8 1.1 0.7 0.4 0.6 0.8 0.4 1.1
1 60 0.7 1.5 0.8 0.7 0.9 0.6 1.2 1.3 BLQ 0.9 BLQ 0.2 0.9 0.9 0.7 0.4 0.5 0.9 0.4 1.2
1 120 0.8 0.9 0.8 0.5 0.7 0.6 1.2 1.4 0.2 1.0 BLQ 0.2 0.8 1.0 0.7 0.4 0.5 0.9 0.5 1.1
2 -60 0.5 0.4 0.6 0.4 0.6 BLQ NA NA NA NA BLQ 0.2 0.6 0.8 0.5 NA NA NA NA NA
2 -30 0.5 0.7 0.8 0.5 0.7 BLQ NA NA NA NA BLQ 0.2 0.8 0.9 0.5 NA NA NA NA NA
2 1 1.3 1.8 1.6 1.3 8.5 0.5 NA NA NA NA BLQ 1.0 4.5 NS 1.6 NA NA NA NA NA
2 5 0.9 1.5 1.2 0.9 6.0 0.3 NA NA NA NA BLQ 0.5 3.0 NS 1.1 NA NA NA NA NA
2 20 0.7 0.9 0.9 0.8 1.3 0.2 NA NA NA NA BLQ 0.2 1.2 1.1 0.7 NA NA NA NA NA
2 40 0.7 1.0 0.9 0.6 0.9 0.3 NA NA NA NA BLQ 0.2 0.9 1.0 0.8 NA NA NA NA NA
2 60 0.8 1.0 0.9 0.7 0.8 0.3 NA NA NA NA BLQ 0.2 1.0 0.9 0.8 NA NA NA NA NA
2 120 0.9 1.0 1.1 0.4 0.8 0.3 NA NA NA NA BLQ 0.2 0.7 1.2 0.7 NA NA NA NA NA














1 -60 115 43.0 169 171 67.5 46.1 92.4 145.3 216.8 66.8 NA NA NA NA NA NA NA NA NA NA
1 -30 35.0 75.0 195 119 71.5 48.0 39.9 167.5 147.1 54.7 NA NA NA NA NA NA NA NA NA NA
1 1 290 134.1 189 63.6 58.2 27.8 63.4 169.2 130.5 84.5 NA NA NA NA NA NA NA NA NA NA
1 5 233 63.4 57.6 125 115.4 30.7 79.7 54.5 61.5 67.3 NA NA NA NA NA NA NA NA NA NA
1 20 212 48.7 29.3 88.8 43.9 19.4 66.4 109.2 145.3 67.2 NA NA NA NA NA NA NA NA NA NA
1 40 195 78.5 63.8 111 27.9 50.7 60.2 27.1 226.5 49.3 NA NA NA NA NA NA NA NA NA NA
1 60 310 49.4 117 55.1 14.6 52.9 32.8 150.9 213.5 73.0 NA NA NA NA NA NA NA NA NA NA
1 120 105 36.3 135 85.9 109.1 35.3 47.7 115.0 199.1 73.8 NA NA NA NA NA NA NA NA NA NA
2 -60 132 117.2 69.3 107 121.0 43.4 119.8 139.6 211.0 NA NA NA NA NA NA NA NA NA NA NA
2 -30 116 168.5 76.2 134 148.2 48.9 60.2 159.1 194.8 NA NA NA NA NA NA NA NA NA NA NA
2 1 145 29.3 54.7 56.4 132.7 33.3 62.0 28.6 139.6 NA NA NA NA NA NA NA NA NA NA NA
2 5 109 229.2 68.1 130 225.8 29.3 11.5 97.3 233.6 NA NA NA NA NA NA NA NA NA NA NA
2 20 50 49.2 138 114 78.2 27.2 16.7 109.6 135.9 NA NA NA NA NA NA NA NA NA NA NA
2 40 119 73.4 106 63.5 92.6 27.5 34.5 115.6 122.6 NA NA NA NA NA NA NA NA NA NA NA
2 60 229 67.3 61.8 73.0 175.4 30.6 29.2 111.9 175.3 NA NA NA NA NA NA NA NA NA NA NA
2 120 157 25.8 48.1 83.7 126.9 26.9 29.0 123.8 139.2 NA NA NA NA NA NA NA NA NA NA NA
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2 w Cft -J § 1—I w Ul -J vo 2 s ■Jt -J VO *— w Ul vs
1 -60 65.9 74.1 77.4 57.3 63.3 45.4 NA NA NA NA 106 103 14.7 NA 51.9 71.4 NA NA NA NA
1 -30 49.8 107 63.2 66.2 43.7 42.9 NA NA NA NA 111 90.9 14.6 NA 40.9 73.8 NA NA NA NA
1 1 70.1 59.4 57.8 288 38.3 38.0 NA NA NA NA 119 102 10.6 NA 46.5 73.8 NA NA NA NA
1 5 52.4 75.3 54.8 69.1 41.8 47.6 NA NA NA NA 127 71.4 12.1 NA 40.7 76.2 NA NA NA NA
1 20 43.2 37.4 50.8 41.4 18.2 57.9 NA NA NA NA 133 35.7 9.8 NA 54.4 66.0 NA NA NA NA
1 40 177 64.6 42.9 58.4 34.4 66.3 NA NA NA NA 118 52.4 10.4 NA 49.7 70.8 NA NA NA NA
1 60 41.5 56.8 60.4 41.1 34.0 33.7 NA NA NA NA 61.5 48.5 6.0 NA 60.7 43.9 NA NA NA NA
1 120 62.1 256 46.9 54.0 30.7 72.5 NA NA NA NA 82.5 61.7 8.4 NA 41.3 74.9 NA NA NA NA
2 -60 153 NA 33.0 43.4 NA 60.3 NA NA NA NA 139 70.1 9.5 NA NA NA NA NA NA NA
2 -30 146 NA 26.6 67.2 NA 48.0 NA NA NA NA 137 108 11.5 NA NA NA NA NA NA NA
2 1 146 NA 71.9 63.2 NA 61.7 NA NA NA NA 159 116 7.4 NA NA NA NA NA NA NA
2 5 127 NA 66.0 311 NA 59.9 NA NA NA NA 167 141 8.6 NA NA NA NA NA NA NA
2 20 71.4 NA 63.7 37.9 NA 44.7 NA NA NA NA 140 101 8.1 NA NA NA NA NA NA NA
2 40 89.3 NA 57.3 70.7 NA 60.3 NA NA NA NA 136 74.8 8.0 NA NA NA NA NA NA NA
2 60 111 NA 46.8 79.9 NA 76.6 NA NA NA NA 131 78.7 7.0 NA NA NA NA NA NA NA
2 120 108 NA 46.5 47.5 NA 74.6 NA NA NA NA 110 109 7.2 NA NA NA NA NA NA NA







































































1 -30 8.9 14.8 22.0 23.1 9.6 21.7 6.9 24.7 41.8 10.2 14.0 36.3 31.9 6.3 8.8 34.7 11.2 36.6 18.1 4.7
1 1 12.1 15.6 20.0 NA 9.0 13.7 5.4 16.9 35.6 11.7 10.4 31.1 34.9 4.6 9.1 30.8 8.9 25.6 19.8 6.0
1 5 18.4 8.3 17.7 15.5 6.5 14.4 8.3 18.7 30.2 14.4 10.2 30.5 28.4 4.3 6.4 29.1 8.6 29.4 24.1 6.1
1 20 14.5 9.6 14.5 13.2 8.8 12.3 6.9 17.2 26.0 11.3 9.6 29.0 25.0 4.6 7.9 22.8 7.9 32.1 17.8 5.7
1 40 16.3 10.1 21.1 12.0 7.6 11.5 5.9 11.5 30.3 11.3 8.7 26.9 23.5 4.0 8.3 24.5 6.6 28.1 12.4 6.8
1 60 15.0 8.4 13.2 7.2 7.6 13.2 6.8 12.2 22.6 10.0 10.0 26.9 15.1 3.6 5.0 24.1 6.8 15.6 14.4 5.0
1 120 12.3 12.6 17.6 7.3 7.2 16.7 6.1 12.6 28.1 8.3 12.2 27.9 25.1 4.1 6.9 18.8 9.5 32.2 9.3 5.7
2 -60 22.3 16.1 48.9 13.6 11.7 26.2 6.1 22.4 31.3 14.9 NA NA NA NA NA NA NA NA NA NA
2 -30 18.2 16.0 48.8 15.3 12.7 25.7 4.4 21.1 29.3 12.0 NA NA NA NA NA NA NA NA NA NA
2 1 17.2 13.8 44.6 8.5 14.4 14.2 3.4 18.2 27.2 10.5 NA NA NA NA NA NA NA NA NA NA
2 5 21.3 13.3 45.2 9.7 8.9 16.5 3.4 18.6 27.3 10.3 NA NA NA NA NA NA NA NA NA NA
2 20 17.8 11.5 44.1 8.6 10.6 13.4 3.8 18.3 23.8 13.2 NA NA NA NA NA NA NA NA NA NA
2 40 12.5 11.7 35.6 6.5 9.5 11.5 5.1 15.6 27.2 12.3 NA NA NA NA NA NA NA NA NA NA
2 60 12.9 7.0 33.7 8.1 12.9 12.2 3.4 12.4 20.0 11.6 NA NA NA NA NA NA NA NA NA NA
2 120 12.8 10.1 20.6 10.5 11.7 17.6 4.8 10.4 23.7 10.9 NA NA NA NA NA NA NA NA NA NA







g Smoking Controls Non-smoking Controls
101 103 105 107 109 111 115 117 119 201 203 205 207 209 211 213 'Ji 217 <->vs
-60 37 164 25 135 36 80 9 5 4 16 22 44 44 6 12 72 0 27 0 0
-30 45 162 41 123 24 76 2 10 0 26 9 20 21 5 39 56 0 27 7 24
1 37 142 29 128 30 71 NA NA NA NA 12 20 13 14 11 66 NA NA NA NA
5 45 114 29 125 65 90 NA NA NA NA 15 15 21 12 72 88 NA NA NA NA
20 0 108 27 118 15 80 NA NA NA NA 8 13 19 9 12 34 NA NA NA NA
40 47 128 33 116 66 92 NA NA NA NA 11 19 26 8 27 82 NA NA NA NA
60 29 154 23 95 23 56 0 2 2 22 6 15 37 0 36 65 0 23 3 23
120 45 172 41 121 11 92 17 10 6 35 12 26 37 27 40 55 0 64 16 18
-60 35 93 49 161 9 59 NA NA NA NA 2 20 34 5 0 NA NA NA NA NA
-30 37 88 55 114 1 76 2 4 4 29 27 20 24 24 19 33 0 59 18 6
1 47 103 53 238 9 64 NA NA NA NA 16 23 45 8 6 NA NA NA NA NA
5 39 100 37 87 9 70 NA NA NA NA 16 16 34 9 31 NA NA NA NA NA
20 33 83 35 142 19 70 NA NA NA NA 9 22 26 6 21 NA NA NA NA NA
40 39 110 96 169 11 58 NA NA NA NA 20 32 21 23 7 NA NA NA NA NA
60 37 102 29 161 14 63 NA NA NA NA 11 19 30 2 11 NA NA NA NA NA
120 58 119 61 135 19 70 NA NA NA NA 29 36 29 114 7 NA NA NA NA NA


































































1 -30 8.10 4.90 7.20 9.10 6.00 8.20 8.40 8.00 16.00 7.10 9.7 14.5 7.1 6.1 9.8 15.4 10.1 7.5 3.7 2.9
1 1 7.90 5.20 5.70 4.00 3.30 8.40 6.50 7.10 16.60 7.60 NA NA NA NA NA NA NA NA NA NA
1 5 10.40 2.30 7.30 5.20 3.20 8.50 8.80 5.60 17.00 8.00 NA NA NA NA NA NA NA NA NA NA
1 20 7.60 4.20 8.00 2.70 3.40 8.50 7.40 7.20 21.20 4.40 NA NA NA NA NA NA NA NA NA NA
1 40 7.70 4.20 7.20 5.50 2.80 4.30 7.80 5.40 18.60 4.90 NA NA NA NA NA NA NA NA NA NA
1 60 7.70 3.60 2.20 4.40 2.60 5.10 3.80 3.90 16.80 5.30 NA NA NA NA NA NA NA NA NA NA
1 120 10.80 3.40 5.00 2.20 2.80 4.60 4.20 6.00 19.60 6.10 NA NA NA NA NA NA NA NA NA NA
2 -60 8.40 4.30 7.80 2.80 6.80 11.60 8.10 5.90 17.20 12.20 NA NA NA NA NA NA NA NA NA NA
2 -30 9.30 5.20 7.10 5.90 7.00 7.20 4.20 4.50 17.10 11.90 NA NA NA NA NA NA NA NA NA NA
2 1 10.20 3.60 7.00 3.10 6.30 8.50 5.50 4.70 17.00 10.50 NA NA NA NA NA NA NA NA NA NA
2 5 9.60 3.20 7.60 3.30 4.40 7.60 7.50 5.40 16.00 11.00 NA NA NA NA NA NA NA NA NA NA
2 20 8.50 5.20 13.30 4.40 4.10 6.60 6.10 3.90 19.40 9.50 NA NA NA NA NA NA NA NA NA NA
2 40 8.70 4.10 10.30 2.10 6.20 7.00 7.30 4.80 14.20 9.70 NA NA NA NA NA NA NA NA NA NA
2 60 10.00 3.60 6.20 5.30 5.60 5.00 7.10 4.20 17.80 8.20 NA NA NA NA NA NA NA NA NA NA
2 120 7.80 4.20 7.70 4.90 4.00 7.70 6.40 4.50 14.80 8.80 NA NA NA NA NA NA NA NA NA NA








KJ K* tJ K> K* Kl W
2 s Si 3 s - w 'yi -a V© 2 W tn J O - W til J VO
1 -60 6.40 5.00 10.2 6.90 4.00 7.60 NA NA NA NA 18.9 7.10 5.70 4.20 4.40 9.00 NA NA NA NA
1 -30 4.40 7.00 8.70 6.80 3.70 9.40 2.20 4.30 11.0 9.40 18.0 7.50 4.50 5.00 4.20 11.8 8.00 5.00 7.90 10.2
1 1 3.30 6.90 13.0 6.40 4.30 4.80 NA NA NA NA 25.2 6.60 5.30 5.70 4.10 9.50 NA NA NA NA
1 5 4.70 6.40 9.40 5.70 4.20 7.70 NA NA NA NA 33.9 5.70 4.90 5.90 4.10 10.6 NA NA NA NA
1 20 2.70 6.30 7.40 5.40 3.90 6.10 NA NA NA NA 31.8 5.60 5.00 4.80 4.20 9.00 NA NA NA NA
1 40 5.00 3.00 9.30 4.60 3.60 8.00 NA NA NA NA 25.5 6.60 5.00 4.50 4.30 10.4 NA NA NA NA
1 60 3.90 3.80 8.10 2.70 3.00 5.60 NA NA NA NA 21.3 6.60 5.20 4.00 4.10 7.80 NA NA NA NA
1 120 3.30 5.70 8.00 3.30 3.90 7.40 NA NA NA NA 19.8 6.40 3.80 4.20 4.00 6.60 NA NA NA NA
2 -60 6.50 7.40 9.20 3.10 5.90 9.60 NA NA NA NA 37.2 6.40 4.70 5.40 6.10 NA NA NA NA NA
2 -30 8.20 6.30 8.90 2.0 5.70 10.1 NA NA NA NA 31.8 6.50 7.40 6.10 6.70 NA NA NA NA NA
2 1 6.80 7.10 8.80 3.00 5.10 7.80 NA NA NA NA 36.3 8.00 3.70 6.40 6.00 NA NA NA NA NA
2 5 6.80 6.70 8.40 3.30 5.10 7.10 NA NA NA NA 33.6 6.30 5.20 6.40 5.30 NA NA NA NA NA
2 20 6.50 6.00 8.40 2.90 5.60 6.90 NA NA NA NA 30.3 7.10 4.70 5.40 6.30 NA NA NA NA NA
2 40 3.60 4.80 9.30 4.20 4.20 7.30 NA NA NA NA 35.7 6.50 4.70 5.30 5.60 NA NA NA NA NA
2 60 3.60 4.70 6.90 3.10 4.90 7.20 NA NA NA NA 25.2 6.50 4.50 5.00 5.50 NA NA NA NA NA
2 120 5.30 5.00 8.00 3.10 4.70 6.60 NA NA NA NA 24.3 8.10 2.80 4.80 4.80 NA NA NA NA. NA





































































1 -30 425 329 268 417 359 308 906 509 465 660 482 285 335 818 495 320 514 775 385 677
1 1 451 363 272 ns 378 336 914 509 491 682 NA NA NA NA NA NA NA NA NA NA
1 5 447 ns 281 433 384 339 920 519 482 675 NA NA NA NA NA NA NA NA NA NA
1 20 470 348 281 432 211 355 907 510 487 668 NA NA NA NA NA NA NA NA NA NA
1 40 479 366 294 486 412 362 927 516 495 833 NA NA NA NA NA NA NA NA NA NA
1 60 520 355 317 425 410 361 977 545 509 851 NA NA NA NA NA NA NA NA NA NA
1 120 537 369 309 440 425 384 907 551 532 782 NA NA NA NA NA NA NA NA NA NA
2 -60 407 317 217 447 602 419 809 397 511 589 NA NA NA NA NA NA NA NA NA NA
2 -30 401 315 210 447 632 433 812 409 499 560 NA NA NA NA NA NA NA NA NA NA
2 1 413 344 139 239 662 474 815 449 525 585 NA NA NA NA NA NA NA NA NA NA
2 5 425 333 221 464 659 465 828 434 525 583 NA NA NA NA NA NA NA NA NA NA
2 20 419 339 222 472 670 460 861 453 517 583 NA NA NA NA NA NA NA NA NA NA
2 40 433 327 225 477 689 468 855 452 518 614 NA NA NA NA NA NA NA NA NA NA
2 60 465 319 126 477 678 487 855 466 515 670 NA NA NA NA NA NA NA NA NA NA
2 120 460 342 251 476 688 501 825 504 525 652 NA NA NA NA NA NA NA NA NA NA








101 103 105 107 109 111 M 115 -J 119 201 203 205 207 209
to
213 215 LIZ 219
-60 474 378 251 450 548 334 NA NA NA NA 197 329 364 264 515 NA NA NA NA NA
-30 476 364 261 445 489 326 476 843 399 534 186 312 357 260 511 391 243 288 255 301
1 500 371 279 458 508 370 NA NA NA NA 197 337 385 286 543 NA NA NA NA NA
5 477 365 280 448 519 368 NA NA NA NA 202 329 396 302 532 NA NA NA NA NA
20 473 373 282 450 523 355 NA NA NA NA 195 328 414 297 508 NA NA NA NA NA
40 477 386 287 464 532 361 NA NA NA NA 187 343 426 290 509 NA NA NA NA NA
60 507 461 278 447 676 366 NA NA NA NA 180 334 425 299 643 NA NA NA NA NA
120 485 473 293 440 575 377 NA NA NA NA 173 343 446 285 663 NA NA NA NA NA
-60 338 459 304 482 429 283 NA NA NA NA 215 307 345 270 508 NA NA NA NA NA
-30 345 466 331 497 435 292 NA NA NA NA 203 303 339 276 523 NA NA NA NA NA
1 382 507 344 512 466 296 NA NA NA NA 208 320 400 295 553 NA NA NA NA NA
5 362 489 345 509 469 300 NA NA NA NA 215 329 400 305 526 NA NA NA NA NA
20 361 473 341 507 495 291 NA NA NA NA 204 316 412 298 540 NA NA NA NA NA
40 365 497 353 512 507 303 NA NA NA NA 203 318 448 309 547 NA NA NA NA NA
60 355 536 376 531 546 294 NA NA NA NA 210 309 421 311 568 NA NA NA NA NA
120 361 544 391 520 522 309 NA NA NA NA 192 310 455 292 550 NA NA NA NA NA








© g g g § © g g g o e e es* o o o e oh- o tiSi w £ cn 4s vl 06 vo o *■» Si w 4s C/l o\ 06 o
1 -60 5.9 3.6 5.4 3.0 3.0 4.6 4.0 4.3 2.1 2.9 NA NA NA NA NA NA NA NA NA NA
1 -30 6.4 3.2 5.3 3.6 4.2 4.6 3.7 3.9 2.0 2.9 4.2 3.3 5.7 4.4 5.7 4.2 3.7 5.2 3.0 4.2
1 1 6.7 3.5 4.7 3.7 2.6 4.9 3.8 4.2 2.9 3.2 NA NA NA NA NA NA NA NA NA NA
1 5 7.2 1.5 5.1 4.8 3.4 4.6 3.7 4.5 2.9 3.4 NA NA NA NA NA NA NA NA NA NA
1 20 6.4 3.3 5.4 3.2 3.4 4.4 3.6 4.4 2.9 3.6 NA NA NA NA NA NA NA NA NA NA
1 40 6.1 3.4 4.9 2.3 2.5 5.0 3.8 4.3 2.7 2.4 NA NA NA NA NA NA NA NA NA NA
1 60 8.1 3.7 4.7 2.4 2.6 5.0 4.2 4.1 2.5 2.8 NA NA NA NA NA NA NA NA NA NA
1 120 6.7 3.3 4.4 3.0 2.8 5.2 4.1 4.3 2.3 3.0 NA NA NA NA NA NA NA NA NA NA
2 -60 5.9 3.1 4.6 2.1 3.0 4.9 3.5 3.6 2.3 3.8 NA NA NA NA NA NA NA NA NA NA
2 -30 6.7 3.1 4.7 3.3 2.7 4.3 3.2 3.3 2.0 4.2 NA NA NA NA NA NA NA NA NA NA
2 1 6.1 3.5 5.3 3.7 3.4 4.9 3.5 2.9 2.3 4.5 NA NA NA NA NA NA NA NA NA NA
2 5 5.9 3.1 5.5 4.5 3.6 5.0 3.1 4.1 2.9 3.4 NA NA NA NA NA NA NA NA NA NA
2 20 6.2 3.0 5.3 3.7 3.1 4.6 3.3 3.5 2.5 3.4 NA NA NA NA NA NA NA NA NA NA
2 40 5.9 3.1 4.1 3.4 2.8 4.4 3.4 3.4 2.1 2.8 NA NA NA NA NA NA NA NA NA NA
2 60 7.8 3.6 4.6 3.7 3.0 5.0 4.1 2.7 2.0 3.1 NA NA NA NA NA NA NA NA NA NA
2 120 6.1 3.0 4.8 3.0 3.7 5.2 3.9 2.8 1.9 3.4 NA NA NA NA NA NA NA NA NA NA









101 103 105 107 109 111 w SIl 119 201 203 205 207 209 211 213 215 217 219
1 -60 7.3 6.1 5.0 3.0 4.2 3.4 NA NA NA NA 3.2 5.2 4.9 3.4 2.6 3.6 NA NA NA NA
1 -30 5.4 5.5 5.6 4.0 3.9 2.7 4.6 5.8 6.4 5.2 2.7 5.1 4.2 2.9 2.7 4.5 2.3 4.9 4.6 5.4
1 1 5.8 4.9 6.5 3.9 3.4 3.0 NA NA NA NA 2.8 4.8 5.5 3.6 2.9 3.9 NA NA NA NA
1 5 4.6 5.2 5.1 3.1 4.7 3.8 NA NA NA NA 3.4 4.9 5.5 4.2 2.6 4.6 NA NA NA NA
1 20 7.8 5.2 5.7 3.6 4.4 3.7 NA NA NA NA 3.4 5.2 6.0 3.6 3.1 5.5 NA NA NA NA
1 40 7.0 5.1 4.4 3.3 4.4 4.7 NA NA NA NA 2.8 5.2 5.2 3.3 2.9 4.0 NA NA NA NA
1 60 6.9 7.2 5.8 2.5 3.3 3.4 NA NA NA NA 3.8 5.5 4.8 3.2 2.5 4.6 NA NA NA NA
1 120 6.3 5.4 6.4 2.8 2.6 3.1 NA NA NA NA 2.9 6.1 4.1 3.3 2.0 4.2 NA NA NA NA
2 -60 6.7 4.2 6.0 2.9 3.6 3.5 NA NA NA NA 3.1 4.9 4.9 2.9 2.8 NA NA NA NA NA
2 -30 6.2 4.0 5.1 2.8 4.1 3.9 NA NA NA NA 2.7 6.3 5.3 2.3 3.0 NA NA NA NA NA
2 1 6.8 5.1 5.3 2.9 5.3 3.2 NA NA NA NA 3.1 4.2 4.5 3.4 3.5 NA NA NA NA NA
2 5 5.5 4.7 6.3 4.0 4.3 3.9 NA NA NA NA 2.6 5.1 5.7 4.1 2.8 NA NA NA NA NA
2 20 5.2 4.2 4.4 3.3 4.1 4.7 NA NA NA NA 2.9 5.3 4.9 3.5 2.8 NA NA NA NA NA
2 40 4.9 4.0 5.5 2.9 4.6 3.3 NA NA NA NA 3.1 6.7 5.8 3.5 3.1 NA NA NA NA NA
2 60 6.5 4.1 5.6 3.0 4.2 3.5 NA NA NA NA 3.7 4.8 4.3 3.6 3.0 NA NA NA NA NA
2 120 6.4 4.2 4.1 2.4 4.3 3.5 NA NA NA NA 3.0 4.7 4.1 3.2 3.1 NA NA NA NA NA
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Exercise in Ciaudicants is Accompanied by Excessive
Thrombin Generation
P. Bums1, T. Wilmink1, C. Fegan2 and A. W. Bradbury*1
1University Department of Vascular Surgery and department ofHaematology, Heartlands Hospital, Birmingham
Background: exercise in IC leads to ischaemia-reperfusion injury of leg muscles and a systemic inflammatory response, but
the effect of on coagulation is unknown.
Objective: to compare the effect of exercise on thrombin formation and fibrin turnover in patients with IC (n= 10), and age
and sex matched smokers (IS] n= 5) and non-smokers (INS] n — 5) without peripheral vascular disease.
Methods: blood was taken from subjects 60 and 30min before, and 1, 5, 20, 40, 60 and 120min after, treadmill exercise.
Markers of thrombin generation (thrombin-antithrombin complexes [TAT] and prothrombin fragments 1+2 [PF1 + 2])
and fibrin turnover (D-dimer and fibrin degradation products IFbDP]) were assayed at each time point.
Results: following exercise, thrombin generation was significantly greater in the claudicant group compared to the control
groups (Area Under Curve IAUC] post exercise IC vs S vs NS; TAT 3960 vs 1623 vs 1476 vs — 0.007 Kruskal-Wallis
[KW]; PF1 +2 163 vs 107 vs 123 p= 0.024 KW). Pre and post-exercise, fibrin turnover in ciaudicants was similar to
smoking controls, but higher than non-smoking controls. (AUC post exercise IC vs NS; D-dimer 6340 vs 2754 p = 0.055
Mann-Whitney U[MW); FbDP 45113 vs 21511 p = 0.009MW).
Conclusion: when compared to non-claudicants, exercise in IC is associated with excessive production of thrombin. Despite
this, ciaudicants have a similar level offibrin turnover suggesting a possible defect in fibrinolysis. This prothrombotic state
may contribute to the excess thrombotic morbidity and mortality suffered by ciaudicants.
Key Words: Coagulation; Claudication; Ischaemia-reperfusion.
Introduction
Intermittent claudication affects 5% of the middle-
aged (55-75 years) European population. While only
1-2% ciaudicants progress to critical limb ischaemia
each year, they suffer an annual cardiovascular mor¬
tality that is 3-4 times greater than that observed in an
age and sex matched non-claudicant population.1
Although this may simply reflect the burden of
multi-system atherosclerosis, even when the extent of
concomitant coronary and extracranial vascular dis¬
ease is taken into account, ciaudicants still appear to
suffer an excess of thrombotic vascular events.2 The
reasons for this remain ill-defined. However, several
groups have shown that when ciaudicants walk and
then rest they suffer repeated episodes of leg muscle
ischaemia- and reperfusion injury (IRI), which in turn
leads to the development of a systemic inflammatory
response (SIR). It has been suggested that this SIR
* Please address all correspondence to: A. W. Bradbury, Professor of
Vascular Surgery, Lincoln House (Research Institute), Birmingham
Heartlands Hospital, Bordesley Green East, Birmingham,
B9 5SS, U.K.
injures the endothelium, accelerates atherosclerosis
and may increase thrombotic risk.3 However, to date,
the effect of exercise in ciaudicants on haemostasis has
not been adequately defined. The aim of the present
study, therefore, was to compare the effect of treadmill
exercise on thrombin production and fibrin turnover
in ciaudicants and controls without peripheral arterial
disease (PAD).
Methods
Ten smoking male ciaudicants and 10 aged-matched
(±3 years) male controls (five smoking, five non¬
smoking) without PAD were recruited (see Table 1
for inclusion and exclusion criteria and Table 2 for
baseline patient and control characteristics). To avoid
walking patients were transported to hospital by
taxi, and then to a quiet, temperature-controlled
(25-28 °C) room within the Vascular Studies Unit
(VSU) by wheelchair. Subjects were asked to abstain
from smoking, or eating a heavy meal for 1 h prior
to arrival, and avoid unaccustomed exercise in the
1078-5884/03/020150+ 06 $35.00/0 © 2003 Elsevier Science Ltd. All rights reserved.
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Table 1. Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Claudicants Controls
Male
Walking unrestricted by co-morbidity
Claudicant, as defined by Edinburgh
Claudication Questionnaire, for 6 months
Resting ankle-brachial pressure index <0.8
Absolute claudication distance 25-300m
Smoker of equivalent of at least
20 cigarettes per day, for >10 years
No history of peripheral arterial disease
Palpable pedal pulses, and resting
ankle-brachial pressure index 1.0
* Smoker of equivalent of at least
20 cigarettes per day, for >10 years




Current therapy with warfarin
* Smoking controls only,
tNon-smoking controls only.




n= 5 n= 5
Age, years (IQR) 61 69 69 0.57*
(58-70) (60-70) (60-72)
Body mass index, 23 25 27 0.21*
kg/m2
(IQR) (21-25) (23-29) (23-34)
Smoking
Pack years 42 50 0 0.77*
Medical history
IHD 0 0 1
CVD 0 0 0
HT 0 0 0
COAD 6 0 0 0.011
Medication
Aspirin 9 2 1 0.02f
P-blocker 0 0 1
ACEI 0 0 1
PAD
Lowest ABPI 0.56 1.07 1.13 <0.001*
(median)
Walking distance 112 174 174 0.005*
(median), m
Cholesterol 187 197 168 0.33*
(mmol/1)
IQR = interquartile range; IHD= ischaemic heart disease (angina,
myocardial infarction or coronary bypass surgery); CVD = cerebro¬
vascular disease (transient ischaemic attack or stroke); HT= hyper¬
tension; COAD= chronic obstructive airway disease; Ca blocker=
calcium channel blocker; ACEI =ACE inhibitor.
* Kruskal-Wallis.
t Fishers Exact Test.
preceding 24 h. While in the VSU the only exercise
or movement allowed was on the treadmill; for
example, if patients required the toilet they were
taken by wheelchair. All the studies commenced
between 08.30 and 09.00 am. An 18 gauge cannula
inserted into a right antecubital fossa vein, which
Fig. 1. Calculation of the area under the curve (AUC). Total
AUC = area of A-|-B-f-C +D +E-|-F-f-G + H.
was kept patent with boluses of 0.9% saline. After
60 and 90min of sitting, blood was drawn from the
cannula. After sitting for a total of 120min, subjects
underwent a treadmill exercise test (3.5km/h at a
gradient of 12) until the absolute claudication dis¬
tance was reached (claudicants), or for 3min (con¬
trols). At the end of the exercise blood was collected
at 1, 5, 20, 40, 60 and 120 min. Fibrinogen, thrombin-
antithrombin (TAT) complexes and prothrombin
fragments (PF) 1 + 2 (all Dade-Behring, IL, USA);
D-dimer (American Diagnostics, CT, U.S.A.); fibrin-
degradation products FbDPs) (Organon Teknika,
Turnhout, Belgium) were assayed at each time point
using commercial assays. Reference ranges for these
assays are appended.
SPSS version 10.0.5 package (Statistical Package for
Social Sciences Inc,Chicago, IL, U.S.A.) was used for all
statistical analysis. Pre-exercise values were calculated
by taking the average of the results of the two pre-
exercise samples. For samples taken post-exercise, the
area under the curve (AUC) was calculated for
each individual, at each visit (Fig. 1). Subjects mean
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pre-exercise, and post-exercise values were calculated
from the two visits, so that each individual had one
pre-exercise, and one post-exercise value for statistical
analysis. Groups were compared pre- and post-
exercise with the Kruskal-Wallis test. Where this
returned a value of p < 0.05, the Mann-Whitney
Lf-test was used to identify the groups that had signi¬
ficantly different values. A value of p < 0.05 was taken
to be statistically significant.
Results
The groups were well controlled for age and body
mass index (Table 2). Significantly more claudicants
than controls were taking aspirin, which was to be
expected. There were also significantly more claudi¬
cants with chronic obstructive airways disease than in
either control group, even though the smoking con¬
trols had a similar smoking history. At baseline,
fibrinogen concentrations were significantly higher
in claudicants than the non-smoking controls and
trended higher than in smoking controls. These differ¬
ences persisted after exercise. All groups showed a
small rise in fibrinogen concentrations with exercise
(Fig. 2). At baseline, claudicants and the smoking con¬
trols had similar levels of TAT and PF1 + 2. However,
treadmill exercise lead to significantly higher levels of
TAT and PF1 + 2 in the claudicant group than the
controls (Figs 3 and 4). At baseline and post-exercise,
Time (minutes)
Fig. 2. Plot of fibrinogen with time, for the three subject groups. *Average pre-exercise, claudicants vs smoking controls (Mann-Whitney U).
**Average pre-exercise, claudicants vs non-smoking controls (Mann-Whitney U). fAUC post-exercise, claudicants vs smoking controls






Fig. 3. Plot of thrombin-antithrombin complexes with time, for the three subject groups. *Average pre-exercise, between three groups
(Kruskal-Wallis). jAUC post-exercise, claudicants vs smoking controls (Mann-Whitney U). ffAUC post-exercise, claudicants vs
non-smoking controls (Mann-Whitney U).
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Fig. 4. Plot of prothrombin fragments 1+2 with time, for the three subject groups. *Average pre-exercise, between three groups (Kruskal-











Fig. 5. Plot of fibrin-degradation products with time, for the three subject groups. *Average pre-exercise, claudicants vs smoking controls
(Mann-Whitney U). **AUC pre-exercise, claudicants vs non-smoking controls (Mann-Whitney U). fAUC post-exercise, claudicants vs

























Fig. 6. Plot of d-dimer with time, for the three subject groups. *Average pre-exercise, between three groups (Kruskal-Wallis). fAUC post-
exercise, between three groups (Kruskal-Wallis).
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FDP and D-dimer levels were similar in the claudicant
group, and the smoking controls. Claudicants had
consistently higher levels than the non-smoking con¬
trols (Figs 5 and 6).
Discussion
The coagulationmarkersmeasured,and their role in the
haemostatic system, are shown in Fig. 7. The main
findings of the present study are that treadmill exer¬
cise in claudicants is associated with excessive throm¬
bin generation and that this is not accompanied by an
increase in fibrin turnover, which suggests a defect in
fibrinolysis. This pro-thrombotic response to exercise
was not seen in a carefully matched control group.
The effect of exercise on thrombin generation in
claudicants and controls has been examined in three








Fig. 7. Simplified depiction of the coagulation cascade, with the
measured markers highlighted. TAT = thrombin-antithrombin com¬
plexes. PF1 + 2 = prothrombin fragments 1+2. FbDP's= fibrin deg¬
radation products.
previous studies (Table 3). Two studies observed high
baseline TAT and PF1 + 2 but showed no effect of
exercise.4'5 However, the patients in these studies
were incompletely described or controlled for factors
such diabetics, smoking or hypertension that are
known to influence thrombin generation. The third
study, which did include a well-matched control
group, showed similar levels of thrombin generation
at baseline, with a significant increase post-exercise in
the claudicant group.6
Similar studies of patient with coronary artery dis¬
ease (CAD) have shown no increase in thrombin gen¬
eration with exercise, suggesting that the changes
observed in the present study may be due to leg
muscle IRI rather than simply the presence of general¬
ised atherosclerosis.7,8 However, further detailed work
looking at coagulation, fibrinolysis and endothelial
cell function to elucidate the exactmechanisms under¬
lying the current observations is required and currently
underway in this department.
One potential criticism of this study is the poor
matching of the groups with respect to medical and
drug history. However, a previous study of patients
with CAD found that aspirin had no effect on throm¬
bin generation.7 Additionally, although the claudi¬
cants had a higher prevalence of chronic obstructive
airways disease, this was never a restricting factor in
the treadmill exercise.
What is the clinical importance of these findings?
Firstly, the discovery of this pro-thrombotic diathesis
in patients with claudication re-emphasises the need
to institute best medical therapy (BMT) in all PAD
patients.9,10 Secondly, while it has been shown that
long-term compliance with an exercise programme
can improve walking distance11 and ameliorate the
SIR12 in highly selected claudicants, present data sug¬
gest that in certain circumstances lower limb exercise
Table 3. Summary of previous studies examining thrombin generation in claudicants.
Author and year Subjects Sampling time points Baseline differences Effect of exercise Notes
De Buyzere, 19934 34 claudicants 30min rest TAT, PF No change No mention made of
30 age, sex- before sampling higher in in either number of diabetics,
matched Sampled "before claudicants group with smokers, or hypertensives
controls and after". exercise
Herren, 19945 22 claudicants 3 min before TAT, PF No change Groups poorly matched
13 age, sex- and after exercise. higher in in either for smoking, hypertension,
matched No mention of claudicants group with hyperlipidaemia.
controls rest prior to exercise
Mustonen, 19976
sampling
15 claudicants 15min rest. TAT levels Increase in Matched for smoking,
15 age, sex Sampling before, equal in TAT in hypertension,
matched controls and immediately claudicants claudicants, hyperlipidaemia
after exercise and controls no change in
controls
and diabetes mellitus
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could be harmful. Worryingly, while exercise therapy
has been shown to reduce mortality in patients with
coronary artery disease, no such benefit has yet been
demonstrated in patients with PAD.13 At present the
effect of revascularisation, either by means of angio¬
plasty or bypass, on the prothrombotic diathesis
observed in the present study is unknown. However,
one could hypothesise that by restoring normal arter¬
ial flow and abolishing calf muscle IRI, such proce¬
dures might ameliorate SIRS and the haemostatic
changes seen with exercise seen in patients treated
medically. We are currently examining these issues
within the confines of the U.K.-based, multi-centre,
Exercise versus Angioplasty in Claudication Trial
(EXACT) where claudicants are being randomised to
BMT, BMT plus angioplasty and BMT plus supervised
exercise. By combining data from these basic science
and clinical studies it should be possible to tailor
therapy to the individual patient in order tomaximise
safety, clinical and cost-effectiveness.
In conclusion, exercise in claudicants is associated
with excessive thrombin generation, which is not seen
in non-claudicants. Further work is required to deter¬
mine whether this has long-term clinical conse¬
quences or should influence management.
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Clinical review
Management of peripheral arterial disease in primary care
Paul Burns, Stephen Gough, AndrewW Bradbury
Best medical treatment for peripheral arterial disease, including managing hypertension and































One in five of the middle aged (65-75 years)
population of the United Kingdom have evidence of
peripheral arterial disease on clinical examination,
although only a quarter of them have symptoms. The
most common symptom is muscle pain in the lower
limbs on exercise—intermittent claudication.' Invasive
interventions (angioplasty, stenting, surgery) undoubt¬
edly have a role in the management of peripheral arte¬
rial disease. However, in common with coronary artery
disease, the morbidity and mortality associated with
peripheral arterial disease can be greatly reduced, and
the results of intervention significantly improved, by
the institution of so called "best medical treatment,"
much ofwhich can be implemented in primary care.
Sources and selection criteria
We used Medline to identify recent reviews and articles
on the epidemiology, assessment, and treatment of
peripheral arterial disease and intermittent claudica¬
tion, by using the terms "intermittent claudication,"
"peripheral arterial disease," and "peripheral vascular
disease." We also consulted standard textbooks,
national and local guidelines, and service frameworks.
Diagnosis and assessment
A diagnosis of intermittent claudication can usually be





Fig 1 Angiogram showing bilateral femoral artery occlusions in a
patient with claudication
Summary points
Diagnosis of peripheral arterial disease is based
mainly on the history, with examination and ankle
brachial pressure index being used to confirm
and localise the disease
Peripheral arterial disease is a marker for systemic
atherosclerosis; the risk to the limb in claudication
is low, but the risk to life is high
Patients with intermittent claudication should
initially be treated with "best medical treatment";
some patients may be candidates for
percutaneous angioplasty, but this treatment is
not based on evidence
Patients should be referred to a vascular surgeon
if there is doubt about the diagnosis or evidence
ofaortoiliac disease or if the patient has not
responded to best medical treatment or has
severe disease
dication questionnaire is highly specific (91%) and sen¬
sitive (99%) for the condition (table A on bmj.com).2
The differential diagnosis includes both venous and
neurogenic claudication (table 1). Examination usually
reveals weak or absent pulses, and further investiga¬
tions (duplex ultrasonography, angiography) are
usually reserved for the small minority of patients in
whom invasive intervention is being considered (fig 1).
The rationale for best medical treatment
Contrary to popular belief, the risk of a person with
claudication progressing to critical limb ischaemia and
needing amputation is low (< 1% a year). However, the
risk ofdeath,mainly from coronary and cerebrovascular
events, is high (5-10% a year), some three to four times
greater than that of an age and sex matched population
without claudication (fig 2 and fig A on bmj.com "j. Ini¬
tial management should consist of modification of
vascular risk factors and implementation ofbest medical
treatment in the expectation that this will extend life,
reduce still further the risk ofcritical limb ischaemia, and
584 BMJ VOLUME 326 15 MARCH 2003 btnj.com
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improve the patient's functional status. Only when best
medical treatment has been instituted and given
sufficient time to take effect should endovascular or sur¬
gical intervention be considered, as most patients' symp¬
toms improve with best medical treatment to a point
where invasive intervention is no longer needed.1 Best
medical treatment is beneficial even in patients who
eventually need invasive treatment, as the safety,
immediate success, and durability of intervention is
greatly improved in patients who adhere to best medical
treatment15
Components of best medical treatment
Table 2 summarises the components of best medical
treatment and their effects on peripheral arterial
disease, vascular events, and mortality.
Smoking cessation
Complete and permanent cessation of smoking is by far
the single most important factor determining the
outcome of patients with intermittent claudication."''
Unfortunately, rates of cessation after simple oral or
written advice from a doctor are as low as 13% at two
years.6 Randomised controlled trials have shown that
nicotine replacement treatment approximately doubles
the cessation rate in unselected smokers."'"' Bupropion
has a similar benefit when used with intensive support"3
Both treatments are now available on prescription, and
every patient with claudication should be offered
nicotine replacement treatment in the first instance. Not
all nicotine replacement preparations (patches, gum,
sprays) are the same, and if one preparation is
unsuccessful then other preparations, or combinations
with different delivery profiles, should be tried. The
Cochrane group found smoking classes but not alterna¬
tive therapies (hypnotherapy, acupuncture, or "aversive
smoking") to be beneficial.'"'1"4
Antiplatelet agents
The Antiplatelet Trialists' Collaboration showed that
prescription of an antiplatelet agent, usually aspirin,
reduced vascular death in patients with any manifesta¬
tion of atherosclerotic disease by about 25% and that
antiplatelet agents were equally effective in patients
who present with coronary artery disease and with
peripheral arterial disease."1"" Some indirect evidence
shows that some antiplatelet agents may also improve
walking distance in people with claudication."1"
Clopidogrel is at least as effective as, and possibly more
effective than, aspirin in patients with peripheral
arterial disease and has a better side effect profile.""
However, it is much more expensive and is generally
reserved for the sizeable minority of patients with
peripheral arterial disease who cannot take aspirin or
who continue to have events on aspirin. No data exist
to support the routine use of combination treatment
(aspirin and clopidogrel) in patients with peripheral
arterial disease, but trials are under way.
Management of diabetes mellitus
Diagnosis of type 2 diabetes, or its exclusion, is impor¬
tant in patients with peripheral arterial disease (box),
but this is not straightforward." A threshold of fasting
glucose >7.0 mmol/1, as recommended by Diabetes
UK, should be supported by symptoms of diabetes and
may miss a large number of asymptomatic patients
Table 1 Differential diagnosis of intermittent claudication
Characteristic Intermittent claudication Venoua claudication Nerve root pain
Quality of pain Cramping "Bursting" Electric shock-like




Relieved by Standing still Elevation of leg Sitting down,
bending forward
Location Muscle groups (buttock,
thigh, calf)
Whole leg Poorly localised,
can affect whole leg
Legs affected Usually one Usually one Often both
(20-30%). The oral glucose tolerance test is the "gold
standard" but is logistically difficult In practice,
random blood glucose may be the easiest measure to
obtain; a random blood glucose >11.1 mmol/1
(plasma glucose performed in an accredited laboratory
not finger prick, capillary glucose) is diagnostic of type
2 diabetes, and a random blood glucose of 7.0-11.1
mmol/1 should followed with an oral glucose tolerance
test
Hypertension
The benefit of treating hypertension in terms ofreduc¬
ing stroke and coronary events is well accepted; data
indicate a target of less than 140/85 mm Hg for non-
diabetic patients and 140/80 mm Hg for patients with
type 2 diabetes."" However, in the short term a reduc¬
tion in blood pressure may worsen intermittent claudi¬
cation. This is true of whatever drug treatment has
been used, and no evidence exists that p blockers are
particularly culpable.'" The heart outcomes prevention
evaluation study has shown that ramipril, an angio¬
tensin converting enzyme inhibitor, reduces cardiovas¬
cular morbidity and mortality in patients with
peripheral arterial disease by around 25%."15""'
Patients did not have to be hypertensive to be included
in the study, and the observed risk reduction could not
be accounted for by the relatively modest reduction in
blood pressure. The implication ofthe heart outcomes
prevention evaluation study is that most patients with
peripheral arterial disease would benefit from an
angiotensin converting enzyme inhibitor, provided
that treatment is not associated with a deterioration of
renal function due to occult renal artery stenosis.
Exercise
A recent Cochrane review has shown that exercise treat¬
ment can produce a significant and clinicallymeaningful
increase in walking distance (150%) in most people with
claudication who adhere to it"3" Although the exact
Patients presenting to doctor with intermittent claudication (n=100)
T
Will need intervention (n=5)






Fig 2 Outcome for patients with intermittent claudication over five years"
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Table 2 Components of best medical treatment in peripheral arterial disease
Component Recommendation Effect on mortality or vascular events Effect on peripheral arterial disease
Smoking cessation Repeated advice"*
Nicotine replacement therapy or bupropion""3*
Behavioural therapy (smoking cessation
classes)"**
Cessation leads to a reduction in 10 year
mortality from 54% to 18%"*
Rest pain in 0% of quitters
compared with 16% of continued
smokers at seven years"3
Reduction in cholesterol All patients to be on a statin to achieve a 25%
reduction in cholesterol"*
Additional treatment may be needed if HDL is low
or triglycerides aro high (referral to lipid clinic)
HR=0.81 (0.72 to 0.87) for major vascular
event (myocardial infarction, stroke, or
revascularisation)"*
No evidence of clinical benefit"'
Antiplatelet agent Aspirin 75 mg daily"*
Clopidogrel 75 daily If intolerant of aspirin""




Screen for type 2 diabetes"1'*"12" Intensive control with insulin or
sulphonylurea leads to RR=0.94 (0.8 to 1.1)
for total mortality"11
Intensive control with metformin In
overweight patients leads to RR=0.64 (0.45
to 0.91) for total mortality"12
RR=0.51 (0.01 to 19.64) for risk of
lower limb amputation"11*
Blood pressure Reduce blood pressure to <140/85 mm Hg"'!* RR=0.87 (0.81 to 0.94) for total
mortality"1'*
Not known
ACE inhibitors Should be considered in all patients, even if
normatensive"1'*■""*
RR-0 73 (0.61 to 0.86) for composite
endpoint of myocardial infarction, stroke,
and cardiovascular death (in diabetes
RR=0.75 (0.64 to 0.88))"1'*-""*
Not known
Exercise Patients with lower limb disease should be given
written advice about exercise and enrolled in a
supervised programme if available""-""
24% reduction (primary and secondary
prevention) in cardiovascular mortality"5*
Improvement in walking distance of
150%"!0
Cilostazol Useful addition in patients who have
unacceptable symptoms despite adherence to
bast medical therapy"21 "23
Unknown Significant increase in walking
distance"21"23
ACE=angiotensin converting enzyme; HDUhigh density lipoprotein cholesterol; RR=relative risk (95% confidence interval).
•Evidence from patients without peripheral arterial disease.
mechanisms by which exercise leads to clinical improve¬
ment have not been precisely defined, several factors
that help to maximise benefit from exercise treatment
have been identified (table B on bmj.com). The clinical
effectiveness and cost effectiveness ofbest medical treat¬
ment, best medical treatment plus supervised exercise,
and best medical treatment plus angioplasty are
currently being evaluated in the exercise versus
angioplasty in claudication trial funded by Health Tech¬
nology Assessment
Reduction in cholesterol
The heart protection study has shown that lowering
total cholesterol and low density lipoprotein choles-
Rationale for screening for diabetes mellitus in
intermittent claudication
• Up to 20% ofpatients with intermittent claudication
have diabetes; in up to 50% of cases this may be
undiagnosed at the time ofpresentation
• The United Kingdom prospective diabetes study has
shown that intensive glycaemic control reduces the
microvascular complications of type 2 diabetes and
that the use ofmetformin reduces macrovascular
complications in overweight people with diabetes"""'1
• Most studies show that diabetes is a powerful risk
factor for progression to critical limb ischaemia"
• Patients with diabetes should have tighter limits
placed on blood pressure and, possibly, lipid
concentrations" '*
• Diabetic patients are more likely to have spuriously
high ankle pressures'"
• Diabetic patients respond less well to surgical
intervention but gain a greater benefit from medical
treatments for cardiovascular disease than do
non-diabetic patients20
• Many diabetic patients have neuropathy, which, in
combination with arterial insufficiency, puts them at
increased risk ofneuroischaemic tissue loss
terol by 25% with a statin reduces cardiovascular mor¬
tality andmorbidity in patients with peripheral arterial
disease by around a quarter, irrespective of age, sex, or
baseline cholesterol concentration."*The implication is
that every patient with peripheral arterial disease
should be treated with a statin. The lipid profile should
be measured before and six weeks after starting
treatment, to ensure that a 25% reduction in
cholesterol is being achieved and to identify those few
patients with very high cholesterol concentrations or
hypertriglyceridaemia who may benefit from referral
to a specialist lipid clinic
Adjuvant treatment
Cilostazol has been shown to significantly increase (35-
109%) walking distance in people with claudication in
several large double blind placebo controlled ran¬
domised trials."'-"'"21 The precise role of cilostazol
remains to be defined, but a trial of the drug is
probably indicated in patients who have unacceptable
symptoms despite three to six months ofadherence to
best medical treatment. No convincing evidence
supports treatment with other drugs or vitamins,11 but
trials evaluating the effect of folate and vitamin B-12
on hyperhomocysteinaemia, a putative vascular risk
factor, are near completion.
When should a patient be referred to a
vascular surgeon?
Local circumstances vary considerably, but referral is
appropriate if
• The primary care team is not confident ofmaking
the diagnosis, lacks the resources necessary to institute
and monitor best medical treatment, or is concerned
that the symptoms may have an unusual cause
• The patient has unacceptable symptoms despite a
reasonable trial of, and adherence to, best medical
treatment
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• The patient has weak or absent femoral pulse(s) (see
below).
Patient with critical limb ischaemia (rest pain, gan¬
grene, or ulceration) should be referred urgently (pref¬
erably by telephone) to the next vascular surgical clinic.
The patient should also be referred urgently if an
abdominal aortic aneurysm is suspected on abdominal
examination or if the history suggests a carotid
territory transient ischaemia attack or amaurosis fiigax.
Vascular and endovascular surgery
No convincing evidence supports the use ofpercutane¬
ous balloon angioplasty or stenting in patients with
intermittent claudication.14 Two randomised controlled
trials have shown that although successful percutaneous
balloon angioplasty may lead to a short term (six
months) improvement in walking distance, in the longer
term (two years) best medical treatment is better than
percutaneous balloon angioplasty in terms of walking
distance and quality of life measures.4 The exercise
versus angioplasty in claudication trial is further evaluat¬
ing the role ofpercutaneous balloon angioplasty.5 In the
United Kingdom bypass surgery is performed only
infrequently for intermittent claudication because
• The risks of surgery are generally believed to
outweigh the benefits in most patients who improve on
best medical treatment
• Even though symptoms are frequendy unilateral,
most people with claudication have bilateral disease;
revascularising one leg often simply serves to unmask
hitherto asymptomatic contralateral disease.
In general, the threshold for percutaneous balloon
angioplasty, stenting, and surgery is lower in patients
who have predominantly aortoiliac (suprainguinal)
disease because
• In terms ofwalking distance, such patients seem to
benefit less from best medical treatment, although they
gain just as much in terms of protecting life and limb;
this may be because the body is less able to collateralise
around an aortoiliac block
• Percutaneous balloon angioplasty and stenting in
the aorta or iliac arteries is more durable than that
below the inguinal ligament, presumably because
larger calibre, high flow arteries are involved
• Aortoiliac reconstruction deals with both legs at the
same time.
This greater readiness to intervene in patients
with absent or diminished femoral pulses in no way
undermines the key role of best medical treatment
Furthermore, aortoiliac reconstruction in a patient
who also has severe infrainguinal disease is unlikely to
lead to a clinically significant reduction in symptoms.
See bmj.com for more details on endovascular
techniques.4 5 14 2122
Ongoing research
Several recent landmark trials have confirmed the
clinical effectiveness and cost effectiveness of best
medical treatment for peripheral arterial disease, and
further trials are under way. The exercise versus angio¬
plasty in claudication trial will help to define the role of
adjuvant treatments such as percutaneous balloon
angioplasty and supervised exercise (see bmj.com).
The main challenge facing people caring for patients
with peripheral arterial disease is applying what we
Additional educational resources
ABC of arterial and venous disease. i3iW/2000;320.
Review articles on
• Non-invasive methods of arterial and venous
assessment p 698-701
• Acute limb ischaemia: p 764-7
• Chronic limb ischaemia: p 854-7
• Secondary prevention ofarterial disease: p 1262-5
Cochrane review ofexercise therapy in peripheral
arterial disease—Leng GC, Fowler B, Ernst E. Exercise
for intermittent claudication. Cochrane Database Syst
Rev 2000;(2):CD000990
Consensus document on peripheral arterial
disease—TASC Working Group Management of
peripheral arterial disease: transatlantic intersociety
consensus (TASC). EurJ Vise Endovasc Surg
2000;19(suppl A):Sl-244. (250 page evidenced based
document produced by international expert panel,
covering all aspects ofperipheral arterial disease (also
available at wsvw.tasc-pad.org))
Information for patients
The Vascular Surgical Society ofGreat Britain and
Ireland produces patient information sheets on
intermittent claudication, arteriograms, percutaneous
balloon angioplasty, and amputations—available from
www.vssgbi.org
know already. Primary care teams are best placed to
deliver this highly effective and evidence based care,
possibly through the establishment of community
based, nurse led, protocol driven vascular clinics to
which general practitioners can refer any "vascular"
patient who needs best medical treatment Interested
general practitioners or secondary care specialists in
vascular medicine or surgery could oversee such
clinics, which would have clear and widely agreed poli¬
cies for further investigations and referral to secondary
care. Such clinics would need additional funding in the
short term but would be likely to be cost neutral, or
even beneficial, in the medium and long term through
the prevention of expensive vascular events such as
stroke and amputation.
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Interactive case report
A 66 year old woman with a rash: presentation
















Ruth is a 66 year old housewife who presented to her
general practitioner with a two to three month history
of feeling generally "out of sorts" followed by the
development of a rash (figures). The rash first
appeared on her fingers and spread to the backs ofher
hands. The most noticeable changes were on the nail
folds, which became erythematous and swollen. The
rash then spread to the elbows, knees, and V of her
neck. Her husband had noticed a purple pigmentation
around her eyes, and she reported that sunshine made
the rash worse.
Ruth is a fit, active lady who has never smoked and
is teetotal. Her weight is steady and her appetite good.
She is currently taking no drugs, although she took
hormone replacement therapy for 4.5 years after her
menopause 14 years ago.
Ten years ago she was investigated for rectal bleed¬
ing. A foil blood count, liver function tests, and rigid
sigmoidoscopy gave normal results. She has had had
no further episodes of rectal bleeding, although she
gets intermittent bouts ofconstipation.
Questions
1 Ruth's general practitioner wondered if she could
have dermatomyositis. What do you think?
2 What tests would you do next?
3 What would you tell Ruth at this stage and why?
Please respond through bmj.com
Her mother and grandfather both died of bowel
cancer (aged 62 and 48 years).One sister died ofbreast
cancer, but Ruth's mammogram one year before the
episode of rectal bleeding showed no abnormality.
Recently, her other sister died after a dissection of the
ascending aorta.
Competing interests:None declared.
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Second Best Medical Therapy
P. Burns, E. Lima and A. W. Bradbury*
University Department of Vascular Surgery, Heartlands Hospital, Birmingham, U.K.
Background: best medical therapy (BMT) provides patients with peripheral arterial disease (PAD) substantial protection
against future vascular events.
Objective: to determine the quality of BMT received by PAD patients in this vascular surgery unit.
Methods: retrospective case-note review of 50 consecutive patients in each of the following groups: intermittent claudica¬
tion (out-patients), symptomatic carotid artery disease (out-patients), lower limb angioplasty, lower limb bypass surgery,
carotid endarterectomy.
Results: overall BMT use was poor. Fifteen percent of smokers had assistance with smoking cessation noted. Seventy-eight
percent of patients were taking an antiplatelet agent, 38% cholesterol-lowering medication and 51% antihypertensive
medication. Fifty-three percent of patients had a cholesterol measurement, 50% of out-patients had a blood pressure
measurement and 53% of non-diabetics had a random blood glucose performed. Sixteen of the patients with lower limb
disease were given advice about exercise. Patients with a history of coronary artery disease were more likely to be taking
cholesterol lowering, or antihypertensive medication.
Conclusions: BMT is poorly used in patients with PAD, which will result in an excess of cardiovascular morbidity and
mortality. Strategies need to be developed to increase the use of BMT in our patients.
Key Words: Best medical therapy; Peripheral arterial disease.
Introduction
Peripheral arterial disease (PAD) affects appro¬
ximately 20% of the adult population; is the common¬
est single cause of stroke, major amputation and
non-cardiac sudden death; and is also associated
with a marked (3-4 fold) increase in cardiacmorbidity
and mortality due to co-existing coronary artery dis¬
ease (CAD).1 Best medical therapy (BMT) (comprising
principally of smoking cessation strategies, cholesterol
lowering, blood pressure control, diagnosis and con¬
trol of diabetes mellitus (DM), prescription of an anti¬
platelet agent and exercise therapy) has long been
recognised as the cornerstone of management for
patients with CAD because it leads to a very substan¬
tial reduction in future vascular events and is highly
cost-effective.2 Although it is overwhelmingly likely
that BMTwould offer the same degree of protection to
patients with PAD,3 it has been suggested that many
such patients go untreated.4-7 The aim of this study
was to determine the quality of BMT provided to
* Please address all correspondence to: A. W. Bradbury, Professor of
Vascular Surgery, Lincoln House (Research Institute), Birmingham
Heartland, Hospital, Bordesley Green East, Birmingham,
B9 5SS, U.K.
patients with PAD presenting to a hospital based
vascular surgery unit.
Methods
This was a retrospective case-note review of 50 conse¬
cutive patients in each of the following groups:
(1) Patients presenting for the first time to clinic
with intermittent claudication (IC), (2) patients pre¬
senting for the first time to clinic with symptomatic
carotid artery disease, (3) patients undergoing percu¬
taneous balloon angioplasty (PTA) of the lower
limb arteries, (4) patients undergoing lower limb
bypass surgery, and (5) patients undergoing carotid
endarterectomy (CEA).
The institution of each component of BMT (smoking
cessation, antiplatelet agent use, cholesterol lowering
therapy, blood pressure control, diagnosis of diabetes
mellitus and exercise therapy) at the end of each fini¬
shed hospital episode (out-patient visit or in-patient
stay) was recorded. For the purposes of the study
hypercholesterolaemia was defined as a total serum
cholesterol >5.5mmol/l, an abnormal random blood
glucose was defined as > 7mmol/1, and hypertension
as a blood pressure (BP) greater than 160/90mmHg.
1078-5884/02/050400 + 05 $35.00/0 © 2002 Elsevier Science Ltd. All rights reserved.
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In the 54 patients identified as having hypercholes-
terolaemia, either on (n = 32) or off (n = 22) treatment,
new or altered lipid lowering therapy was instituted
in 15. Taken together these data mean that 110 of
the 150 patients undergoing intervention (PBA,
bypass or CEA) had either not be screened or treated,
or were on inadequate treatment for hypercholester-
olaemia (cholesterol still >5.5mmol/l) at the time of
their procedure.
Diabetes screening
Sixty-two (25%) patients were known to be diabetic.
Of the remainder, 99 (53%) were screened for diabetes,
all by random blood glucose, revealing 20 abnormal¬
ities (random blood glucose >7mmol/l). No out¬
patients (n = 4) had an abnormality acted upon; 6 of
16 in-patients with a high random blood glucose had
the result investigated (test repeated, oral glucose
tolerance test, or diabetic referral) (Fig. 4).
Exercise therapy
There is no supervised exercise programme available
at our unit. Ten (7%) patients with lower limb disease
were noted to have been given general advice on
exercise (i.e. "keep walking"), 6 (4%) patients were
noted to have been given specific exercise advice
("walk for 30min, 3 times per week, walking to the
point of maximum claudication before stopping").
Fig. 4. Number of non-diabetic patients who were screened for DM;
found to have an abnormal result, and whether high results were
acted upon. OGTT =Oral glucose tolerance test.
Blood pressure (BP) control
One hundred and twenty-seven (51%) patients were
already receiving anti-hypertensive treatment. All in¬
patients had their BP measured on admissions (data
not shown). Less than 50% of out-patients had their
BP checked, and few patients had abnormal blood
pressure results acted upon (Fig. 5).
Influence of CAD
Fifty-nine (24%) patients had a history of CAD
(angina, myocardial infarction or coronary artery sur¬
gery). These patients were more likely to be taking
cholesterol lowering, or anti-hypertensive medication
at their consultation. However, a history of CAD did
not seem to influence vascular surgeons in whether
patients were screened for hypercholesterolaemia,
hypertension or diabetes (Table 1). Similar proportions
from each group were taking an antiplatelet agent
when seen.
Discussion
The inescapable conclusion to be drawn from this
study is that PAD patients going through this vascular
surgery unit have not been receiving BMT, including a
significant proportion of patients undergoing surgical
or endovascular procedures. This is despite compel¬






























Fig. 5. Flow chart showing number of patients receiving antihyper¬
tensive medication, and the number who had their BP checked,
found to be high, and acted upon.
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in vascular surgery teaching, it will be instituted more
completely.
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Effects of Temperature on Stability of Blood
Homocysteine in Collection Tubes
Containing 3-Deazaadenosine
Diane M. Hill,1* Lisa J. Johnson,2 Paul J. Burns,3 Angela M. Neale,2
Denise M. Harmening,2 and Andrew C. Kenney1
Background: The accuracy of homocysteine (Hey) re¬
sults is currently compromised by the requirement to
separate the plasma within 1 h of sample collection. We
studied the effect of temperature on the stability of
plasma Hey over a 72-h time course in blood collected
into evacuated tubes containing either EDTA alone or
both EDTA and 3-deazaadenosine (3DA).
Methods: We recruited 100 volunteers, including both
diseased and healthy individuals with a range of base¬
line plasma Hey values, from two centers. Blood sam¬
ples were collected into tubes containing EDTA, and
EDTA plus 3DA and stored at ambient temperature
(20-25 °C) or refrigerated (2-8 °C). Aliquots of blood
were centrifuged at various times up to 72 h, the plasma
was removed, and Hey was measured by HPLC.
Results: Plasma Hey measurement covering the sample
collection and storage conditions during the whole time
course was possible on samples from 59 of those re¬
cruited. One-way ANOVA for repeated measureswithin
subjects revealed that only samples that were collected
into tubes containing EDTA plus 3DA and stored refrig¬
erated were stable over 72 h (P = 0.2761).
Conclusions: A combination of 3DA and storage at
2-8 °C will allow collection of samples for plasma Hey
measurement outside of the hospital setting and wider
population screening.
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Homocysteine (Hey),4 usually present in small amounts
in plasma, is formed in mammals solely from methionine
(I). McCully and Ragsdale (2, 3) highlighted the impor¬
tance of this pathway when they found that marked
increases in plasma Hey are a common factor in the
presence of vascular lesions, which were brought about
either by enzyme deficiencies in methionine metabolism
or experimentally in rabbits. Since these initial observa¬
tions were reported, links between hyperhomocysteine-
mia and a multitude of disorders have been postulated,
including cancer (4), neural tubes defects (5), cognitive
decline (6), and dementia (7). However, there is still
argument about whether increased Hey is the cause or
result of tissue damage (8). Those studies exhibiting a link
between Hey and vascular disease tend to show that
relatively small changes in Hey concentration lead to
large increases in relative risk. In a metaanalysis of 27
such studies (9), a 5 pmol/L Hey increase led to odds
ratios for coronary artery disease of 1.6 (95% confidence
interval, 1.4-1.7) in men and 1.8 (95% confidence interval,
1.3-1.9) in women. Dietary fortification with folic acid
supplements has been shown to decrease Hey concentra¬
tions (70-72), but the results of prospective studies are
needed to show whether lowering Hey is beneficial in
reducing the risk of disease (73-75). If confirmed, then the
debate is strengthened in favor of screening programs
designed to lower the incidence of heart disease. Such
moves have been facilitated by the recent emergence of
commercial systems allowing the routine clinical labora¬
tory to perform testing previously performed only in
research facilities.
The remaining problem is how to stabilize plasma Hey
concentrations in blood before processing, centrifugation,
and storage. Erythrocyte Hey concentrations are ~10-fold
4 Nonstandard abbreviations: Hey, homocysteine; 3DA, 3-deazaadenosine;
and SAHH, S-adenosylhomocysteine hydrolase.
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lower than in plasma; therefore, any increase in plasma
Hey after sample collection is not attributable to leakage
from the cells, but from continued metabolism and excre¬
tion into the plasma (16). The liver and pancreas are
mainly responsible for Hey removal in vivo (1). Because
this removal pathway is absent in vitro, Hey has been
shown to increase by as much as 10% per hour over the
first few hours after sample collection (16,17). The cur¬
rent recommendation is to place samples on ice and
centrifuge within 1 h. Plasma Hey may then be stable for
at least 24 h at room temperature and for several months,
if not years, when stored frozen (17).
If a 5 pmol/L increase is associated with an 80%
increased risk of vascular disease, artifactual increases in
plasma Hey caused by delays in sample processing could
easily lead to false-positive results being reported. Al¬
though the treatment for hyperhomocysteinemia is simple
and noninvasive, proper risk assessment demands accu¬
rate data.
Storage temperature (18-21), acid citrate (18,22-24),
sodium fluoride (25,26), and erythrocyte lysis (27-29)
have all been considered in attempts to stabilize plasma
Hey. However, several of these methods cause sample
dilution, either through the addition of liquid or, partic¬
ularly with sodium fluoride, through osmotic effects
caused by production of hypertonic plasma (30). To date,
the only method that has been shown to stabilize Hey
concentrations in whole blood for any longer than a few
hours, without readjustment of reference intervals or
immediate centrifugation, is the use of 3-deazaadenosine
(3DA) (31). At 100 pmol/L in EDTA whole blood, al
Khafaji et al. (31) reported that 3DA stabilized plasma
Hey for 72 h at room temperature before centrifugation.
3DA prevents Hey production through competitive inhi¬
bition of the enzyme S-adenosylhomocysteine hydrolase
(SAHH), the final enzyme in Hey production from methi¬
onine.
In pilot studies (32), we investigated the use of 100
/xmol/L 3DA in EDTA whole blood before developing a
commercially available evacuated blood collection sys¬
tem. However, because 3DA acts through competitive
inhibition, its effectiveness is influenced by temperature.
To avoid ambiguity when using phrases such as "ambi¬
ent" temperature, we controlled storage temperatures
between 20 and 25 °C; however, the mean Hey increased
from 8.5 /xmol/L to 11.5 /xmol/L over 72 h. At 2-8 °C, the
mean Hey decreased by a statistically insignificant 0.5
/xmol/L.
In light of the pilot study results, a trial batch of
evacuated tubes was produced that contained 3DA spray-
dried into tubes containing EDTA. Here we report clinical
validation of these blood collection tubes, conducted in
such a way as to confirm whether a combined effect of
low temperature and 3DA was sufficient to provide
long-term stability of plasma Hey in whole blood.
Most studies on sample stability have been conducted
on apparently healthy populations. In the clinical valida¬
tion of our tubes, we were interested in comparing the
stability of samples collected from a more diverse popu¬
lation, including patients with vascular disease and el¬
derly patients, in addition to healthy volunteers.
Materials and Methods
Volunteers were recruited in accordance with the current
revision of the Helsinki Declaration of 2000 (33). The only
exclusion criterion was individuals known to have re¬
cently taken drugs that can interfere with the method
used for Hey analysis (captopril, cysteamine, N-acetylcys-
teine, and N-2-mercaptopropionyl glycine).
To ensure a range of starting concentrations, two
centers were selected such that blood was collected from
50 individuals, patients, and employees at a hospital in
the United Kingdom (Birmingham Heartlands Hospital)
and from another 50 volunteers, mainly healthy students
and employees, at a university campus in the US (Univer¬
sity of Maryland at Baltimore). Local approval was ob¬
tained from the appropriate ethics committees, and in¬
formed consent was given by all participants.
Blood was collected, by venipuncture, into tripotas-
sium EDTA Vacutainer™ Tubes (Becton Dickinson) and
DS30 Hey Blood Collection Tubes (Drew Scientific Ltd.,
Barrow in Furness, United Kingdom). The DS30 Hey
blood collection tubes contain dipotassium EDTA as
anticoagulant and 100 /xmol/L 3DA (final concentration)
to inhibit Hey production. Each tube was evacuated to
collect 2.5 mL of whole blood. Once collected, each tube
was mixed and aliquoted for storage at ambient temper¬
ature (20-25 °C) and under refrigeration at 2-8 °C. Sam¬
ples were taken from each blood tube for baseline Hey
measurements. At 3, 6, 24, and 72 h after blood collection,
an aliquot of blood was removed from each tube at each
storage temperature and centrifuged for 10 min at
11 OOOg. The plasma was removed and stored at —80 °C
until analysis.
Hey measurement was performed at two sites using
the Drew DS30 Hey Analyzer (Drew Scientific). The Drew
analyzer uses reversed-phase HPLC with fluorescence
detection to separate ammonium 7-fluorobenzo-2-oxa-l,3-
diazole-4-sulfonate (SBD-F)-derivatized thiols in plasma.
Reduction of disulfide bonds by tris(2-carboxyethyl)phos-
phine allows measurement of all forms of homocysteine.
To avoid between-batch variability, each individual's set
of samples was measured within a single run. Within-
batch imprecision for this method has been shown to be
<2% (34).
Changes in Hey concentration for each storage condi¬
tion over time were assessed for statistical significance by
one-way ANOVA within subjects with repeated mea¬
sures.
Results
Of the 100 volunteers recruited, 59 yielded a complete set
of results for all time points and storage conditions under
investigation. Reasons for lost results included poor
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bleeds from elderly volunteers and identifiable mistakes
in sample analysis. Incomplete datasets were not in¬
cluded.
The 59 volunteers comprised 38 females and 21 males.
The median age was 47 years, with a range of 17-91 years.
Initial plasma Hey values ranged from 3.9 to 28.7/xmol/L.
Shown in Fig. 1 are the changes in plasma Hey con¬
centration over time. One-way ANOVA within subjects
with repeated measures showed that only a combination
of the DS30 Hey blood tube and refrigerated storage
provided stability of plasma Hey concentrations in whole
blood at all times up to 72 h (no significant difference, P —
0.2761). Hey changes under the three other storage con¬
ditions were all highly significant (P <0.0001).
Using tire Tukey co-procedure (35), we assessed the
time taken for Hey values to change significantly from
baseline for each condition. In EDTA alone, Hey increased
significantly before 3 h had elapsed, regardless of whether
the tubes were refrigerated or left at ambient temperature.
However, in DS30 Hey blood collection tubes, 3DA used
in combination with EDTA provided added stability at
ambient temperature (6 h).
DS30 Hey blood tube samples from 17 individuals
yielded enough blood to allow analysis of plasma after 1
week (168 h) at 2-8 °C. However, these volunteers did not
produce a full dataset for the other storage conditions.
Again, no change in Hey concentration was observed (P =
0.4690). The initial mean Hey for this group was 14.0
/xmol/L. Even after 1 week at 2-8 °C, the concentration
had increased by only 0.3 /xmol/L.
Previous stability studies have reported changes in
Hey over time as either percentages or absolute changes
Length of storage of whole blood (hours)
Fig. 1. Effect of whole-blood storage on plasma total Hey over 72 h in
standard EDTA tubes or in DS30 Hey blood tubes.
Data points are the mean ± 2 SE (error bars) for samples from 59 individuals.
•, DS30 Hey blood tube stored at 2-8 °C; ♦. EDTA tube stored at 2-8 °C; O,
DS30 Hey blood tube stored at 20-25 °C; X, EDTA tube stored at 20-25 °C.
against initial values. In the present study, in the absence
of inhibitor, whole-blood samples stored at 20-25 °C
showed an average Hey increase of 8% per hour in tire
first few hours after sample collection, but those individ¬
uals whose Hey was at the lower end of the reference
interval [5.2-15.1 /xmol/L (36)] showed increases as large
as 20% per hour. Dividing the study population into 5
/xmol/L bands (Table 1), according to baseline Hey,
highlighted a significant difference (P <0.001) in the
percentage change in plasma Hey in the whole-blood
samples over 72 h across the different bands. When
analyzed according to absolute changes in Hey, this
statistical significance disappeared (P = 0.1460). This
shows that the mass of Hey produced over time varies
little between blood samples taken from a large group of
individuals, even over a wide range of initial Hey concen¬
trations. It therefore follows that the percentage change
will be greater in those samples with the lowest starting
concentrations.
In light of these findings, we believed that data ob¬
tained from individuals with higher starting Hey might
mask any changes over time in those samples with initial
Hey in the lower groups. We therefore subdivided the
data into two groups (slO /xmol/L and >10 /xmol/L)
containing 43 and 16 individuals, respectively, and ana¬
lyzed them (Table 2). Irrespective of the baseline Hey,
storage of whole blood at 2-8 °C in EDTA or 20-25 °C in
the presence or absence of 3DA led to significant changes
in plasma Hey over 72 h (P <0.0001), whereas samples
showed stability over 3 days of storage at 2-8 °C in the
DS30 Hey blood tube independent of whether the initial
Hey was less than or greater than 10 /xmol/L (P = 0.3682
and 0.3140, respectively).
Discussion
If blood samples are stored under ambient conditions
before centrifugation, Hey production by erythrocytes
leads to an increase in plasma concentrations (16,17).
Previously, 10% per hour has been quoted as the initial
rate of Hey production after venipuncture; a similar
average rate was observed in the present study (8% per
hour). However, an inverse relationship existed between
baseline Hey and the rate of Hey production (expressed as
a percentage of the initial Hey). Consequently, because a
5 /xmol/L increase in Hey may be associated with a 80%
increased risk of vascular disease (9), strict sampling
conditions must be observed to prevent false increases in
plasma concentrations.
Storage on ice before centrifugation may stabilize
plasma Hey for up to 6 h (20), although current recom¬
mendations suggest that processing should occur within
1 h. As we were interested in providing a solution to
sample collection away from a centralized laboratory, we
chose to look at refrigerated conditions. However, for
samples in which EDTA alone was used, the maximum
stability was only 3 h.
If ice is unavailable, acid citrate may also provide
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Table 1. Percentage and absolute changes In plasma Hey concentrations In EDTA whole blood over 72 h of storage at
20-25 °C.
Hey values, funol/L Initial Hey," i±mol/L Absolute change," /imol/L Percentage change" n
0 to <5 4.5 (0.1) 23.8 (1.6) 526.9 (36.7) 9
5 to <10 6.8 (0.2) 26.1 (1.2) 397.0 (22.0) 34
10 to <15 12.7 (0.6) 29.8 (4.0) 241.9 (37.2) 7
15 to <20 17.1 (0.8) 20.8 (3.6) 121.2 (20.6) 4
20 to <25 23.0 (0.9) 20.0 (0.9) 87.5 (5.7) 3
25 to <30 27.5 (1.4) 19.8 (2.7) 72.7 (13.6) 2
"Results are mean (SE).
stability for up to 6 h at "room temperature". However, at
higher temperatures, samples are less stable (24). Ducros
et al. (18) found that sample stability also depends on the
method of analysis. Chromatographic methods showed
sample stability for at least 4 h in acid citrate at room
temperature, whereas Hey results increased over the same
time course with an immunochemical method (fluores¬
cence polarization immunoassay). Similar findings were
reported by Salazar et al. (23) and O'Broin et al. (22), who
showed a significant increase after 2 h or a 10% increase
after 6 h, respectively. Whereas chromatographic methods
measure Hey itself or a Hey derivative, immunochemical
methods are indirect. Hey is estimated by the amount of
its metabolic precursor, S-adenosylhomocysteine, formed
during the assay by the reverse reaction of the enzyme
SAHH. In acid citrate, the low pH may prevent Hey build
up by inhibiting SAHH, but precursor build up is not
prevented, thereby giving tire impression of sample insta¬
bility. Where stability is reported, there are conflicting
reports about whether acid citrate increases (22,24) or
decreases (23) baseline Hey compared with EDTA sam¬
ples kept on ice. This confusion may be related to correc¬
tions for dilution because acid citrate is added as a liquid,
requiring hematocrit estimates. Either way, separate ref¬
erence intervals are required for interpretation.
Similar problems complicate Hey measurements on
capillary whole-blood lysates (27-29). The method ap¬
pears quite attractive: a simple fingerprick followed by
cell lysis, with stability for 2 days at ambient temperature
provided by deactivation of the enzymes that produce
Hey. However, even after correction for dilution caused
by the lysing agents, results are lower than in plasma
because of further dilution by low intracellular Hey
concentrations.
Sodium fluoride samples at 2-3 h after collection have
shown Hey concentrations similar to baseline EDTA val¬
ues (25,26). On closer inspection, however, Hey contin¬
ued to increase over time. The effect was attributable to an
initial concentration drop caused by the formation of
hypertonic saline, which led to fluid shifts. This observa¬
tion was confirmed by Hughes et al. (30), who saw a
sodium fluoride concentration-dependent decrease in he¬
matocrit. Fluoride inhibits anaerobic glycolysis and,
therefore, ATP production, which is required for methio¬
nine conversion to S-adenosylmethionine, the first step in
Hey production. However, Hey production may continue
because of cellular reserves of S-adenosylmethionine, first
postulated by Andersson et al. (16).
Despite these studies, each method has its own weak¬
nesses. After the publication by al Khafaji et al. (31), we
investigated the production of evacuated blood tubes
containing 3DA. These tubes promised stability for up to
72 h under ambient conditions, without recalculation of
Hey results or changes to currently accepted reference
Table 2. Plasma Hey concentrations In whole blood over time, subdivided into Initial values of £10 jumol/L (n = 43) and
>10 /nmol/L (n = 16), for each storage condition.
Mean (SE) Hey concentration, /imol/L, at incubation time of
Storage Initial Hey,
Sample temperature, °C fimol/L 0 h 3 h 6 h 24 h 72 h P"
EDTA 20-25 <10 6.3 (0.2) 8.0 (0.3)° 10.0 (0.3)° 18.9 (0.6)° 32.0 (1.0)" <0.0001°
>10 17.6(1.4) 19.4 (1.5) 21.1 (1.3) 28.6 (1.4)° 42.0 (2.0)° <0.0001°
DS30 Hey blood tubes 20-25 <10 6.2 (0.3) 6.2 (0.3) 6.2 (0.2) 7.6 (0.3)" 14.9 (0.7)" <0.0001°
>10 17.3 (1.5) 17.1 (1.4) 17.3 (1.5) 17.9 (1.2) 24.2 (1.6)° <0.0001°
EDTA 2-8 <10 6.4 (0.2) 6.6 (0.3) 6.9 (0.3)° 8.0(0.3)" 9.9 (0.3)° <0.0001°
>10 17.5 (1.5) 18.1 (1.5) 18.7 (1.4)° 19.7 (1.5)° 21.6 (1.4)° <0.0001°
DS30 Hey blood tubes 2-8 S.10 6.2 (0.2) 6.1 (0.2) 6.1 (0.3) 6.1 (0.3) 6.1 (0.2) 0.3682°
>10 17.2 (1.5) 17.4 (1.4) 17.0 (1.5) 17.1 (1.5) 16.8 (1.4) 0.3410°
J P values calculated using one-way within-subject ANOVA (repeated measures).
b Significant differences from 0 h by Tukey's co-procedure (a = 0.05).
c Highly significant.
d Not significant.
Clinical Chemistry 48, No. 11, 2002 2021
ranges. However, as observed with acid citrate, stability
was temperature-dependent (32). In pilot studies at 20-
25 °C, plasma Hey increased from a mean of 8.5 pmol/L
to 11.5 pmol/L over 72 h, an increase of 35%, which
conflicted with the 10% increase previously reported (31).
Even with a 3DA concentration of 200 pmol/L, Hey
production could not be prevented (D.M. Hill and A.C.
Kenney, unpublished results). We therefore considered a
combination of SAHH inhibition by use of 3DA and a
slowing of Hey precursor production by chilling to
2-8 °C. Controls were used to ensure that pilot study
results were confirmed and to verify that chilling alone
was not sufficient for sample stabilization.
Because volunteers were recruited to observe the ef¬
fects of Hey stabilization at a range of baseline Hey
values, ANOVA was performed within subjects. Only
samples that were collected in DS30 Hey blood collection
tubes and stored refrigerated (2-8 °C) showed stability
over 72 h.
The mean plasma Hey for each storage condition over
time is shown in Fig. 1. Under ambient conditions (20-
25 °C), the rapid increase in Hey in samples collected into
EDTA alone is clearly visible. Even at 72 h, Hey produc¬
tion is evident. Therefore, if whole blood is left at room
temperature for only a few hours without a preservative
to stabilize Hey, false-positive results may be reported.
Chilling samples or storage at ambient temperature in the
presence of a SAHH inhibitor (3DA) may both stabilize
Hey to some degree. In fact, 3DA at 20-25 °C stabilizes
samples for 6 or even 24 h, depending on the initial Hey
concentration. This offers advantages for samples col¬
lected near the site of processing, providing some relief in
the requirement to have ice on hand and to deliver the
sample quickly to the laboratory. However, if there is a
longer delay in transport, refrigerated storage in DS30
Hey blood collection tubes can offer prolonged stability
for 72 h and possibly up to 1 week.
Sample cooling may slow the processes involved in
Hey production. This theory appears to be supported by
the data shown in Fig. 1, where a slow but steady increase
in plasma Hey occurs over 72 h in EDTA samples stored
at 2-8 °C. In contrast, 3DA inhibits Hey production in the
early period under ambient conditions. However, the
block is at the final stage in Hey production. As the
precursors to Hey accumulate, SAHH inhibition by 3DA
is finally overcome. A combination approach appears to
be more effective, as chilling will prevent the build up of
S-adenosylhomocysteine.
Despite the wide range of initial Hey values observed,
the absolute increase in Hey in unpreserved samples
showed very little difference after 72 h of storage. Conse¬
quentially, we observed significant differences in the
percentage change over time that showed an inverse
relationship to baseline Hey. Similar phenomena have
been noted previously over 24 h by Fiskerstrand et al.(19)
and most recently over 4 h by Duarte et al. (37). It follows
that the thiol pool or the rate of Hey production must be
very similar within the collected samples. Andersson et al.
(16) suggested that Hey in whole-blood samples may be
produced from a preformed pool of S-adenosylmethi-
onine. If this is the case, it appears that the concentration
of this pool is very similar within blood samples, is
independent of Hey concentration, and therefore, is inde¬
pendent of the efficiency of remethylation in vivo.
We observed significant differences in the degree of
error in measurements when samples were stored for
prolonged periods without a preservative, according to
baseline Hey concentrations (Table 1). Investigators and
clinicians must be aware of this effect when claims are
made about stability.
This trial was designed to investigate stability in as
wide a range of starting Hey concentrations as was
possible to obtain from an unscreened group, such that
stability could be compared in a healthy population vs a
group that could be defined as having increased Hcry.
When the sample population was divided into two
groups, those with higher initial Hey concentrations were
stable over longer periods, e.g., up to 24 h compared with
up to 6 h, in the Drew DS30 Hey collection tubes stored at
20-25 °C. Moreover, any concern over whether significant
differences in Hey had been masked in the samples that
were stored at 2-8 °C in DS30 Hey blood tubes because of
the presence of individuals with high baseline Hey con¬
centrations was unfounded.
We report the first commercially available blood col¬
lection tube to allow stability of plasma Hey in whole
blood over the course of 3 days without the need for
centrifugation. Although we realize that the requirement
for refrigeration is not ideal, several samples may be
collected and stored in doctors' offices or in mobile
clinical trial facilities before they have to be transported to
a centralized laboratory for processing, thereby facilitat¬
ing wider population screening. If refrigerated conditions
are not readily available, the use of DS30 Hey blood
collection tubes may offer sample stability over 6 h, within
a hospital environment, which may be particularly useful
in cardiovascular clinics. These tubes can be used with a
range of methods, providing that the method does not
rely on the action of SAHH; consequently, tubes contain¬
ing 3DA should not be used in some of the immuno¬
chemical methods currently available (38, 39).
Ultimately, our aim is to produce a method of whole-
blood collection that allows transport at a range of ambi¬
ent temperatures. In the interim, we have developed a
method that allows samples to be collected and stored for
up to 72 h before laboratory intervention. We have
successfully used this procedure to offer a mail-in Hey
test where local testing was not available.
We thank all those who helped in the course of this study,
including Dr. Paul Haggart, who assisted in collection of
blood samples at Birmingham Heartlands Hospital; F.
Giltrap and R. Hadley, who assisted in sample handling
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and analysis; and R.E. Ashby (Cranfield University, UK),
who helped with the statistical interpretation of the data
collected. This study was funded entirely by Drew Scien¬
tific Ltd.
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REVIEW ARTICLE
What Constitutes Best Medical Therapy for
Peripheral Arterial Disease?
P. Burns, E. Lima and A. W. Bradbury*
University Department of Vascular Surgery, Heartlands Hospital, Birmingham, U.K.
Peripheral arterial disease (PAD) is associated with a high morbidity and mortality, largely from coronary and cerebro¬
vascular disease, which often overshadows the PAD itself. Best Medical Therapy (BMT), comprising smoking cessation,
antiplatelet agent use, cholesterol reduction, exercise therapy, and the diagnosis and treatment of hypertension and diabetes
mellitus; is evidenced based and can result in significant reductions in cardiovascular risk, as well as some improvement in
PAD. Previous data have largely been restricted to patients with coronary artery disease, and their relevance to PAD has
been extrapolated. However, data are now starting to become available, such as the Heart Protection Study, with data
specific to PAD patients. This article reviews the data regarding the use of BMT in patients with PAD, and based on this,
makes recommendations for the use of BMT in this group of patients.
Key Words: Best medical therapy; Peripheral arterial disease.
Introduction
Peripheral arterial disease (PAD) is common, with
over 20% of the population having asymptomatic dis¬
ease, and up to 5% having lower limb symptoms; most
commonly, intermittent claudication.1 Although inter¬
mittent claudication is relatively benign in terms of
limb-loss (1-2% per year), it is associated with a vas¬
cular mortality (5-10% per year) 2-4 times greater
than that of an age and sex matched non-claudicant
population; a risk that is, in fact, greater than that
experienced by patients with angina.2 There are
several reasons for this.
• PAD is a marker for severe, multi-system athero¬
sclerosis affecting the cerebral, visceral and coron¬
ary arteries.3
• In the presence of exercise-limiting intermittent
claudication, even severe ischaemic heart disease
may be asymptomatic and thus go unrecognised
and untreated.
• There is some evidence that repeated ischaemia-
reperfusion of leg muscles may lead to a systemic
• Please address all correspondence to: A. W. Bradbury, Professor of
Vascular Surgery, Lincoln House (Research Institute), Birmingham
Heartlands Hospital, Bordesley Green East, Birmingham, B9
5SS, U.K.
inflammatory response that accelerates athero¬
sclerosis and promotes thrombotic events.4
• But most importantly, research into the benefits of
risk factor modification and best medical treatment
(BMT) in PAD patients has lagged far behind that
directed towards symptomatic ischaemic heart dis¬
ease. This in turn has resulted in:
• a less compelling evidence base for treatment.
• a lack of awareness of the vascular risk faced by
these patients.
• a belief that the costs of instituting BMT in
patients with PAD could not be justified.
For these reasons, rather than viewing the PAD
patient in a holistic way as a vascular "time-bomb",
those treating PAD have tended to focus on the arter¬
ial lesion and its surgical or endovascular (angio¬
plasty, stenting) treatment. Unfortunately, with the
notable exception of carotid intervention for high-
grade symptomatic disease,5-7 there is little or no
level 1 evidence to support intervention for PAD that
is not immediately life or limb-threatening. What little
data are available suggest that invasive intervention
for claudication can lead to an early (1 year) improve¬
ment in symptoms, but there is no evidence this is
sustained. 11 Such interventions are expensive,
1078-5884/02/010006 + 07 $35.00/0 © 2002 Elsevier Science Ltd. All rights reserved.
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potentially hazardous, usually of limited durability
and do not impact upon the patients' high underling
vascular risk.10,11 By contrast, there is increasing and
compelling evidence that BMT comprising anti-
smoking strategies, antiplatelet agents, lipid lowering
and exercise programmes dramatically reduce the
vascular risk and significant increase functional sta¬
tus.12'13 BMT is also relatively inexpensive and virtu¬
ally free from risk. With the release of data from the
Heart Protection Study, which included over 6000
patients with PAD and confirmed the benefits of
lipid lowering, it is timely to review what BMT should
comprise and how it can be instituted universally in
patients with PAD.14
Anti-smoking strategies
There is overwhelming evidence that smoking is the
single most important risk factor for the development
and progression of PAD and that it significantly
increases the risk, and reduces the success, of periph¬
eral arterial intervention.12,15-20 Despite the clear
benefits of smoking cessation in PAD patients, only
a minority (11-48%) of patients manage to quit. 1
Simple oral advice is ineffective,22 but more intensive
counselling has been shown to be effective in unselect-
ed smokers, although not in PAD patients.23-25 Nico¬
tine replacement therapy, whether delivered by patch,
gum, intranasal spray, inhaler or sublingual tablet, is
safe, and leads to significant improvements in smok¬
ing cessation (odds ratio 1.72, 95% confidence interval
1.60-1.84); at least in the short term.26,27 Bupropion is
at least as effective as nicotine replacement therapy,
but appears to confer no additional benefit in combin¬
ation with nicotine replacement therapy.28 The
Cochrane group on tobacco addiction has found alter¬
native therapies such as acupuncture, hypnotherapy,
and "aversive smoking", to be ineffective.-9-31
Statin better Statin worse Baseline Simvastatin Placebo
♦
—I 1
0.6 0.8 1.0 1.2
Relative Risk
Pathology
(n=10 269) (n=10 267)
Previous MI 1007 1225





All patients 2042 2606
Fig. 1. Benefit of 40 mg simvastatin from The Heart Protection Study.
Number of vascular events by prior disease. Data taken from
www.hpsinfo.org. MI: myocardial infarction; CHD: coronary heart
disease; CVD: cerebrovascular disease.
results are awaited, but this could have significant
implications for cholesterol lowering in patients with
PAD. Whether there is benefit from raising high
density lipoproteins, and reducing triglycerides levels
is less clear. 6
In summary, all patients with PAD should have
their cholesterol reduced with aggressive statin ther¬
apy, regardless of starting total cholesterol. In the
longer term it seems possible that statin therapy will
be indicated for any patient with objective evidence of
asymptomatic PAD; for example, as demonstrated by
a reduced ankle: brachial pressure index. As patents
expire, and generic drugs become available, the finan¬
cial consequences of these massive changes in pre¬
scribing practice will ease and, of course, the
prevention of large numbers of vascular events will
also help to offset the costs.
Hypercholesterolemia
Hypercholesterolemia is clearly an independent risk
factor for the development and progression of
PAD.2,15,16/32 Cholesterol lowering has been shown to
slow the progression of peripheral atherosclerosis in a
number of large, including randomised, anatomical
and pathological studies, 3,34 although none have
shown benefit with respect to PAD symptoms. The
recently concluded Heart Protection Study has, for
the first time, demonstrated a benefit of statins in
PAD patients by reducing coronary events by 20%.
Furthermore, this was achieved irrespective of start¬
ing total cholesterol35 (Fig. 1). Detailed, peer-reviewed
Antiplatelet Therapy
Early studies suggested antiplatelet agents could pro¬
duce angiographic improvement,37 increase walking
distance,38'3 and reduce the requirement for vascular
intervention.40 There is overwhelming evidence from
the Antiplatelet Trialists' Collaboration that the pre¬
scription of an anti-platelet agent, usually aspirin,
reduces vascular death in patients with symptomatic
atherosclerotic disease by about 25%.41 Most of the
studies were in patients with ischaemic heart disease
and, when taken in isolation, data from the few stu¬
dies looking specifically at patients with PAD were
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not conclusive. However, more recently, a review of 24
trials has shown that, when compared with placebo,
APA treatment reduced the risk of death by about a
quarter in patients with PAD.42
In summary, all patients with PAD should be on an
antiplatelet agents because it reduces vascular event
and death, improves the patency rates of surgery and
endovascular interventions and may improve walking
distance. For reasons of cost, non-enteric aspirin
(75mg) is a reasonable first-line choice as there is no
clear evidence that a higher dose is more effective (but
will cause more adverse events) or that enteric coating
is associated with less gastric upset (and is more
expensive). Patients who cannot take aspirin should
be considered for clopidogrel.
Exercise
There is little doubt that exercise leads to a significant
improvement in exercise tolerance (most studies show
at least a doubling in walking distance) in patients
with PAD.43"45 It is also likely, though not specifically
proved, that exercise will reduce vascular risk. How¬
ever, clinicians and academics alike have largely
neglected this simple, inexpensive and effective ther¬
apy; and as such, many important questions remain
unanswered.
How does exercise work? Whilst early animal stu¬
dies suggested that exercise may improve blood flow
by the development of collaterals, studies in humans
using venous occlusion plethysmography, Xenon-133
clearance and duplex ultrasonography have not con¬
firmed this.46 Despite this, exercise training can lead to
increased clearance of Xenon-133 injected into calf
muscles, possibly indicating that blood is being
diverted towards more active muscles. Exercise train¬
ing in claudicants leads to increases in oxidative
enzymes, and enhanced utilization of fatty acids in
the calf muscles, maximising the use of oxygen deliv¬
ered to the tissues. Improvements in walking distance
may also be due to improvements in walking
biomechanics47 and blood rheology.48
What is the best form of exercise? It has generally
been thought to be walking but recent data have sug¬
gested that arm exercise, may be at least as beneficial,
which further questions the mechanism by which
exercise achieves its benefit.49
Does exercise have beneficial effects on risk factor
profile? A small non-randomised controlled trail
showed that exercise training for claudicants, can
lead to modest reductions in blood pressure, choles¬
terol and glucose levels.51 Whether this translates to a
significant improvement in cardiovascular risk, has
not been specifically determined in claudicants, but
data from ischaemic heart disease patients suggests
that it may.50
Should exercise be supervised and, if so, how and
for how long? Supervised exercise programmes
would seem intuitively to be better, but there is little
evidence to support this. Gardner and Poehlman
reviewed 21 studies of exercise therapy in PAD, and
found that supervised exercise programmes were no
better than unsupervised. A small randomised study
of 54 patients, comparing a 12 week supervised exer¬
cise programme and unsupervised exercise, did sug¬
gest that the supervised programme was superior
(improvement in maximum walking distance 207 vs
70% at 6 months). What is unclear, is the durability of
any benefit. It might be speculated that any advantage
of supervised exercise will diminish with time,
although there is no evidence to support this.
Until these issues are addressed one must approach
this aspect of care in a pragmatic way based upon
local resources. PAD patients should certainly be
repeatedly and specifically informed that exercise is
beneficial and that it is not (as far as we know) harm¬
ful to try to "walk through" their claudication pain.
Written advice may be a useful adjunct although this
suggestion is not evidence-based. Although super¬
vised programmes may be superior, at least in the
U.K., such programmes are not widely available. The
ongoing, U.K.-based, Heath Technology Assessment
funded Exercise versus angioplasty in claudication
trial (EXACT) will provide more information about
the relative benefits of exercise and angioplasty
when it reports (for more information please contact
the senior author).
Diabetes
Diabetics have a 3-5 fold increased risk of PAD, and
are at increased risk of progression from intermittent
claudication to critical limb ischaemia.52'53 The U.K.
Prospective Diabetes Study has shown that intensive
control decreased the risk of microvascular but not
macrovascular vascular complications of the dis¬
ease.54 However, it is extremely important that the
diagnosis of diabetes be specifically confirmed or
excluded in patients with PAD because it will affect
other areas of their treatment, such as blood pressure
and lipid control.55,56
Blood Pressure Control
Hypertension, particularly, systolic hypertension,
is associated with a three-fold increase in the risk
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of developing PAD.57-59 No study has specifically
investigated PAD patients but it is quite clear that in
general the treatment of hypertension significantly
reduces coronary events and stroke.60 Traditionally,
blood pressure has been treated to a level of 160/90,
but more recent data suggest that tighter control (130—
140/85mmHg) might confer additional benefits.61 It is
frequently taught that /3 blockers are contra-indicated
PAD, but there is no evidence to support this.62
Other Risk Factors
Hyperhomocysteinaemia is becoming increasingly
recognised as an important risk factor for develop¬
ment of atherosclerosis, and cross-sectional studies
have linked it specifically to PAD.63 However, the
effect of reducing homocysteine levels has yet to
defined, but should be answered by several ongoing
trials. Observational studies have suggested that low
levels of anti-oxidant vitamins are associated with
PAD, although no studies, including the Heart Protec¬
tion Study, have yet shown any benefit from vitamin
supplementation.14,64'65
The relationship between alcohol and PAD appears
to be J shaped, with minimal risk occurring at around
2 units of alcohol per day.66 Excess alcohol consump¬
tion is clearly associated with an increased vascular
risk. Oestrogen has been proposed as being cardio
protective, on the basis of reduced cardiovascular
morbidity and mortality in women taking hormone
replacement therapy, but a recent randomised con¬
trolled trials showed no difference in cardiovascular
events between groups randomised to oestrogen/
progestogen, and placebo.67 In summary, these factors
may represent important risk factors in PAD, but at
present there is insufficient evidence to justify target¬
ing them for treatment.
Prevalence of BMT use in PAD
Despite the overwhelming evidence for BMT in
patients with PAD, clinical experience and the
literature indicated that it has been poorly applied in
the past (Table 1). The proportion of patients taking
any kind of anti-thrombotic therapy or warfarin
ranges from 39% to 66%, and prevalence of cholesterol
lowering therapy ranges from 5% to 46%. Patients
who also have symptomatic ischaemic heart disease
seem more likely to be treated but, in general there
seems little or no relationship between the prevalence
of treatment, the severity of the underlying disease
and thus the potential benefits of BMT. 71 In other
words, treatment is haphazard rather that the result
of evidence.
The current situation is unacceptable, and clearly
strategies need to be put in place to ensure that PAD
patients do not miss out on evidence-based life saving
treatment. The initial step needs to be the education
of health professionals working with PAD patients
about the increased cardiovascular risk of these
patients, and the benefits of BMT. Articles such as
this should raise the profile of these important issues.
One strategy to increase the institution of BMT is
the use of record cards (Fig. 2). These chart the level
of individual risk factors over time, and allow easy
recognition for healthcare professionals of untreated,
or inadequately treated risk factors. These charts
could be held in the case notes, or by the patient.
Another possibility for increasing BMT use is to have
dedicated staff in out-patient clinics. This is an ideal
role for clinical nurse specialists, who are increasing in
number. Whatever technique is employed, it is
important to co-ordinate the patient7s care with
primary care.
Summary
There is overwhelming evidence for the efficacy of
BMT in PAD, in terms of cardiovascular risk reduc¬
tion, and improvement in PAD symptoms. Recom¬
mendations for the use of BMT, based on the best
evidence available to date are presented in Table 2.
Despite the evidence of benefit, BMT is grossly
Table 1. The use of cholesterol-lowering and anti-thrombotic therapy (antiplatelet agent of warfarin) in patients with PAD.
Study n Patient population n with IHD (%) n receiving
Cholesterol-lowering Anti-thrombotic
therapy (%) therapy (%)
Clark et al. (1999)68 299 Admitted for angiography 106 (36) 26 (9) 140 (47)
Anand et al. (1999)70 195 Admitted for peripheral 106 (54) 31 (16) 94 (49)
arterial surgery
Bismuth et al. (2000)69 147 Critical limb ischaemia 66 (45) 8 (5) 58 (39)
McDermott et al. (1997)71 202 ABPI < 0.9 or abnormal 103(51) 93(46) 133(66)
Doppler waveform
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Table 2. Recommendations for best medical therapy (BMT) in
patients with PAD.












Statin therapy if total cholesterol >5.0
Additional treatment will be
required if HDL low, or triglycerides
high (Referral to lipid clinic)
Aspirin
Clopidogrel if aspirin intolerant
Screen for diabetes mellitus
Reduce blood pressure to < 140/80mmHg
Patients with lower limb disease should
be prescribed a supervised exercise
programme
underused in PAD patients. If BMT use increases, this
will lead to a decrease in cardiovascular morbidity
and mortality, a reduction in the requirement for
peripheral vascular intervention, and an improve¬
ment in outcome for those interventions that are
required. It is imperative that those involved in the
care of patients with PAD are aware of the benefit of
BMT, and develop strategies to help improve its
implementation.
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Introduction
In addition to well-established risk factors such as
smoking, diabetes, hypercholesterolaemia and hyper¬
tension, an increasing number of novel humoral and
endothelial factors have recently been implicated in
the aetiology and progression of vascular disease.
Thrombophilia may be defined as a propensity to
thrombosis secondary to abnormalities in hae-
mostasis.1 Thrombophilia has long been recognised as
contributing to venous thrombosis, but is increasingly
associated with arterial disease. It is important because
screening may identify patients at high risk of throm¬
bosis who may then be offered prophylaxis. This re¬
view will focus on the prevalence and significance of
thrombophilic states associated with peripheral ar¬
terial occlusive disease (PAOD) and discuss possible
strategies for screening and treatment.
Prevalence of Thrombophilia
General coagulation activation
If thrombophilia is important in PAOD then there
should be evidence of activation of coagulation in
affected patients. Thrombin and fibrinogen, and prod¬
ucts of their metabolism, including thrombin-anti-
thrombin (TAT) complexes, prothrombin fragments
(PF) 1+2 and fibrin degradation products (FDPs) can
be used to measure coagulation activation. Cross-
sectional2"5 and longitudinal6 epidemiological studies
* Please address all correspondence to: P. Burns, Birmingham Heart¬
lands Hospital, Bordesley Green East, Birmingham B9 5SS.
have demonstrated an association between activation
of coagulation and PAOD. Furthermore, in 1988, Boneu
showed that PAOD was associated with inhibition of
fibrinolysis.7 In young patients (<51 years old) under¬
going lower limb revascularisation, as many as 76%
may have a hypercoagulable state (increased platelet
aggregation or coagulation abnormality).8
Homocysteine
A mild elevation of homocysteine levels (hyper-
homocysteinaemia) affects 5% or more of the popu¬
lation and is increasingly recognised as an independent
risk factor for atherosclerosis and thrombosis.9 Hyper-
homocysteinaemia can cause increased Factor V ac¬
tivity, possibly via a decrease in thrombomodulin cell
surface activity and a corresponding decrease in ac¬
tivated protein C (Fig. 1).10-13 The prevalence of hy-
perhomocysteinaemia in PAOD may be between 50
and 60%14-16 and many cross-sectional studies have
demonstrated a clear association between plasma
homocysteine levels and PAOD.17
Antithrombin III
Anti-thrombin III (AT III) is an endogenous anti-co¬
agulant, produced by the liver, which inactivates
thrombin and factor Xa. Deficiency ofAT III is inherited
in an autosomal dominant fashion. In a population-
based study of 7983 subjects over 55 years old 3.1%
had deficiency of AT III, defined as <75% activity.18
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Fig. 1. Overview of coagulation system.
Fibrinogen
Fibrinogen is the substrate on which the end-product
of the coagulation cascade, thrombin, acts to produce
fibrin, and ultimately, a blood clot. Its effects are
diverse and include increases in blood viscosity, red
cell aggregation, platelet aggregation and activation.1*
Fibrinogen deposited in the arterial intima may also
lead to smooth muscle cell proliferation and leukocyte
migration.20"23 Hyperfibrinogenaemia has long been
associated with cardiovascular disease and is present
in more than 50% of patients with PAOD.24"26
Antiphospholipid antibodies
Antiphospholipid antibodies (aPL) are a group of auto
antibodies originally thought to be targeted towards
negatively charged phospholipid, although recent
work suggests that they are directed against p2-gly-
coprotein I.27 aPLs are of two types, detected by dif¬
ferent laboratory methods: the anticardiolipin
antibody (aCL) enzyme linked immunoassay and the
lupus anticoagulant (LAC) coagulation assay. Al¬
though the lupus assay relies on the in-vitro effect of
aPL to prolong coagulation assays, the in-vivo effect is
procoagulant, the mechanism for which is uncertain.
Antiphospholipid antibodies may inhibit protein C
and protein S, and have prothrombotic effects via
enhanced platelet reactivity or endothelial cell surface
molecules such as heparan sulphate and tissue factor.27
Cross-sectional studies have shown that the pre¬
valence of aPL amongst patients with PAOD requiring
intervention varies between 26% and 45%.23-30 This
mostly comprises patients with aCL who constitute
84-94% the total. A small proportion of patients with
aPL have both LAC and aCL (2-3%).28,30,31 No studies
have yet compared the prevalence of aPL in PAOD
with the prevalence in the general population, and no
large cross-sectional studies have been performed to
give a population prevalence of aPL.
Protein C deficiency
Protein C is a vitamin K dependent protein which,
when activated by the thrombin-thrombomodulin
complex, inactivates factors Va and Villa (Fig. 1).
Protein C deficiency is established as a risk factor for
venous thrombosis, but its role in arterial pathology
is less clear. Few studies have investigated the pre¬
valence of protein C deficiency in PAOD. In a recent
study of 116 claudicants, deficiency of protein C was
found in 2 (1.7%).31 Other studies have shown the
prevalence of protein C deficiency to be between 2.5
and 15% in PAOD patients, but no comparisons were
made with control groups.8,32"34
Activated protein C resistance/factor V Leiden
Activated protein C (APC) resistance is the most com¬
mon inherited risk factor for thrombosis. The pre¬
valence varies in different ethnic populations; in U.K.
it is 3.5-4.9%, Africans 0% and in Cyprus 13%.35,36 The
most common cause of APC resistance is a mutation
in the factor V gene leading to the replacement of
Arginine 506 with Glutamine, (factor V Leiden, fVL)
which renders it more resistant to degradation by
protein C. This is responsible for 90-95% of APC
resistance, the remainder of which is made up of
acquired conditions such as aPL, pregnancy and the
oral contraceptive pill.37-40 APC resistance is measured
using a plasma assay and exogenous activated protein
C, and is indicated by a lowering of the APC ratio
(normal range 2.2 to 2.6). Thiswill identify themajority,
but not all of patients with fVL. fVL may also be
identified directly using genomic analysis, but not all
mutations lead to lowering of the APC ratio. fVL is
thought to underlie 18-30% of venous thromboses, but
its importance in arterial disease is less well defined.
Both APC resistance and fVL have been dem¬
onstrated to be more common in patients with PAOD
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compared with the general population. Sampram
found the prevalence of fVL and APC resistance (de¬
fined as ratio <2.6) to be higher (26.4%) in 359 patients
with PAOD than in 278 controls (12.2%).41 A smaller
study by Foley in patients who had undergone lower
limb arterial bypass surgery reported a 17.8% pre¬
valence of fVL, compared with a local population
prevalence of 3.5%.35 Evans only reported one positive
APC resistant patient in 116 claudicants.31 Variations
in these reported figures may be explained by the
preferential use ofDNA analysis or APC ratio to define
fVL; variations in the lower end of the normal range
for defining the normal APC ratio and the severity of
the presenting PAOD.
Protein S deficiency
Protein S is a vitamin K dependent plasma protein
and an essential co-factor for the anticoagulant and
profibrinolytic effect of activated protein C.42 Protein
S deficiency has been identified as a cause of venous
thrombosis, and more recently has been proposed as
a factor in arterial disease. The prevalence of protein
S deficiency in the general population is thought to
be around 0.7%.43 There are only a few small studies
investigating the prevalence of protein S deficiency in
PAOD. Allart in 1990 showed protein S deficiency to
be present in 3 out of 45 patients (8%) less than 45
years old who required surgical treatment for PAOD.42
A study of 33 patients undergoing arterial surgery,
and 10 controls found a prevalence of protein S de¬
ficiency in PAOD patients of 15%. Although no stat¬
istical difference was shown between patients and
healthy controls, all five subjects with protein S levels
less than normal were PAOD patients.44
Prothrombin 20210A
A G to A transition at position 20210A of the pro¬
thrombin gene is associated with an increased risk of
venous thrombosis, although the underlying mech¬
anism is not clear. The prevalence of this mutation is
1.2% to 4.3% in patients with venous thrombosis,
5.7% in patients with PAOD, and 0.7% in controls.45'46
However, no specific studies have been performed
investigating the association between prothrombin
20210A and arterial disease.
Despite studies screening for different states, using
a variety of methods, in patients with a range of
disease severity, it is clear that there is an increased
prevalence of thrombophilic states in PAOD, perhaps
as high as 60%. Although common, the clinical rel¬
evance of thrombophilia in PAOD is a more important
issue, which will now be discussed.
Significance of Thrombophilia
Studies ofgeneral coagulation activation
There is a correlation between the level of coagulation
activation and the severity of PAOD as determined
by walking distance,4 ankle-brachial pressure index
(ABPI),47'48 duplex ultrasonography, angiography49 and
clinical symptoms.25 For example, Ray reported the
prevalence of thrombophilia (protein C deficiency,
protein S deficiency, antithrombin III deficiency, lupus
anticoagulant) to be 11% in controls, 27% in claudicants
and 40% in patients who had received a re¬
vascularisation.34
The importance of a hypercoagulable state in PAOD
has also been revealed through the association between
coagulation abnormalities and the progression of
PAOD. In the Edinburgh Artery Study, whole blood
viscosity, plasma viscosity and fibrinogen levels were
predictive of the requirement for vascular interven¬
tion,50 or fall in ABPI,6 over a six-year follow-up period.
Furthermore, whole blood viscosity, and fibrinogen
levels have been shown to be predictive for the pro¬
gression of PAOD as determined by walking distance.51
Thrombophilic states may also be important causes
of failure of arterial interventions. In 1994, Ray studied
124 patients undergoing arterial reconstruction and
reported 75 graft occlusions after a mean follow up of
44 months.34 Almost half (49%) of these were sub¬
sequently identified as having a thrombophilia, com¬
pared with 27% of patent reconstructions.
Abnormalities identified in the graft occlusion group
were: protein C deficiency (21% of occlusions), protein
S deficiency (17%), lupus anticoagulant (25%) and
multiple abnormalities (12%). A subsequent pro¬
spective study, investigated the presence of a throm¬
bophilia prior to arterial reconstruction in 60 patients
with one-year follow-up.52 A pre-operative throm¬
bophilia was identified in 65% of patients whose graft
subsequently occluded within one year, compared
with 20% of those with a patent graft (p<0.05). The
presence of thrombophilia was particularly significant
in early graft failures, where 11 of the 12 occlusions
within one month had a pre-operative hyper¬
coagulable abnormality. A prospective study of 137
patients undergoing a mixture of arterial re¬
constructions identified 14 patients (10%) with a hy¬
percoagulable state.33 Three of these patients (27%)
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suffered a graft thrombosis within 30 days, compared
with two of 123 patients with a normal thrombophilia
screen (1.6%). Eldrup Jorgensen studied 20 young (<51
years old) patients undergoing aorto-iliac (7) or infra-
inguinal (13) vascular surgery.8 Four patients suffered
an early (<30 days) post-operative thrombosis, all of
who had thrombophilia identified pre-operatively.
Patients with multiple coagulation abnormalities ap¬
pear to be at special risk. Thus, of 124 patients under¬
going revascularisation studied by Ray, 11 had
multiple thrombophilias, all of whom had had a pre¬
vious revascularisation. Nine of these patients had a
further occlusion during the follow-up period.34
Homocysteine
Hyperhomocysteinaemic patients have an increased
rate of vein graft stenosis and increased failure of
bypass grafts and angioplasty.16,53 Patients undergoing
peripheral arterial bypass surgerywith elevated homo¬
cysteine have evidence of pre-existing intimal hy¬
perplasia in saphenous vein biopsies.15 A prospective
study investigating hyperhomocysteinaemia and pro¬
gression of PAOD, with mean follow-up of 37 months
found a trend towards an association, but this was
not statistically significant.54 This may, however, rep¬
resent a type II error as only a relatively small number
of patients (22) were judged to have progression of
PAOD during follow-up.
Fibrinogen
Fibrinogen levels correlate with the severity of PAOD,
higher levels being associated with more severe dis¬
ease, as determined by claudication distance,25 angio¬
graphy,55,56 and ABPI.47,49,57 Hyperfibrinogenaemia has
been shown to be predictive for the progression of
PAOD, as measured by change in claudication dis¬
tance,51 or the requirement for intervention.50
Given that hyperfibrinogenaemia is associated with
the development and progression of PAOD, it is un¬
surprising that high levels of fibrinogen are predictive
of failure of interventions for PAOD.58 Prospective
studies have shown that hyperfibrinogenaemia is as¬
sociated with failure of vein and prosthetic femoral
popliteal bypass grafts.59"62 In addition, associations
have been demonstrated between raised fibrinogen
levels and graft stenosis, implying that it is not simply
an increased thrombotic tendency underlying the fail¬
ure of such interventions.58,63 Data regarding fibrinogen
and patency following percutaneous angioplasty are
conflicting. Two prospective studies have shown that
hyperfibrinogenaemia is associated with poorer pat¬
ency rates, while another prospective study showed
that high fibrinogen levels measured prior to an¬
gioplasty were associated with improved patency
rates.64416
At present there are no selective treatments available
to lower fibrinogen and consequently no reported trials
confirming benefit in treating hyperfibrinogenaemia.
While there is a great deal of evidence associating
fibrinogen levels and PAOD, it is difficult to conclude
that this relationship is causal until such trials are
available. Fibrinogen is an acute phase protein, and
its increased levels in arterial disease may merely be
representative of an underlying low-grade in¬
flammatory process.
Antiphospholipid antibodies
No studies to date have demonstrated an association
between the prevalence of aPL and the progression
of PAOD. However, aPL and the antiphospholipid
syndrome are associated with an increased risk of
thrombotic complications of vascular surgery, al¬
though the majority of these studies are retrospec¬
tive.28,67"69 Ahn retrospectively identified seven patients
with aPL who underwent a total of 18 vascular pro¬
cedures.70 Three of these patients, none of whom were
anticoagulated developed multiple post-operative
thrombotic complications and all eventually required
amputation. The remaining four vascular patients in
this study were taking steroids, anticoagulants, or
vitamin K at the time of the initial operation. A similar
study found that 16 of 19 patients with aPL undergoing
a vascular procedure suffered a thrombosis, 12 of
who died.71 In a retrospective report of 234 patients
undergoing vascular surgery, aPLs were associated
with a shorter bypass patency period (17 vs 58 weeks)
and a risk of occlusion that was 5.6 times greater than
patients without aPLs.28
The only prospective study to investigate the as¬
sociation between aPL and the outcome of vascular
intervention, showed a trend towards the presence of
aPL and failure of arterial bypass surgery, but this
did not reach statistical significance.30 This result is
unfortunately confounded by the fact that, sig¬
nificantly more of the aPL group were anticoagulated
post-operatively thus diminishing any likely difference
between the groups.
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Ouriel prospectively monitored 76 patients who
underwent lower limb revascularisation for a mean of
47 months. 60% of those with APC resistance (defined
as APC ratio <2.0) had an occlusion of their graft, while
only 24% of those without APC resistance suffered a
graft failure (p<0.02).72 A similar finding was seen in
Sampram's study in which 32% of those with fVL and
49% of those with APC resistance suffered a graft
occlusion (both p<0.001).41 A study from Foley et al.
reported no association between fVL and graft oc¬
clusion, but excluded patients whose graft occluded
within six weeks of surgery, a time that others have
reported as important in graft occlusion associated
with thrombophilia.35
Protein S deficiency
Although the prevalence of protein S deficiency is
higher in patients with PAOD, its significance is un¬
known. Allart investigated the families of young (<45
years old) PAOD patients who were found to be
heterozygotes for protein S deficiency, but no as¬
sociation was found between likelihood of protein
S deficiency, and arterial thrombosis.42 This finding
corroborated a previous study, which showed that
relatives ofprotein S deficient individuals did not have
an increased incidence of arterial thrombosis.73
Deficiency of protein S was identified in 4 of 20
patients (20%) whose arterial reconstruction failed
compared with 6 of 40 (15%) of those with a successful
reconstruction at 30 days post surgery, although this
difference did not reach statistical significance.42
Antithrombin III deficiency
In Van der Bom's population study, examination of
7983 subjects revealed a complex relationship between
level of AT III and ABPI.18 In men, mild PAOD was
associated with a high level of ATIII, while severe
PAODwas associated with lower levels ofATIII.Whilst
in women, there was in an inverse relationship be¬
tween ABPI and ATIII level. The authors suggest that
levels of ATIII rise in the presence of cardiovascular
disease as a protective mechanism, but as vascular
disease progresses, ATIII becomes consumed, leading
to lower levels. The reason for the difference between
the sexes is not clear.
The poor results of intervention in patients with
Table 1. Patients to be investigated for thrombophilia.
1 Venous thromboembolism before the age of 40-45 years
2 Recurrent venous thrombosis or thrombophlebitis
3 Thrombosis in an unusual site, e.g. mesenteric vein, cerebral
vein etc.
4 Unexplained neonatal thrombosis
5 Skin necrosis, particularly if on coumarins
6 Arterial thrombosis before the age 30 years
7 Relatives of patients with thrombophilic abnormality
8 Patients with clear family history of venous thrombosis
9 Unexplained prolonged activated partial thromboplastin time
10 Patients with recurrent foetal loss, idiopathic
thrombocytopaenia or SLE
thrombophilias, in terms of intervention failure and
mortality, reinforce the clinical importance of these
states in patients with PAOD. The presence of two or
more co-existent thrombophilias, seems to have an
additive effect, and be particularly dangerous clin¬
ically. However, many thrombophilic states may be
asymptomatic formany years and the "two-hit" hypo¬
thesis suggests that thrombophilic states only become
apparent when a subject is exposed to some other
thrombogenic trigger such as surgery, oestrogen-con¬
taining medication, dehydration or systemic upset.
Clinical implications
Screening
The British Committee for Standards in Haematology
(BCSH) identified 10 groups of patients who should
be screened for thrombophilia (Table l).1 The treatment
of thrombophilic abnormalities is complex, and the
decision for treatment, which may be lifelong anti¬
coagulation, should only be made after careful con¬
sideration of the patient, the individual thrombophilia
and any triggering factors that may have precipitated
a previous thrombosis. It is our recommendation that
such patients are referred to a haematologist.
In patients with PAOD who do not fall into one of
the groups in Table 1, thrombophilia screening is
still likely to reveal an abnormality in approximately
30-60% of patients. In those who are not undergoing
a vascular intervention, there is no evidence to suggest
that treatment of the thrombophilia will alter the pro¬
gression of arterial disease. There is evidence however,
that patients with a thrombophilia undergoing a vas¬
cular intervention have a poor prognosis, with in¬
creased risk of graft occlusion, limb loss and death,
and this can be partially offset by treatment. It is
therefore recommended that all patients undergoing
a vascular intervention should be screened for a throm¬
bophilic tendency.
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Testing for thrombophilia should depend on the
individual abnormality. Antiphospholipid antibodies,
activated protein C resistance, and hyperhomo-
cysteinaemia are the commonest abnormalities, and
should form the basis of a thrombophilia screen.
Screening for protein C and S deficiency, prothrombin
20210A, and antithrombin III deficiency may be useful,
but likely to yield less positive results, although no
less significant.
Assays for homocysteine have previously been dif¬
ficult to perform, due to the requirement for immediate
cooling of the sample and separation within 1 h. New
techniques are being developed to improve the sta¬
bility of blood samples for homocysteine analysis,
increasing the ease by which homocysteine assays can
be performed.7475
The cost of thrombophilia screening is used as an
argument against its use. However, if screening were
targeted to high-risk groups, such as those in Table 1,
or those undergoing intervention, the cost of screening
may be offset against the reduced risk of failure of
vascular intervention. The treatment of intervention
failure may include prolonged hospital stay, repeated
intervention, or amputation, all with significant costs.
A more detailed cost-benefit analysis is beyond the
scope of this article, and would be difficult to perform
given that the lack of trials in this area means the
true benefit of screening and/or treatment cannot be
quantified.
Treatment
Although numerous different treatments are available
for thrombophilias, they have not been formally
studied in patients with PAOD to determine whether
improved outcomes can be attained.
Hyperhomocysteinaemia
Patients with hyperhomocysteinaemia,who are under¬
going a vascular intervention, should be treated with
homocysteine lowering therapy prior to surgery if
there is sufficient time. If the surgery is urgent, con¬
sideration should be given to formally anticoagulating
these patients until the level of homocysteine can be
reduced. Hyperhomocysteinaemia may be corrected
simply with folic acid, and vitamins Bi2 and/or B6,
although it has yet to be demonstrated whether such
treatmentwill lead to a reduction in cardiovascular risk
or improvement in patency rates. Trials are presently
being undertaken to determine whether lowering
homocysteine levels is beneficial in terms of outcome
for vascular patients both in PAOD and in cardiac
and cerebrovascular disease. It seems sensible in the
absence of current evidence however, to lower homo¬
cysteine levels in PAOD patients undergoing inter¬
vention.
Anti-coagulation
Anticoagulation in non-thrombophilic patients is of
benefit in femoro-popliteal bypass grafts when com¬
pared with no treatment, but when compared to as¬
pirin, the data are conflicting.76 The largest study was a
multicentre, randomised controlled trial investigating
the effectiveness of oral anticoagulation (to maintain
an INR 4.0-4.5) against aspirin (80mg daily) in 2690
patients undergoing infrainguinal bypass surgery,77
which showed no overall benefit of either treatment
in preventing graft occlusion. Patients with anti¬
phospholipid antibodies who are anticoagulated (with
heparin and subsequently warfarin) when they under¬
went vascular surgery were noticed to suffer fewer
complications.70 No studies to date have prospectively
investigated the use of anticoagulation in PAOD
patients with a thrombophilia. However, Khamashita
et al. retrospectively studied the effectiveness of anti¬
coagulation in patients with antiphospholipid syn¬
drome.78 They showed that anticoagulation with
warfarin to an international normalised ratio (INR)
of >3 was significantly more effective in preventing
recurrent thrombosis than anticoagulating to an INR
<3, or aspirin. This study was not confined to patients
with PAOD, but is significant in demonstrating a
benefit of aggressive anticoagulation in thrombophilia.
Steroids
Whilst the thrombophilias discussed previously are
not thought to be associated with a vasculitis, patients
with the lupus anticoagulant who are taking steroids
seem to have a reduced thrombotic risk.70 The pro¬
tective effect of steroids in conjunction with aspirin
has been demonstrated previously in obstetric patients,
and leads to a decrease in lupus anticoagulant levels.79
There are no data on the use of steroids for PAOD
patients with thrombophilia.
Anti-platelet agents
Aspirin is beneficial in obstetric patients with the
lupus anticoagulant.80 The use of aspirin has not been
investigated in PAOD with a thrombophilia, but it is
suggested that it be used in patients with aPL, with
no history of thrombosis. Patientswith aPL undergoing
surgery, or with a history of thrombosis should be
formally anticoagulated, as these patients are at high
risk of thrombosis.
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Factor replacement
An alternative treatment for patients with protein C
or S deficiency undergoing surgery is the use of peri¬
operative fresh frozen plasma or protein C concentrate.
In the case of peripheral vascular surgery, patients
will usually require formal anticoagulation to ensure
the patency of the graft.
Nucleic acid therapy
Recently, oligonucleotides have been shown to have
in-vitro anticoagulant effects through specific protein
binding.81 It remains to be seen whether this will
translate into improved outcomes in thrombophilias.
Conclusion
The evidence to date supports an association between
certain thrombophilias and peripheral vascular dis¬
ease. Hyperhomocysteinaemia, hyperfibrinogenaemia,
APCR and aPL syndrome are more common in PAOD,
but there is no clear evidence for the other throm¬
bophilias.
Thrombophilic states in general are associated with
an increased failure rate of vascular reconstruction.
This is particularly marked when considering patients
with multiple thrombophilias, and early intervention
failures. No conclusive evidence yet exists to show
that treatment of these thrombophilic states can lead
to an improvement in the course of PAOD, or the
results of intervention. While it may be appropriate to
anticoagulate patients identified with a thrombophilia
who are undergoing a vascular intervention, it cannot
yet be justified to recommend screening of all patients
with PAOD for thrombophilia. There is a pressing need
for well-designed trials of therapeutic intervention in
patients with thrombophilia to determine whether
outcomes are genuinely improved.
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